"PubSID","Name"
"0036080953","Antibody-dependent-cellular cytotoxicity"
"0036080953","Apoptosis"
"0036080953","Bone marrow transplantation"
"0036080953","CAMPATH (alemtuzumab, MabCAMPATH)"
"0036080953","CD52 antigen"
"0036080953","Chronic lymphocytic leukemia"
"0036080953","Complement-dependent cytolysis"
"0036080953","First-dose reaction"
"0036080953","Fludarabine"
"0036080953","Immunosuppression"
"0036080953","Lymphoid malignancies"
"0036080953","Lymphopenia"
"0036080953","Monoclonal antibody"
"0036080953","Non-Hodgkin lymphoma, rituximab"
"0036080953","T-cell prolymphocytic leukemia"
"0036273648","B-cell"
"0036273648","Campath"
"0036273648","Chronic"
"0036273648","Leukemia"
"0036276657","Campath-1H, leukemia, B-cell"
"0036276657","Chronic"
"0036276657","Monoclonal antibody"
"0036273609","Bone marrow transplantation"
"0036273609","CAMPATH"
"0036273609","CD52"
"0036273609","Graft-versus-host disease"
"0036273609","Immunosuppression"
"0036273609","T-cell depletion"
"0036275222","Alemtuzumab"
"0036275222","B-cell"
"0036275222","Campath-1H"
"0036275222","Chronic"
"0036275222","Leukemia"
"0036275222","Monoclonal antibody"
"0036277109","Alemtuzumab"
"0036277109","Alkylating agents"
"0036277109","B-cell"
"0036277109","Chronic"
"0036277109","Leukemia"
"0036277109","Monoclonal antibody Campath-1H"
"0036277109","Remission induction"
"0036277109","Vincristine"
"0036275123","Alemtuzumab"
"0036275123","Campath-1H"
"0036275123","Leukemia"
"0036275123","Lymphoma"
"0036275123","Prolymphocytic"
"0036275123","T-cell"
"0035559387","Campath-1H"
"0035559387","Chlorambucil"
"0035559387","Chronic lymphocytic leukemia"
"0035559387","Corticosteroids"
"0035559387","Fludarabine"
"0035559387","Infection"
"0035559387","Prophylaxis"
"0035516174","alemtuzumab"
"0035516174","allogeneic bone marrow transplant"
"0035516174","chronic lymphocytic leukaemia"
"0035516174","monoclonal antibody"
"0035516174","prolymphocytic leukaemia"
"0035516174","therapy"
"0034864666","Immunotherapy"
"0034864666","Monoclonal antibody"
"0034864666","Non-Hodgkin's lymphoma"
"0034864666","Radioimmunotherapy"
"0034864666","Rituximab"
"0034941907","Allogeneic"
"0034941907","Bone marrow transplant"
"0034941907","Graft versus host disease"
"0035967493","Organ transplantation"
"0035967493","Tolerance"
"0036072285","Chronic myeloid leukemia"
"0036072285","Gastrointestinal stromal tumors"
"0036072285","Gleevec"
"0036072285","Imatinib mesylate"
"0036072285","Molecular targeting"
"0036072285","Protein-tyrosine kinase inhibitor"
"0036081738","CD117"
"0036081738","Diagnosis"
"0036081738","Gastrointestinal stromal tumor"
"0036081738","GIST"
"0036081738","Guidelines"
"0036081738","KIT"
"0036081738","Sarcoma"
"0035990924","Akt"
"0035990924","Apoptosis"
"0035990924","Cancer"
"0035990924","Cell cycle"
"0035990924","Diabetes"
"0035990924","PKB"
"0035990893","Cyclin-dependent kinases"
"0035990893","Epidermal growth factor kinase"
"0035990893","PKI166"
"0035990893","Protein kinase inhibitors"
"0035990893","STI571"
"0036301863","Allelic losses"
"0036301863","Gastrointestinal stromal tumor"
"0036301863","KIT mutation"
"0036301863","Prognosis"
"0036301863","Sarcoma"
"0036301722","CD117"
"0036301722","Diagnosis"
"0036301722","Gastrointestinal stromal tumor"
"0036301722","Guidelines"
"0036301722","KIT"
"0036301722","Sarcoma"
"0036019064","Comparative molecular field analysis (CoMFA)"
"0036019064","Comparative molecular similarity index analysis (CoMSIA)"
"0036019064","Homology modeling"
"0036019064","Molecular docking"
"0036019064","Pharmacophore analysis"
"0036019064","Protein kinase inhibitors"
"0036019064","Quantitative structure-activity relationships (QSAR)"
"0036019064","Structure-based drug design"
"0036244517","Leukemia"
"0036244517","Lymphoma"
"0036244517","Molecular targeting"
"0036244517","Monoclonal antibodies"
"0036245352","Decitabine"
"0036245352","Homoharring tonine"
"0036245352","Imatinib mesylate"
"0036245352","Interferon"
"0036245352","Transplant"
"0036234952","Chronic myelogenous leukemia"
"0036234952","Drug development"
"0036234952","Signal transduction"
"0036234952","Tyrosine kinase inhibitors"
"0036217230","Arsenic trioxide"
"0036217230","Bcr-Abl"
"0036217230","Farnesyltransferase"
"0036217230","Imatinib mesylate"
"0036217230","Leukemia"
"0036217230","Tyrosine kinase"
"0036207093","BCR-ABL"
"0036207093","Chronic myeloid leukaemia"
"0036207093","Fluorescence in situ hybridisation"
"0036207093","Ph chromosome"
"0036207093","Polymerase chain reaction"
"0036207093","Real time polymerase chain reaction"
"0036207093","Reverse-transcriptase polymerase chain reaction"
"0036125395","Acute lymphoblastic leukemia"
"0036125395","Allogeneic stem cell transplantation"
"0036125395","BCR-ABL"
"0036125395","Philadelphia chromosome"
"0036125395","ST1571"
"0036125395","Tyrosine kinase inhibitors"
"0037075889","Gene expression"
"0037075889","Leukemia"
"0037075889","Microarray"
"0036189039","Imatinib mesylate"
"0036189039","STI571"
"0036189039","Targeted therapy"
"0036240251","Bcr-Abl"
"0036240251","Drug resistance"
"0036240251","Leukemia"
"0036240251","Selective therapy"
"0036240251","STI-571"
"0036179862","Bcr-Abl"
"0036179862","CML"
"0036179862","STI571"
"0036179862","Tyrosine kinase"
"0036179862","Tyrosine kinase inhibitor"
"0035735828","Dendritic cells"
"0035735828","Haemopoietic stem cells"
"0035735828","Kit"
"0035735828","Signal transduction"
"0035735828","Stem cell factor"
"0035735828","STI571"
"0035743340","Clinical trials"
"0035743340","Inhibitors"
"0035743340","Protein kinases"
"0035743340","Receptor tyrosine kinases"
"0035743340","Serine/threonine kinases"
"0035743340","Targets"
"0035743340","Tumor therapy"
"0035979656","Bcr-Abl"
"0035979656","Chronic myelogenous leukemia"
"0035979656","STI571"
"0035979656","Tyrosine kinase inhibitor"
"33947529458","Acute lymphoblastic leukaemia"
"33947529458","Ara-G"
"33947529458","Lymphoblastic lymphoma"
"33947529458","Nelarabine"
"33748114785","Arranon Â®"
"33748114785","Leukemia"
"33748114785","Lymphoma"
"33748114785","Nelarabine"
"33748114785","Nucleoside"
"33748114785","T cell"
"33646550489","Cladribine"
"33646550489","Clofarabine"
"33646550489","Fludarabine"
"33646550489","Immucillin H"
"33646550489","Nelarabine"
"33646550489","Pentostatin"
"0035724240","BCR-ABL"
"0035724240","Chronic myelogenous leukaemia"
"0035724240","Signal transduction"
"0035724240","STI571"
"0035724240","Therapy"
"0035724240","Tyrosine kinase inhibitor"
"34447108810","Angiogenesis"
"34447108810","Anti-angiogenic therapy"
"34447108810","Bevacizumab"
"34447108810","Pegaptinib"
"34447108810","Ranibizumab"
"34447108810","Sorafenib"
"34447108810","Sunitinib"
"34447108810","VEGF"
"34447321307","Bladder cancer"
"34447321307","Germ cell tumour"
"34447321307","Molecular therapy"
"34447321307","Oncology"
"34447321307","Prostate cancer"
"34447321307","Renal cell carcinoma"
"34447321307","Targeted therapy"
"34447321307","Tyrosine kinase inhibitor"
"34548850080","Kinase inhibitor"
"34548850080","VEGFR"
"33947610173","Bevacizumab"
"33947610173","Breast cancer"
"33947610173","Cyclooxygenase-2"
"33947610173","Targeting therapy"
"33947610173","Trastuzumab"
"34248372373","EGFR"
"34248372373","Targeted therapy"
"34248372373","Tyrosine kinase inhibitors"
"34248372373","VEGF"
"33846621955","Review"
"33846621955","Small molecule tyrosine kinase inhibitors"
"33846621955","Solid tumors"
"33846621955","Tyrosine kinase inhibitors"
"33846200478","Bevacizumab"
"33846200478","Interferon"
"33846200478","Interleukin-2"
"33846200478","Renal cell cancer"
"33846200478","Sorafenib"
"33846200478","Sunitinib"
"33846200478","Tyrosine kinase inhibitors"
"33947669287","Bevacizumab"
"33947669287","Molecular biology"
"33947669287","Renal cell carcinoma"
"33947669287","Sorafenib"
"33947669287","Sunitinib"
"33947669287","Temsirolimus"
"33846051511","Bevacizumab"
"33846051511","CAIX"
"33846051511","COX-2"
"33846051511","Cytokines"
"33846051511","Renal carcinoma"
"33846051511","Sorafenib"
"33846051511","Sunitinib"
"33846051511","Temsirolimus"
"33846051511","VEGF"
"33846084359","Bevacizumab"
"33846084359","Immunotherapy"
"33846084359","mTOR"
"33846084359","Renal cell carcinoma"
"33846084359","Sorafenib"
"33846084359","Sunitinib"
"33846084359","VEGF"
"33750941018","Angiogenesis"
"33750941018","Antiangiogenesis inhibitor"
"33750941018","Targeted therapy"
"33750941018","VEGF"
"33750711391","Kinase inhibition"
"33750711391","Metastatic"
"33750711391","Renal cell carcinoma"
"33750711391","Systemic therapy"
"33750711391","Targeted drugs"
"39049181210","Immunotherapy"
"39049181210","Kinase inhibitors"
"39049181210","Sorafenib"
"39049181210","Sunitinib"
"39049181210","Vaccine therapy"
"33747197773","Antiangiogenic therapy"
"33747197773","New regimens"
"33747197773","Renal cancer"
"33747197773","Targeted therapies"
"33748581389","Metastatic systemic therapy"
"33748581389","Renal cell carcinoma"
"33748581389","Targeted drugs"
"33748643613","Adjuvant therapy"
"33748643613","Bevacizumab"
"33748643613","Ixabepilone"
"33748643613","Lapatinib"
"33748643613","Pertuzumab"
"33746591262","Angiogenesis"
"33746591262","Clinical trials"
"33746591262","Tyrosine kinase inhibitors"
"33746591262","VEGFR"
"33747042577","Bevacizumab"
"33747042577","Interferon"
"33747042577","Interleukin-2"
"33747042577","Renal cell cancer"
"33747042577","Sorafenib"
"33747042577","Sunitinib"
"33747042577","Tyrosine kinase inhibitors"
"33745253801","Drug-induced liver injury"
"33745253801","GIST"
"33745253801","Hepatotoxicity"
"33745253801","Imatinib"
"33746127995","BAY 43-9006"
"33746127995","Bevacizumab"
"33746127995","Carcinoma"
"33746127995","Renal cell"
"33746127995","SU 11248"
"33746127995","VEGF"
"33746127995","VHL"
"33646448005","Antiangiogenic"
"33646448005","Antitumour"
"33646448005","GIST"
"33646448005","Inhibitor"
"33646448005","Multitargeted tyrosine kinase"
"33646448005","RCC"
"33646448005","Solid tumours"
"33646448005","SU11248"
"33646448005","Sunitinib"
"33644840580","Bevacizumab"
"33644840580","CCI-779"
"33644840580","Erlotinib"
"33644840580","Sorafenib"
"33644840580","Sunitinib"
"33644840580","Von Hippel-Lindau"
"33745005282","AG-013736"
"33745005282","Epidermal growth factor receptor"
"33745005282","Raf kinase inhibitors"
"33745005282","Sorafenib"
"33745005282","Vascular endothelial growth factor Trap"
"84942194252","chemotherapy"
"84942194252","gastric cancer"
"84942194252","immune checkpoint inhibitor"
"84942194252","metastatic"
"84942194252","recurrent"
"84942194252","targeted therapy"
"84953881828","Anti-CTLA-4"
"84953881828","Anti-PD1"
"84953881828","Cabozantinib"
"84953881828","Everolimus"
"84953881828","Hepatocellular carcinoma"
"84953881828","Immunotherapy"
"84953881828","Lenvatinib"
"84953881828","Oncolytic virus"
"84953881828","Ramucirumab"
"84953881828","Receptor tyrosine kinase inhibitor"
"84953881828","Refametinib"
"84953881828","Regorafenib"
"84953881828","Sorafenib"
"84953881828","Tivantinib"
"84953881828","Trebananib"
"84935027410","Angiogenesis"
"84935027410","Bevacizumab"
"84935027410","Bladder"
"84935027410","Bladder cancer"
"84935027410","Cabozantinib"
"84935027410","Metastases"
"84935027410","Metastasis"
"84935027410","Metastatic bladder cancer"
"84935027410","Metastatic urothelial carcinoma"
"84935027410","Pazopanib"
"84935027410","Ramucirumab"
"84935027410","RECIST"
"84935027410","Sorafenib"
"84935027410","Sunitinib"
"84935027410","Targeted agents"
"84935027410","Targeted therapies"
"84935027410","Urothelial"
"84935027410","Urothelial carcinoma"
"84935027410","VEGF"
"84946235122","anemia"
"84946235122","neutropenia"
"84946235122","ramucirumab"
"84946235122","thrombocytopenia"
"84938840932","Angiogenesis"
"84938840932","gastric cancer"
"84938840932","ramucirumab"
"84938840932","review"
"84937517268","Advanced gastric cancer"
"84937517268","Angiogenesis"
"84937517268","Bevacizumab"
"84937517268","Ramucirumab"
"84922665326","Angiogenesis"
"84922665326","Bevacizumab"
"84922665326","Nivolumab"
"84922665326","Ramucirumab"
"84922665326","Vascular endothelial growth factor"
"84928295481","Gastric cancer"
"84928295481","HER-2"
"84928295481","Targeted therapy"
"84928295481","Trastuzumab"
"84928295481","VEGFR-2"
"84937032951","antiangiogenic drugs"
"84937032951","BIBF1120"
"84937032951","nintedanib"
"84937032951","non-small cell lung cancer"
"84937032951","NSCLC"
"84937032951","tyrosine kinase inhibitor"
"84929190537","C-mesenchymal-epithelial transition inhibitor"
"84929190537","C-mesenchymal-epithelial transition pathway"
"84929190537","Gastric cancer"
"84929190537","Molecular targeted agents"
"84931457947","Angiogenesis"
"84931457947","Antibody"
"84931457947","Non-small cell lung cancer"
"84931457947","Tyrosine kinase inhibitor"
"84921345093","Biosimilar antibodies"
"84921345093","Cancer"
"84921345093","Clinical studies"
"84921345093","European Medicines Agency"
"84921345093","Food and Drug Administration"
"84921345093","Immune-mediated disorders"
"84921345093","Monoclonal antibodies"
"84923281576","Antibody"
"84923281576","EGFR"
"84923281576","Esophageal cancer"
"84923281576","Gastric cancer"
"84923281576","Gastroesophageal cancer"
"84923281576","Her2"
"84923281576","MET"
"84923281576","Targeted therapy"
"84923281576","VEGF"
"84916918721","Anti-angiogenic therapy"
"84916918721","Biomarkers"
"84916918721","Breast cancer"
"84916918721","Vascular endothelial growth factor"
"84928531309","BCLC RECIST"
"84928531309","BCLC staging"
"84928531309","hepatocellular carcinoma"
"84928531309","RECIST"
"84928531309","survival"
"84928531309","treatment"
"84928531309","trial design"
"84921362441","anti-VEGFR monoclonal antibodies"
"84921362441","gastric cancer"
"84921362441","ramucirumab"
"84921362441","vascular endothelial growth factor receptor"
"84927649692","Adjuvant"
"84927649692","Chemoradiation"
"84927649692","Chemotherapy"
"84927649692","Gastric cancer"
"84927649692","Preoperative"
"84928044744","Biomarkers"
"84928044744","Gastric cancer"
"84928044744","HER2"
"84928044744","Predictive"
"84928044744","Prognostic"
"84909989459","Epidermal growth factors pathway"
"84909989459","Gastric cancer"
"84909989459","Human epidermal growth factor receptor 2 protein"
"84909989459","Molecular targeting therapy"
"84909989459","Vascular endothelial growth factors/Vascular endothelial growth factor receptor pathway"
"84923279264","Angiogenesis"
"84923279264","Antiangiogenic"
"84923279264","Bevacizumab"
"84923279264","Metastatic colorectal cancer"
"84923279264","Ramucirumab"
"84923279264","Regorafenib"
"84923279264","Ziv-aflibercept"
"84910003792","Chemoradiation"
"84910003792","Chemotherapy"
"84910003792","Gastric cancer"
"84910003792","Localized"
"84910003792","Metastatic"
"84921728501","Hepatocellular carcinoma"
"84921728501","Management"
"84921728501","Patients selection"
"84921728501","RECIST"
"84921728501","Systemic treatment"
"84921728501","Tumour response"
"84906777617","Chemotherapy"
"84906777617","Eradication"
"84906777617","Follow-up"
"84906777617","Gastric cancer"
"84906777617","Helicobacter pylori"
"84906777617","Ramucirumab"
"84925610511","Angiogenesis"
"84925610511","Antiangiogenic therapy"
"84925610511","Gastric cancer"
"84925610511","Vascular endothelial growth factor"
"84916199585","Bevacizumab"
"84916199585","Gastric cancer"
"84916199585","Ramucirumab"
"84916199585","VEGF"
"84902313634","Gastric cancer"
"84902313634","MET-inhibitors"
"84902313634","Pertuzumab"
"84902313634","Ramucirumab"
"84902313634","Target therapy"
"84905025438","5-fluorouracil"
"84905025438","advanced gastric cancer"
"84905025438","chemotherapy"
"84905025438","cisplatin"
"84905025438","docetaxel"
"84905025438","targeted agents"
"84905025438","trastuzumab"
"84905858700","Angiogenesis"
"84905858700","Metastatic esophageal and gastric cancer"
"84905858700","Ramucirumab"
"84905858700","Target therapy"
"84901586010","chemoembolization"
"84901586010","hepatocellular carcinoma"
"84901586010","irreversible electroporation"
"84901586010","microwave ablation"
"84901586010","radioembolization"
"84901586010","radiofrequency ablation"
"84901586010","sorafenib"
"84905253056","Cancer"
"84905253056","Gastric"
"84905253056","Mutation"
"84905253056","Proteomics"
"84905253056","Sequencing"
"84905253056","Targeted therapy"
"84905827126","Angiogenesis"
"84905827126","Breast cancer"
"84905827126","Cancer"
"84905827126","Clinical trials"
"84905827126","MAb"
"84905827126","Ramucirumab"
"84905827126","VEGF"
"84905827126","VEGFR-2"
"84903175348","Biological"
"84903175348","Esophageal"
"84903175348","Esophagogastric"
"84903175348","Gastric"
"84903175348","Gastroesophageal"
"84903175348","Molecular"
"84903175348","Oesophageal"
"84903175348","Personalized"
"84903175348","Targeted"
"84903175348","Treatment"
"84944746471","Metastatic colon cancer"
"84944746471","Molecular profiling"
"84944746471","Regorafenib"
"84944746471","Targeted therapy"
"84958202246","Antibodies"
"84958202246","Antibodies"
"84958202246","Avelumab"
"84958202246","Bevacizumab"
"84958202246","Carboplatin"
"84958202246","Carcinoma"
"84958202246","Cisplatin"
"84958202246","Gemcitabine"
"84958202246","Immunotherapy"
"84958202246","MEDI4736"
"84958202246","Molecular targeted therapy"
"84958202246","Monoclonal"
"84958202246","MPDL3280A"
"84958202246","MSB0010718C"
"84958202246","Nivolumab"
"84958202246","Non-small-cell lung cancer"
"84958202246","Pembrolizumab"
"84958202246","Pemetrexed"
"84958202246","Programmed cell death-1 receptor"
"84958202246","Ramucirumab"
"84958202246","Squamous cell"
"84942307259","Angiogenesis"
"84942307259","Gastric cancer"
"84942307259","IMC-1121B"
"84942307259","Ramucirumab"
"84942307259","Targeted therapy"
"84942307259","Vascular endothelial growth factor receptor-2"
"84938236267","Gastric cancer"
"84938236267","Gastroesophageal cancer"
"84938236267","Ramucirumab"
"84938709400","bevacizumab"
"84938709400","cetuximab"
"84938709400","obinutuzumab"
"84938709400","ramucirumab"
"84938709400","rituximab"
"84938709400","trastuzumab"
"84928990257","Brivanib"
"84928990257","Erlotinib"
"84928990257","Everolimus"
"84928990257","Hepatocellular carcinoma"
"84928990257","Linifanib"
"84928990257","Molecular targeted therapy"
"84928990257","Ramucirumab"
"84928990257","Regorafenib"
"84928990257","Sorafenib"
"84928990257","Sunitinib"
"84928990257","Tivantinib"
"84930651849","AMG 337"
"84930651849","Colorectal cancer"
"84930651849","Gastric cancer"
"84930651849","Onartuzumab"
"84930651849","Pembrolizumab"
"84930651849","Ramucirumab"
"84930651849","Target therapy"
"85015497707","Angiogenesis"
"85015497707","Antibodies anti-VEGFR2"
"85015497707","Apatinib"
"85015497707","Breast cancer"
"85015497707","Gastric cancer"
"85015497707","Lung cancer"
"85015497707","Ramucirumab"
"85015497707","Vascular endothelial growth factor receptor 2 (VEGFR2)"
"84945456021","Clinical trials"
"84945456021","Hepatocellular carcinoma"
"84945456021","Molecularly targeted therapy"
"84945456021","Novel agents"
"84945456021","Sorafenib"
"84908282604","Antiangiogenic"
"84908282604","Breast cancer"
"84908282604","Gastric cancer"
"84908282604","Lung cancer"
"84908282604","Ramucirumab"
"84914095200","Angiogenesis"
"84914095200","bevacizumab"
"84914095200","esophageal cancer"
"84914095200","gastric cancer"
"84914095200","ramucirumab"
"0029937765","Campath-1H"
"0029937765","chronic lymphocytic leukaemia"
"0029937765","monoclonal antibody"
"0029937765","therapy"
"0033522647","Antibody humanization"
"0033522647","CAMPATH-1H"
"0033522647","CD52"
"0033522647","Protein crystallography"
"0033522647","Therapeutic antibodies"
"0035555519","Bone marrow"
"0035555519","CAMPATH"
"0035555519","CD52"
"0035555519","Half-life"
"0035555519","Pharmacokinetics"
"0035555519","Stem cell"
"0035555519","T-cell depletion"
"0036470439","CAMPATH"
"0036470439","CD52"
"0036470439","Immunofluorescence"
"0036470439","Pharmacokinetics"
"0036470439","Validation"
"0029875268","Antiglobulin response"
"0029875268","CAMPATH-1H"
"0029875268","Immunotherapy"
"0029875268","Monoclonal antibody"
"0029875268","Rheumatoid arthritis"
"0030964964","Campath-1H"
"0030964964","CLL"
"0032005642","Anti-CD52"
"0032005642","B and T cells"
"0032005642","B and T leukemias"
"0032005642","Campath-1H"
"0035075989","Anti-CD52 antibody"
"0035075989","Flow cytometric analysis"
"0035075989","Monoclonal antibody"
"0036941305","CAMPATH-1H"
"0036941305","Monoclonal antibody therapy"
"0036941305","Multicenter phase I/II study"
"0036941305","non-Hodgkin's lymphoma"
"0033949148","CAMPATH-1"
"0033949148","Graftfailure"
"0033949148","GVHD"
"0033949148","HLA-identical sibling"
"0033949148","Peripheral blood progenitor cells"
"0033949148","T cell depletion"
"0030877079","Acute lymphoblastic leukemia"
"0030877079","Autologous bone marrow transplantation"
"0030877079","Campath-IM"
"0030877079","Interstitial pneumonitis purging"
"0030877079","Relapse total-body irradiation"
"0034027095","Allogeneic transplantation"
"0034027095","BEAM"
"0034027095","CAMPATH"
"0034027095","Lymphoma"
"0029869119","CAMPATH-1H"
"0029869119","Cytokines"
"0029869119","Lymphocytes"
"0029869119","Multiple sclerosis"
"0029869119","Symptoms"
"0030453977","adverse reaction"
"0030453977","Fc receptor"
"0030453977","humanized"
"0030453977","monoclonal antibody"
"0030453977","serotherapy"
"0030300084","CAMPATH"
"0030300084","Immunotherapy"
"0030300084","Low grade lymphoma"
"0030300084","Monoclonal antibody"
"0030300084","Non-Hodgkin's lymphoma"
"0035091343","Ibritumomab tiuxetan"
"0035091343","IDEC-Y2B8"
"0035091343","Monoclonal antibody"
"0035091343","Non-Hodgkin's lymphoma"
"0035091343","Radioimmunotherapy"
"0035091343","Rituximab"
"0034844737","CLL"
"0034844737","Leukemia"
"0034844737","Transplantation"
"0034775122","B cell"
"0034775122","CD20"
"0034775122","CD22"
"0034775122","CD52"
"0034775122","IL-4"
"0034775122","Monoclonal antibody"
"0025652892","Anitbody therapy"
"0025652892","CAMPATH-1"
"0025652892","Leukemia"
"0025652892","Lymphoma"
"0031027623","B-PLL"
"0031027623","CAMPATH-1H"
"0031027623","CLL"
"0031027623","Fludarabine"
"0031027623","MonoclonaI antibody"
"0034062199","B-CLL"
"0034062199","Campath-1H"
"0034062199","Monoclonal antibodies"
"0036335916","Chronic lymphocytic leukemia"
"0036335916","Fludarabine regimen"
"0036335916","Refractory CLL"
"0036335916","Salvage therapy"
"0032715454","Autologous blood cell transplantation"
"0032715454","Molecular responses"
"0032715454","Multiple myeloma"
"0033002175","Autologous transplantation"
"0033002175","Fludarabine"
"0033002175","Myeloid leukaemia"
"0033002175","Stem cells"
"0002299891","Nucleic acid sequence quantification"
"0002299891","Perkin Elmer/applied biosystems 7700 sequence detector"
"0002299891","Quantitative real-time polymerase chain reaction"
"0027462047","Anti-sperm monoclonal antibodies"
"0027462047","CAMPATH-1"
"0027462047","CDw52 antigen"
"0027462047","epididymis"
"0027462047","GPI anchor"
"0027462047","seminal plasma"
"0027462047","spermatozoa"
"0030089901","CAMPATH-1"
"0030089901","CD antigens"
"0030089901","Epididymis"
"0030089901","Immunosuppression"
"0030089901","Sperm maturation"
"17644442155","Campath-1M"
"17644442155","Immunoselection"
"17644442155","Sequential T cell depletion"
"0034090521","BM"
"0034090521","CAMPATH"
"0034090521","PBSC"
"0034090521","T-cell depletion"
"9444232751","B cell lymphoma"
"9444232751","BMT"
"9444232751","Children"
"9444232751","Risk factors"
"0029928384","Campath"
"0029928384","Graft rejection"
"0029928384","GVHD"
"0034765992","Bone marrow, cyclosporin"
"0034765992","CAMPATH"
"0034765992","CD52"
"0034765992","PBSC"
"0034765992","Registry"
"0034765992","T-cell depletion"
"0023615397","Class switch"
"0023615397","Isotope"
"0023615397","Monoclonal antibody"
"0023615397","Reverse passive hemagglutination"
"0023615397","Serotherapy"
"0023615397","Sib selection"
"9444257631","Childhood ALL"
"9444257631","T-cell depletion"
"9444257631","Unrelated donor BMT"
"0029948935","Aplastic anaemia"
"0029948935","Campath-1G"
"0029948935","Chimaerism"
"0034790089","Alternative donor"
"0034790089","Aplastic anaemia"
"0034790089","BMT"
"0034790089","Campath"
"0034790089","Low-dose TBI"
"17944366282","Allogeneic transplantation"
"17944366282","BEAM"
"17944366282","CAMPATH"
"17944366282","Donor lymphocyte infusion"
"17944366282","Lymphoproliferative disorders"
"17944366282","Stem-cell transplantation"
"0030993535","FcRB"
"0030993535","FcRn"
"0030993535","FcRp"
"0030993535","IgG catabolism"
"0030993535","Passive immunity"
"0030993535","Receptor recycling"
"0030993535","Transmission"
"0034761825","Immunosuppression"
"0034761825","Opportunistic infections"
"0034761825","T-cell depletion"
"0031945659","Allogeneic"
"0031945659","Campath"
"0031945659","Immune reconstitution"
"0031945659","NK cells"
"0031945659","T cells"
"0033655656","Acute myeloid leukemia"
"0033655656","Bone marrow transplantation"
"0033655656","Unrelated donor"
"0035133203","Bone marrow transplantation"
"0035133203","Chronic myeloid leukaemia"
"0035133203","Cytomegalovirus"
"0035133203","Unrelated donor"
"0033546980","Campath 1H"
"0033546980","Monoclonal antibody"
"0033546980","Quantitative MRI"
"0033546980","Secondary progressive MS"
"0030960290","Biologic therapy"
"0030960290","Campath-1H"
"0030960290","Clinical trial"
"0030960290","Monoclonal antibody"
"0030960290","Rheumatoid arthritis"
"0033775935","Indolent lymphoma"
"0033775935","Large-cell lymphoma"
"0033775935","Monoclonal antibodies"
"0033775935","Radioimmunoconjugates"
"0033775935","Rituximab"
"0033506258","Breast cancer"
"0033506258","Lymphoma"
"0033506258","Monoclonal antibodies"
"0033506258","Side effects"
"0033506258","Toxicity"
"0031664666","Chronic lymphocytic leukemia"
"0031664666","IDEC-C2B8"
"0031664666","Immunotherapy"
"0031664666","Rituximab"
"0031664666","Tumor lysis syndrome"
"0032736341","AIDS"
"0032736341","Chronic lymphocytic lymphoma"
"0032736341","IDEC-C2B8"
"0032736341","Immunotherapy"
"0032736341","Lymphoproliferative disorder"
"0032736341","Non-Hodgkin's lymphoma"
"0032736341","Rituximab"
"0032736341","Tumor lysis syndrome"
"0028345579","CLL"
"0028345579","Infections"
"0028345579","Survival"
"0028345579","Treatment"
"0026744046","chronic lymphocytic leukemia"
"0026744046","immunoglobulins"
"0026744046","infections"
"0032886463","Hypogammaglobulinemia"
"0032886463","Immunodeficiency"
"0032886463","Infections"
"0032886463","Purine analogues"
"0031422845","Cytopenia"
"0031422845","Hemolysis"
"0031422845","Infections"
"0031422845","Purine analogues"
"0031422845","Splenectomy"
"0029080221","Chronic lymphocytic leukemia"
"0029080221","Fludarabine"
"0029080221","Immunocytic lymphoma"
"0029080221","Immunosuppression"
"0029080221","Infectious rate"
"0029080221","NHL"
"0030927872","Chronic lymphocytic leukemia"
"0030927872","Fludarabine"
"0030927872","Opportunistic infections"
"0028999305","chronic lymphocytic leukemia"
"0028999305","fludarabine"
"0028999305","lowâgrade lymphoma"
"0028999305","opportunistic infections"
"0028999305","pneumocystis carinii"
"0034656999","Colon"
"0034656999","Incidence rate"
"0034656999","Joinpoint"
"0034656999","Mortality"
"0034656999","Neoplasm"
"0034656999","Race"
"0034656999","Rectum"
"0034656999","Screening"
"0034656999","Surveillance"
"0030914793","Chronic lymphocytic leukemia"
"0030914793","Life expectancy"
"0030914793","Natural history"
"0028307594","Advanced CLL"
"0028307594","CHOP regimen"
"0028307594","Lymphocytic leukemia"
"0028307594","Randomized clinical trials"
"0028307594","Treatment"
"0034063889","Chronic lymphocytic leukaemia"
"0034063889","Cladribine"
"0034063889","Efficiency"
"0034063889","Prednisone"
"0034063889","Side- effects"
"0032707533","B-cell malignancies"
"0032707533","Biology"
"0032707533","Chronic lymphocytic leukemia"
"0032707533","Chronic lymphoproliferative disorders"
"0032707533","CLL"
"0032707533","CLL etiology"
"0032707533","Cytogenetics"
"0032707533","Diagnosis"
"0032707533","Treatment"
"0030007085","B-cell chronic lymphocytic leukemia"
"0030007085","Fludarabine"
"0030007085","Treatment"
"0027302504","chronic lymphocytic leukemia"
"0027302504","fludarabine"
"0027302504","immunosuppression"
"0027302504","infection rate"
"0032881934","CLL"
"0032881934","Fludarabine"
"0032881934","Response"
"0032881934","Toxicity"
"0034515054","B-CC-elderly"
"0034515054","Cyclophosphamide"
"0034515054","Fludarabine"
"0030972725","Fludarabine"
"0030972725","Mitoxantrone"
"0030972725","Non-Hodgkin's lymphoma"
"0030972725","Response rate"
"0031454435","Idarubicin"
"0031454435","Non-Hodgkin lymphomas"
"0032415158","Chronic lymphocytic leukemia"
"0032415158","Fludarabine"
"0032415158","GMCSF"
"0032415158","Lymphoma, indolent, follicular, small lymphocytic"
"0032415158","Mitoxantrone"
"0032415158","Pneumocysti carinii pneumonia"
"0034048789","B-CLL"
"0034048789","Oral idarubicin"
"0034048789","Phase II study"
"0029036444","Chronic lymphocytic leukemia"
"0029036444","Doxorubicin"
"0029036444","Fludarabine"
"0345471455","Chronic lymphocytic leukaemia"
"0345471455","Epirubicin"
"0345471455","Fludarabine"
"0009355277","Cisplatin"
"0009355277","Cytotoxicity"
"0009355277","Dna repair"
"0009355277","Fludarabine"
"0009355277","Malanoma"
"0009355277","Ovarian cancer"
"0033406619","Arabinosyl cytosine"
"0033406619","Chronic lymphocyte leukemia"
"0033406619","cis-platinum"
"0033406619","CLL"
"0033406619","Combination chemotherapy"
"0033406619","Failire regimen"
"0033406619","Fludarabine"
"0033406619","Resistant disease"
"6844258870","ATM"
"6844258870","Fluorescent in situ hybridization"
"6844258870","Mutations"
"6844258870","Single-strand conformation polymorphism"
"6844258870","T-prolymphocytic leukaemia"
"6844258870","Tumour suppressor"
"7844243243","T-prolymphocytic leukaemia"
"0032856636","Chronic lymphocytic leukemia"
"0032856636","IgG subclasses"
"0032856636","Immunoglobulins"
"0032856636","Infection"
"0032856636","Mannan-binding lectin"
"0029783494","Chronic lymphatic leukemia"
"0029783494","Complement"
"0027283739","chronic lymphocytic leukemia"
"0027283739","fludarabine"
"0027283739","immunodeficiency"
"0027283739","NHL"
"0027283739","opportunistic infections"
"0027283739","T lymphocyte"
"0344867044","2-chlorodeoxyadenosine"
"0344867044","Chronic lymphocytic leukemia"
"0344867044","Efficiency"
"0344867044","Immunophenotyping"
"0344867044","Side-effects"
"0344867044","Younger patients"
"0345593600","2-Chlorodeoxyadenosine"
"0345593600","Chronic lymphocytic leukemia"
"0345593600","Efficiency"
"0345593600","Elderly patients"
"0345593600","Side effects"
"0030877290","Antimicrobial prophylaxis"
"0030877290","Bone marrow transplantation"
"0030877290","Chronic lymphocytic leukemia"
"0030877290","Fludarabine"
"0030877290","Immunocompromised host"
"0030877290","Listeriosis"
"0030877290","Opportunistic infections"
"0030877290","Toxoplasmosis"
"0030696074","CLL"
"0030696074","Fludarabine"
"0030696074","G-CSF"
"0030696074","Infections"
"0030696074","Myelosuppression"
"0030321441","Chronic lymphocytic leukemia"
"0030321441","Infections"
"0030321441","Intravenous immunoglobulins"
"0030321441","Prophylaxis"
"0031837813","B cell leukaemias"
"0031837813","B lymphocytes"
"0031837813","CD19 and CD 20 antigens"
"0031837813","Quantitative flow cytometry"
"0030800131","B lymphoma"
"0030800131","CD20"
"0030800131","Cytotoxicity"
"0030800131","Sensitization"
"0034575137","Anti-CD20 monoclonal antibody"
"0034575137","Chronic lymphocytic leukemia"
"0034575137","Follicular non-Hodgkin's lymphoma"
"0034575137","Waldenstrom's macroglobulinemia"
"0028987120","allogeneic BMT"
"0028987120","donor lymphocytes"
"0028987120","Tâcell depletion"
"0031022899","Campath-1H"
"0031022899","CD52"
"0031022899","clonal"
"0031022899","monoclonal antibody"
"0031022899","T cells"
"0034066127","Leukaemia"
"0034066127","Lymphoma"
"0034066127","Monoclonal antibodies"
"0034066127","Radioimmunotherapy"
"0032791210","Bcl-2"
"0032791210","CD20 antigen"
"0032791210","Follicular NHL"
"0032791210","Rituximab"
"0034045586","Adhesion molecules"
"0034045586","CellCeptÂ®"
"0034045586","Chronic rejection"
"0034045586","Immunosuppression"
"0034045586","Inosine monophosphate dehydrogenase"
"0034045586","Mycophenolate mofetil"
"0034045586","Mycophenolic acid"
"0034045586","Nitric oxide"
"0032774414","Graft survival"
"0032774414","Mycophenolate mofetil"
"0032774414","Patient survival"
"0032774414","Renal transplantation"
"0032832979","Allogeneic bone marrow transplantation"
"0032832979","Chronic graft-versus-host disease"
"0032832979","Mycophenolate mofetil"
"0032832979","Salvage therapy"
"0032832979","Tacrolimus"
"0034102824","Chronic GVHD"
"0034102824","Mycophenolate mofetil"
"0034102824","Pediatric bone marrow transplantation"
"0032884873","Graft-versus-host disease"
"0032884873","Mismatched marrow transplantation"
"0032884873","Tacrolimus"
"0032105481","Cellular proliferation"
"0032105481","Cyclin- dependent kinases"
"0032105481","Immunosuppression"
"0032105481","mTOR"
"0032105481","Organ transplantation"
"0032105481","p70s6 kinase"
"0032105481","PHAS 1"
"0032105481","Rapamycin"
"0032105481","Signal transduction"
"0032105481","Sirolimus"
"0028869086","Binding proteins"
"0028869086","Immunosuppression"
"0028869086","Mechanism of action"
"0028869086","Rapamycin"
"0028869086","Transplantation"
"0034571546","Graft-versus-host disease"
"0034571546","Rapamycin"
"0034571546","Suppressor cells"
"0034571546","Tolerance"
"10544242968","Engraftment"
"10544242968","Graft rejection"
"10544242968","T cell depletion"
"0032146529","Allogeneic"
"0032146529","Animal models"
"0032146529","Immune tolerance"
"0032146529","T lymphocytes"
"0032146529","Transplantation"
"0032146529","Transplantation immunology"
"0034043418","CD40L"
"0034043418","Platelets"
"0034043418","X-linked hyper IgM syndrome"
"0029065035","Deoxyspergualin"
"0029065035","NKT-01"
"0029065035","Pharmacokinetics"
"0029065035","Phase I study"
"0032989225","Heat shock protein 70"
"0032989225","Immunosuppressant"
"0032989225","Murine graft vs host disease prevention"
"0032989225","Tresperimus"
"0033642532","Antimalarials"
"0033642532","Chronic GVHD"
"0033642532","Graft-versus-host disease"
"0033642532","Hydroxychloroquine"
"0030915659","Allograft"
"0030915659","Antigen-Dependent events"
"0030915659","Antigen-Independent events"
"0030915659","Chronic rejection"
"0030915659","Risk factor"
"0028046109","Keywords: stromal tumour, smooth muscle tumour, CD34, mesenteric fibromatosis"
"0031857113","C-kit"
"0031857113","Leiomyoma"
"0031857113","Schwannoma"
"0031857113","Stomach"
"0032935024","CD117"
"0032935024","CD34"
"0032935024","Electron microscopy"
"0032935024","Gastrointestinal autonomic neural tumor (GANT)"
"0032935024","Gastrointestinal stromal tumor (GIST)"
"0032935024","Interstitial cells of Cajal (ICC)"
"0032935024","Kit"
"0032935024","Leiomyoma"
"0032935024","Leiomyosarcoma"
"0032935024","Muscle-specific actin"
"0032935024","PGP"
"0032935024","Schwannoma"
"0035142836","Gastrointestinal stromal tumors"
"0035142836","GI autonomic nerve tumors"
"0035142836","GI tract"
"0035142836","Smooth muscle actin"
"0035085055","C-kit Gene"
"0035085055","Gastrointestinal stromal tumors"
"0035085055","Gastrointestinal tract"
"0035085055","Interstitial cells of Cajal"
"0035085055","Mutation"
"0035051044","BCR/ABL"
"0035051044","Leukaemia"
"0035051044","Resistance"
"0035051044","STI571"
"0035051044","Therapy"
"0028890359","anal cancer"
"0028890359","colorectal cancer"
"0028890359","esophageal cancer"
"0028890359","gastric cancer"
"0028890359","histology"
"0028890359","incidence"
"0028890359","intestinal cancer"
"0028890359","prognosis"
"0028890359","SEER"
"0028890359","staging"
"0034015511","Classification"
"0034015511","Gastrointestinal stromal tumor"
"0034015511","GIST"
"0034015511","Histogenesis"
"0034015511","Pathogenesis"
"0034015511","Prognosis"
"0034956005","CD117"
"0034956005","KIT"
"0034956005","Sarcoma"
"0034956005","STI-571"
"0034956005","Workshop"
"0032421213","Leiomyoma"
"0032421213","Sarcoma"
"0032421213","Small intestine"
"0032421213","Stomach"
"0032421213","Tumour"
"0032884854","C-kit"
"0032884854","Genetics"
"0032884854","GIST"
"0032884854","Leiomyosarcoma"
"0032884854","Pathology"
"0027163784","Gastrointestinal stromal tumor"
"0027163784","Leiomyosarcoma of intestines"
"0027163784","Stromal intestinal sarcoma"
"0025761860","Immunohistochem istry"
"0025761860","Intestine"
"0025761860","Leiomyoma"
"0025761860","Leiomyosarcoma"
"0025761860","Schwannoma"
"0025761860","Stomach"
"0034933716","CD117"
"0034933716","CD34"
"0034933716","Gastrointestinal autonomic nerve tumor (GANT)"
"0034933716","Gastrointestinal stromal tumor (GIST)"
"0034933716","KIT"
"0034933716","Ultrastructure"
"0036319991","CD117"
"0036319991","GIST"
"0036319991","Immunohistochemistry"
"0036319991","KIT"
"0036319991","Sarcoma"
"0036319991","STI571"
"0026543765","Skeinoid fiber"
"0026543765","Small intestinal stromal tumors"
"0026543765","Ultrastructure"
"0033793213","C-kit"
"0033793213","Gastrointestinal stromal tumor"
"0033793213","Genetics"
"0033793213","Immunohistochemistry"
"0033793213","Leiomyoma"
"0033793213","Leiomyosarcoma"
"0033793213","Pathology"
"0032862462","C-kit"
"0032862462","GIST"
"0032862462","Immunohistochemistry"
"0032862462","Leiomyosarcoma"
"0034109008","Gastrointestinal stromal tumor"
"0034109008","Leiomyosarcoma"
"0034109008","Sarcoma"
"0033779686","CD117"
"0033779686","CD34"
"0033779686","Interstitial cells of Cajal"
"0033779686","Stromal tumor of the gallbladder"
"0032955439","Bowel"
"0032955439","Colon"
"0032955439","Duodennm"
"0032955439","Esophagus"
"0032955439","GIST"
"0032955439","Ileum"
"0032955439","Jejunum"
"0032955439","Leiomyoma"
"0032955439","Leiomyosarcoma"
"0032955439","Mesentery"
"0032955439","Omentum"
"0032955439","Rectum"
"0032955439","Stomach"
"0030995906","GIST"
"0030995906","Jejunum"
"0030995906","Sarcoma"
"0030995906","Small intestine"
"0030995906","Stromal tumor"
"0032796637","Colon"
"0032796637","GIST"
"0032796637","Sarcoma"
"0032796637","Stromal tumor"
"0032798392","Anus"
"0032798392","GIST"
"0032798392","Rectum"
"0032798392","Sarcoma"
"0032798392","Stromal tumor"
"0033974638","C-kit"
"0033974638","Gastrointestinal stromal tumor"
"0033974638","Genetics"
"0033974638","GIST"
"0033974638","Immunhistochemistry"
"0033974638","Leiomyoma"
"0033974638","Leiomyosarcoma"
"0033974638","Pathology"
"0028795581","Electron microscopy"
"0028795581","Gastrointestinal neoplasms"
"0028795581","Immunohistochemistry"
"0028795581","Prognostic factors"
"0028795581","Stromal tumors"
"0034956385","AGC kinase"
"0034956385","Akt"
"0034956385","PI 3-kinase"
"0034956385","PKB"
"0034956385","PKC"
"0034956385","Protein kinase"
"0029804116","Insulin signalling"
"0029804116","Phosphatidylinositol 3-kinase"
"0029804116","Protein kinase B"
"0029804116","Protein phosphorylation"
"0030590875","Akt or RAC kinase"
"0030590875","Insulin"
"0030590875","Kinase specificity"
"0030590875","Kinase substrate"
"0030590875","PI 3-kinase"
"0030590875","Protein kinase B"
"0030590875","S6 kinase"
"0029942186","mitogenic activation"
"0029942186","phosphatase inhibitors"
"0029942186","phosphatidylinositol 3-kinase"
"0029942186","signal transduction"
"0033596127","Apoptosis"
"0033596127","Cancer therapy"
"0033596127","Hepatocyte"
"0033596127","IAPs"
"0033596127","Lymphocytes"
"0033596127","Neurodegenerative diseases"
"0033596127","NF-ÎºB"
"0033596127","Rel"
"0033596127","Transcription factor"
"0033596127","Tumor necrosis factor"
"0031811054","CDC2"
"0031811054","CDK2"
"0031811054","Cell cycle"
"0031811054","CGP 41251"
"0031811054","Protein kinase C"
"0031811054","Radiosensitization"
"0031762618","Bcl-2"
"0031762618","Chemotherapy"
"0031762618","p53"
"0031762618","PKC"
"0034161251","AGC kinase"
"0034161251","AKT"
"0034161251","PDK1"
"0034161251","PIF"
"0034161251","Protein kinase A"
"0035882103","AGC kinase"
"0035882103","Docking sites"
"0035882103","PKC"
"0035882103","Protein kinase"
"0035882103","RSK"
"0033199841","Insulin"
"0033199841","Mass spectrometry"
"0033199841","Protein kinase B"
"0033199841","Signal transduction"
"0035448879","Gamma irradiation"
"0035448879","Glucose tolerance"
"0035448879","Mouse embryo fibroblasts"
"0035448879","Seminiferous tubular atrophy"
"0035448879","Thymocytes"
"0026667730","Chromosome alterations"
"0026667730","Gene amplification"
"0026667730","Src homology 2-like domain"
"0033084143","Lipid binding"
"0033084143","Protein kinase B"
"0033084143","Signal transduction"
"0033084143","Surface plasmon resonance"
"0032533225","Cyclin D1"
"0032533225","Glycogen synthase kinase-3"
"0032533225","Nuclear transport"
"0032533225","Proteolysis"
"0032533225","Ras signaling"
"18844478996","Antiangiogenic in vitro and in vivo"
"18844478996","In vitro antiproliferation"
"18844478996","In vivo antitumor"
"18844478996","Protein kinase C subtypes"
"18844478996","Protein kinase inhibitors"
"18844478996","Vascular endothelial growth factor receptor"
"0242612949","ERK"
"0242612949","Growth factor"
"0242612949","MSK1"
"0242612949","PDK1"
"0242612949","RSK2"
"0033769436","Adipocytes"
"0033769436","Phosphoinositide-dependent protein kinase-1"
"0033769436","Protein kinase B"
"0033769436","Src kinase"
"0033769436","Tyrosine phosphorylation"
"0035896366","Adipose"
"0035896366","Diabetes"
"0035896366","GLUT4"
"0035896366","Glycogen synthase kinase-3"
"0035896366","Insulin"
"0035896366","Muscle"
"0035896366","Phosphoinositide 3-kinase"
"0025882091","homology to protein kinase A and protein kinase C"
"0025882091","MCF-7 and W138 cells"
"0025882091","protein phosphorylation"
"0025882091","signal transduction"
"0034663568","Lipid"
"0034663568","Phosphoinositide"
"0034663568","Phospholipase"
"0034663568","PI 3-kinase"
"0034663568","Recruitment"
"0033599029","Akt"
"0033599029","ErbB4"
"0033599029","Integrin-linked kinase"
"0033599029","Phosphatidylinositol 3-kinase"
"0033599029","Protein kinase B"
"0033599029","Site-directed mutagenesis"
"0034951384","Chronic myelogenous leukemia"
"0034951384","Philadelphia chromosome"
"0034951384","STI571"
"0034951384","Tyrosine kinase"
"0032535490","Osmotic shock"
"0032535490","Phosphorylation"
"0032535490","Protein kinase B"
"0032535490","Protein phosphatase 2A"
"0032535490","Signal transduction"
"0034718540","PDK1"
"0034718540","PI(3)K"
"0034718540","PP2A"
"0035826163","Anticancer drugs"
"0035826163","Apoptosis"
"0035826163","Caspase"
"0035826163","CD95"
"0035826163","Staurosporine"
"0035804215","Colon cancer"
"0035804215","Cyclin D1"
"0035804215","E-cadherin"
"0035804215","GSK-3"
"0034921007","Adhesion"
"0034921007","Anoikis"
"0034921007","Cytoskeleton"
"0034921007","Integrin"
"0034921007","Migration"
"0034921007","Tumor suppressor"
"18244419034","Integrin-linked kinase"
"18244419034","Phosphorylation"
"18244419034","Protein kinase B"
"18244419034","Serine-threonine protein kinase"
"18244419034","Transcriptional activation"
"18244419034","Wnt signaling"
"0035809918","Cell adhesion"
"0035809918","Cytoskeleton"
"0035809918","Drosophila"
"0035809918","Integrins"
"0035809918","Kinase"
"0034735569","Apoptosis"
"0034735569","Cytochrome c"
"0034735569","Mitochondria"
"0034735569","Neuron"
"0034735569","Protein serine-threonine kinase"
"0033774897","Phosphotyrosine"
"0033774897","SH2"
"0033774897","Signal transduction"
"0033774897","Structure-based drug design"
"0033774897","Tyrosine kinase"
"0033774897","Tyrosine phosphatase"
"0034306450","PD 184352"
"0034306450","PD 98059"
"0034306450","Protein phosphorylation"
"0034306450","SB 203580"
"0034306450","U0126"
"0029993339","cancer"
"0029993339","cyclin-dependent kinase"
"0029993339","drug design"
"0029993339","flavopiridol"
"0029993339","protein kinase inhibitors"
"0031028163","Anti-tumor agent"
"0031028163","Cell cycle"
"0031028163","Cyclin-dependent kinase"
"0031028163","Protein-kinase inhibitor"
"0031028163","Purine"
"0035990907","Activity modulation sites"
"0035990907","ATP-binding site"
"0035990907","Drug design"
"0035990907","Induced fit"
"0035990907","Ligand contact surface"
"0035990907","Protein kinase A"
"0029440002","Adenosine triphosphate"
"0029440002","Bioactive conformation"
"0029440002","Dianilinophthalimides"
"0029440002","Docking"
"0029440002","EGF-receptor kinase"
"0034130669","CDK1"
"0034130669","Cyclin-dependent kinase"
"0034130669","Inhibitor"
"0034130669","Olomoucine"
"0034130669","Structure-based design"
"0030484505","Adaptor proteins"
"0030484505","Bcr-Abl"
"0030484505","Chronic myelogenous leukemia"
"0030484505","CrkL"
"0030484505","Grb2"
"0030484505","shc"
"0030484505","Signal transduction"
"0030484505","Tyrosine kinase"
"0034689031","Blast crisis"
"0034689031","Cell death"
"0034689031","CGP 57148"
"0034689031","Interleukin 3"
"0034689031","Promoter"
"0033554061","Anticancer agents"
"0033554061","Cdk4"
"0033554061","Inhibitors"
"0033554061","Novel"
"0033554061","pRb"
"12644284504","Cdk2"
"12644284504","Cdk4"
"12644284504","Cell cycle"
"12644284504","Cyclin D1"
"12644284504","p107"
"12644284504","RB protein"
"0033900827","Anticancer agents"
"0033900827","Cyclin-dependent kinase inhibitors"
"0033900827","Flavopiridol"
"0033900827","UCN-01"
"0034176490","Alzheimer's disease"
"0034176490","Anticancer agents"
"0034176490","Antineurodegenerative agents"
"0034176490","Antiparasitic agents"
"0034176490","Antiviral agents"
"0034176490","Apoptosis"
"0034176490","Cell cycle"
"0034176490","Cyclin-dependent kinase"
"0034176490","Protein kinase inhibitors"
"0035835825","Inducible oncogene"
"0035835825","Mouse models"
"0035835825","Sporadic cancer"
"0035835825","Tumor suppressor"
"0035470983","Bioluminescence"
"0035470983","Fluorescence"
"0035470983","Imaging"
"0035470983","In vivo"
"0035470983","Luciferase"
"0035470983","Luminescence"
"0029090514","cancer"
"0029090514","CDK inhibitor specificity"
"0029090514","drug design"
"0029090514","protein kinase inhibitors"
"0029090514","Xâray crystallography"
"0034722901","Apoptosis"
"0034722901","Cell cycle"
"0034722901","Cyclin D1"
"0034722901","Cyclin-dependent kinases"
"0034722901","Flavopiridol"
"0034722901","Protein kinases"
"0034722901","UCN-01"
"0034674245","Cdk-inhibitors"
"0034674245","Cdk4"
"0034674245","Cell cycle"
"0034674245","Epithelial cells"
"0034674245","G1 arrest"
"0034674245","Growth"
"0034674245","TGF-Î²"
"0034618674","Cdk4"
"0034618674","Cell cycle"
"0034618674","Fascaplysin"
"0034618674","G1 arrest"
"0034618674","Inhibition"
"0034618674","p16"
"0034618674","pRb"
"0034800665","Cdk4"
"0034800665","Cyclin D"
"0034800665","Kinase inhibitors"
"0031731295","ATP-competitive inhibitors"
"0031731295","Epidermal growth factor receptor tyrosine kinase"
"0031731295","Pharmacophore model"
"0031731295","Protein tyrosine kinase inhibitors"
"0031731295","Pyrazolo-pyrimidines"
"0031731295","Pyrido-pyrimidines"
"0031731295","Quinazolines"
"0033026444","ATP competitive inhibitors"
"0033026444","Epidermal growth factor receptor tyrosine kinase"
"0033026444","Pharmacophore model"
"0033026444","Platelet-derived growth factor receptor tyrosine kinase"
"0033026444","Protein tyrosine kinase inhibitors"
"0034788453","ATP-competitive inhibitors"
"0034788453","GlivecTM"
"0034788453","Pharmacophore model"
"0034788453","PKI166"
"0034788453","PTK787"
"0034788453","STI571"
"0034788453","Tyrosine kinase inhibitors"
"0034788453","ZK224584"
"0035899418","C-KIT"
"0035899418","Gastrointestional Stromal Tumors(GIST)"
"0035899418","STI571"
"0032549036","Carcinoma"
"0032549036","Growth factor"
"0032549036","Oncogene"
"0032549036","Receptor"
"0032549036","Signal transduction"
"0032549036","Tyrosine kinase"
"7144227965","Cancer"
"7144227965","Epidermal growth factor receptor"
"7144227965","Signalling"
"7144227965","Tyrosine kinase"
"0034693878","ATM"
"0034693878","Bcr-Abl"
"0034693878","p53"
"0034693878","p73"
"0034693878","Retinoblastoma tumor suppressor"
"0033003074","bcr-abl"
"0033003074","Chronic myeloid leukemia"
"0033003074","Philadelphia translocation"
"0033003074","Signal transduction"
"0030057160","anti proliferative effect"
"0030057160","phenylamino-pyrimidine"
"0030057160","protein kinase C"
"0030057160","signal transduction"
"0026534605","aneurysm surgery"
"0026534605","calcium antagonist"
"0026534605","cerebral vasospasm"
"0026534605","subarachnoid hemorrhage"
"0031877977","AT-877"
"0031877977","Coronary diseases"
"0031877977","Fasudil"
"0031877977","HA 1077"
"0031877977","Protein kinase inhibitors"
"0031877977","Stroke"
"0031877977","Vasospasm"
"0024828113","Interleukin 2"
"0024828113","Platelet"
"0024828113","Protein kinase C"
"0024828113","Selective inhibition"
"0024828113","T cell"
"0031052014","p70 S6 kinase"
"0031052014","PKC"
"0031052014","Protein kinase inhibitor"
"0031052014","Rsk"
"0034607382","Anhydrate"
"0034607382","Bioavailability"
"0034607382","Hydrochloride salt"
"0034607382","LY333531"
"0034607382","Mesylate salt"
"0034607382","Monohydrate"
"0034607382","Pharmaceutical salt form"
"0034607382","Protein kinase C(Î²) inhibitor"
"0034607382","Solubility"
"0028988138","Cytokine"
"0028988138","HSP27"
"0028988138","LPS"
"0028988138","MAP kinase"
"0028988138","Osmotic stress"
"0028988138","Protein kinase inhibitor"
"0032102902","Inflammation"
"0032102902","Protein kinase inhibitors"
"0032102902","SB 203580"
"0032102902","Stress-activated protein kinases"
"0032102902","TGFÎ² receptor"
"0028106163","anilinoquinazoline"
"0028106163","cancer"
"0028106163","enzyme kinetics"
"0028106163","pH-dependence"
"0028106163","structure-based searching"
"0028106163","temperature-dependence"
"0034722893","Anti-angiogenesis"
"0034722893","Anti-tumor"
"0034722893","Tyrosine kinase inhibitors"
"0029166667","cell proliferation"
"0029166667","growth factor"
"0029166667","protein phosphorylation"
"0032901378","CREB"
"0032901378","MAPKAP-K2"
"0032901378","MSK1"
"0032901378","p38"
"0032901378","SAPK2"
"0032901378","SB203580"
"0033200390","Kinase inhibitor"
"0033200390","Modeling"
"0033200390","PP1"
"0033200390","Selective"
"0033200390","Src"
"0031409736","ALL"
"0031409736","Apoptosis"
"0031409736","BCR/ABL"
"0031409736","CML"
"0031409736","Tyrosine kinase inhibitors"
"0033572876","Blastic phase"
"0033572876","Chronic myelogenous leukemia"
"0033572876","Chronic myeloid leukemia"
"0033572876","Decitabine"
"0033572876","Therapy"
"0028059309","ES cells"
"0028059309","Kidney development"
"0028059309","mouse genetics"
"0028059309","PDGF"
"0030808324","Apoptosis"
"0030808324","Cell migration"
"0030808324","Cell proliferation"
"0030808324","Growth factor"
"0030808324","Mouse"
"0030808324","Neural crest"
"0030808324","Patch"
"0030808324","PDGFÎ±R"
"0030808324","Somite"
"0032442642","C-kit"
"0032442642","GIST"
"0032442642","Proto-onkogene"
"0034883994","Anus"
"0034883994","c-kit"
"0034883994","Genetics"
"0034883994","GIST"
"0034883994","Immunohistochemistry"
"0034883994","Leiomyoma"
"0034883994","Leiomyosarcoma"
"0034883994","Pathology"
"0034883994","Rectum"
"0030891486","Gastrointestinal stromal tumor"
"0030891486","Ileum"
"0030891486","Jejunum"
"0033771977","C-kit"
"0033771977","Gastrointestinal stromal tumors"
"0033771977","Genetics"
"0033771977","Immunohistochemistry"
"0033771977","Leiomyoma"
"0033771977","Leiomyosarcoma"
"0033771977","Pathology"
"0034766329","Appendix"
"0034766329","GIST"
"0034766329","Immunohistochemistry"
"0034766329","Leiomyoma"
"0029975817","epithelioid leiomyosarcoma"
"0029975817","gastrointestinal autonomic nerve tumor"
"0029975817","gastrointestinal stromal sarcoma"
"0029975817","Gastrointestinal stromal tumor"
"0029975817","leiomyoblastoma"
"0029975817","leiomyosarcoma"
"0031904592","DNA ploidy"
"0031904592","FNCLCC grade"
"0031904592","Gastrointestinal stromal tumor"
"0031904592","Immunohistochemistry"
"0031904592","Ki- 67"
"0031904592","Prognosis"
"0031904592","Proliferation"
"0034049784","Gastrointestinal stromal tumors"
"0034049784","Immunohistochemistry"
"0034049784","Oncoproteins"
"0034049784","Prognosis"
"0019769391","leiomyoblastoma"
"0019769391","leiomyoma"
"0019769391","leiomyosarcoma"
"0019769391","nuclear DNA content"
"0027281397","Esophagus"
"0027281397","Gastrointestinal tract"
"0027281397","Leiomyoma"
"0027281397","Leiomyosarcoma"
"0027281397","Small bowel"
"0027281397","Stomach"
"0027281397","Stromal tumor"
"0026504486","Flow cytometry"
"0026504486","Gastrointestinal tract"
"0026504486","Leiomyoma"
"0026504486","Leiomyosarcoma"
"0026504486","Stromal neoplasm"
"0027497621","Ag-NOR"
"0027497621","Flow cytometry"
"0027497621","Leiomyoma"
"0027497621","Leiomyosarcoma"
"0027497621","Nucleolar organizer regions"
"0027497621","Ploidy"
"0028344003","Flow cytometry"
"0028344003","Gastrointestinal tract"
"0028344003","Ploidy"
"0028344003","Smooth muscle tumours"
"0028344003","Stromal tumours"
"30344449215","CGH"
"30344449215","GIST"
"30344449215","Mesenchymal tumors of gastrointestinal tract"
"0035171612","Anti-cancer treatment"
"0035171612","Cellular senescence"
"0035171612","Inhibitors"
"0035171612","Oncogenesis"
"0035171612","Telomerase"
"15144348712","Gastrointestinal stromal tumor (GIST)"
"15144348712","Ki-67"
"15144348712","P53"
"15144348712","Telomerase"
"15144348712","Telomere"
"0034993741","Acute myelogenous leukemia"
"0034993741","AML"
"0034993741","c-KIT"
"0034993741","Gastrointestinal stromal tumors"
"0034993741","GIST"
"0034993741","Mastocytosis"
"0034993741","Myelodysplasia"
"0034993741","Sinonasal T-cell lymphoma"
"0033545568","c-kit"
"0033545568","Gastrointestinal tract"
"0033545568","Gene mutation"
"0033545568","Oncogene"
"0033545568","Sarcoma"
"0033372634","C-kit"
"0033372634","GIST"
"0033372634","Mutation"
"0035066051","C-kit proto-oncogene"
"0035066051","Extracellular domain"
"0035066051","Gastrointestinal stromal tumour"
"0035066051","Mutation"
"0034981645","C-kit"
"0034981645","Exons 9 and 13"
"0034981645","GIST"
"0034981645","Mutation"
"0034693799","Human genome"
"0034693799","Mouse"
"0034693799","Non-receptor"
"0034693799","Ortholog"
"0034693799","Receptor"
"0034693799","Tyrosine kinase"
"0031887743","Anticancer agents"
"0031887743","Inhibitors"
"0031887743","Signal transduction"
"0031887743","Tyrosine-specific protein kinases"
"0033786922","Enzyme"
"0033786922","Growth factor receptor"
"0033786922","Signal transduction"
"0033786922","Tyrosine phosphorylation"
"0033786922","X-ray crystallography"
"0034722889","EGF receptor"
"0034722889","ERBB2"
"0034722889","IMC-C225"
"0034722889","Trastuzumab"
"0034722889","ZD 1939"
"0031466305","Cell cycle"
"0031466305","Cyclin"
"0031466305","Kinase structure"
"0031466305","Protein kinase"
"0035000643","Cytokines"
"0035000643","Endotoxin"
"0035000643","p38 MAPK inhibition"
"0035000643","Sepsis"
"0033103867","Anglogenesis"
"0033103867","Kinase insert domain"
"0033103867","Signal transduction"
"0033103867","Tyrosine kinase"
"0033103867","X- ray structure"
"0034962383","3D QSAR"
"0034962383","ACE inhibitor"
"0034962383","Anti-HIV"
"0034962383","Cancer"
"0034962383","Drug design"
"0034962383","Elemene"
"0034962383","PARM"
"0034962383","Pseudoreceptor model"
"0036179603","Metastatic breast cancer"
"0036179603","Monoclonal antibody"
"0036179603","Pharmacodynamics"
"0036179603","Pharmacokinetics"
"0036179603","Therapeutic use"
"0034028576","3D-QSAR"
"0034028576","CoMFA analysis"
"0034028576","Conformational flexibility"
"0034028576","Conformational propensity"
"0034028576","Imidazoleglycerol phosphate dehydratase"
"0033824781","5-HT(1A)"
"0033824781","HASL"
"0033824781","Multiconformer"
"0033824781","Receptor modelling"
"0033824781","Thienopyrimidinone Ligands (TP)"
"0034837053","Autoimmune disease"
"0034837053","Cyclosporin A"
"0034837053","Immunosuppression"
"0034837053","Lck inhibitor"
"0034837053","Src kinase"
"0034837053","T-cell signaling"
"0034837053","Transplantation"
"0034837053","Tyrosine kinase"
"0031881498","Flavonoid derivatives"
"0031881498","Molecular orbital calculations"
"0031881498","p56(lck) protein tyrosine kinase"
"0031881498","QSAR"
"0035036460","Cancer"
"0035036460","CDK inhibitors"
"0035036460","CDK1"
"0035036460","CDK2"
"0035036460","Cell cycle"
"0035036460","Clinical trials"
"0035036460","Molecular modeling"
"0035036460","Physicochemical properties"
"0035036460","Proliferative disorders"
"0035036460","Purine analogs"
"0035036460","QSAR"
"0035036460","SAR"
"0033915678","Comparative molecular field analysis"
"0033915678","Computer methods"
"0033915678","Drug design"
"0033915678","Three-dimensional QSAR"
"0033915678","X-ray crystallography"
"0034663722","All-atom contact analysis"
"0034663722","Explicit hydrogens"
"0034663722","Reversed leucines"
"0034663722","Side-chain rotamer library"
"0034663722","Structure validation"
"0034663722","Van der Waals analysis"
"0036145846","Comparative modeling"
"0036145846","Fold assessment"
"0036145846","Fold assignment"
"0036145846","Large scale protein structure modeling"
"0036145846","Model evaluation"
"0036145846","Statistical potentials"
"0035025191","Database searching"
"0035025191","Flexible docking"
"0035025191","Incremental construction"
"0035025191","Molecular docking"
"0035025191","Virtual screening"
"0036137713","HIV-1"
"0036137713","Peptidomimetic inhibitors"
"0036137713","Protein flexibility"
"0032738842","Drug design"
"0032738842","Flexible docking"
"0032738842","Molecular docking"
"0032738842","Molecular flexibility"
"0032738842","Protein-ligand interaction"
"0032738842","Validation"
"0031552362","Docking problem"
"0031552362","Genetic algorithm"
"0031552362","Molecular recognition"
"0031552362","Protein ligand docking"
"0035409903","Angjogenesis"
"0035409903","Antagonists"
"0035409903","VEGF"
"0034852862","Diacylglycerol"
"0034852862","Endothelial dysfunction"
"0034852862","Insulin resistance"
"0034852862","PKC"
"0034852862","PKC isoenzymes"
"0034852862","PKC-Î²"
"0034852862","Protein kinase C"
"0034852862","Vascular complications"
"0034852862","Vascular permeability"
"0034010742","Alzheimer's disease"
"0034010742","Cyclin-dependent kinases"
"0034010742","Glycogen synthase kinase"
"0034010742","Hymenialdisine"
"0034010742","Tau"
"0034089542","3-D QSAR"
"0034089542","Cyclin-dependent kinase inhibitors"
"0034089542","Paullones"
"0034089542","Protein homology modeling"
"0034089542","Quantum mechanical calculations"
"0034089542","Structure-based drug design"
"0035477020","Cancer"
"0035477020","Diabetes"
"0035477020","Insulin"
"0035477020","Neurodegeneration"
"0035477020","Wnt"
"0034793734","Cancer"
"0034793734","Crystal structure"
"0034793734","Growth-factor receptor"
"0034793734","IGF-1"
"0034793734","Protein tyrosine kinase"
"0033485672","Brain"
"0033485672","DAP-kinase"
"0033485672","Development"
"0033485672","Ischemia"
"0033485672","Neuronal cell death"
"0033869862","Arsenic"
"0033869862","Benzene"
"0033869862","Leucocythaemia"
"0033869862","Philadelphia chromosome"
"0033869862","Weisses Blut"
"0026754768","Cancer"
"0026754768","Immunotherapy"
"0026754768","Monoclonal antibody"
"0026655066","B cells"
"0026655066","CLL"
"0026655066","flow cytometry"
"0026655066","fluorescence"
"0026655066","lymphomas"
"0034517516","B-cell lymphoma"
"0034517516","Campath-1H"
"0034517516","CD20 antigen"
"0034517516","CD52 antigen"
"0034517516","CLL"
"0034517516","IDEC-C2B8"
"0034517516","Monoclonal antibodies"
"0034517516","Rituximab"
"0033996883","Anti CD-20 antibody"
"0033996883","Follicular lymphoma"
"0033996883","Immunotherapy"
"0033996883","Mantle-cell lymphoma"
"0033996883","Rituximab"
"0034809276","B-cell lymphoma"
"0034809276","CD20"
"0034809276","Malignant lymphoma"
"0034809276","Monoclonal antibody therapy"
"0034809276","Rituximab"
"0032421923","B-cell lymphoma"
"0032421923","Immunotoxin"
"0032421923","Monoclonal antibody"
"0032421923","Radioimmunotherapy"
"0021222051","CFU-GM"
"0021222051","leukemia diagnosis"
"0021222051","leukemic colony-forming cells"
"0021222051","Myeloid surface antigen"
"0035078244","Leukemia"
"0035078244","Transcription factor"
"0035078244","Translocation"
"0033611572","Degradation"
"0033611572","Leukaemia"
"0033611572","Nuclear dot"
"0033611572","PML"
"0033611572","t(15;17)"
"0033611572","Translocation"
"0031031003","chronic myeloid leukaemia"
"0031031003","myeloproliferative disorders"
"0031031003","platelet dysfunction"
"0031031003","thrombocytosis"
"0030799255","Chronic myeloid leukaemia"
"0030799255","Marrow transplantation"
"0030799255","Unrelated donor"
"0030707663","BMT"
"0030707663","CML"
"0030707663","Long-term outcome"
"2642680046","Allogeneic"
"2642680046","BMT"
"2642680046","CML"
"2642680046","Interferon"
"0031969517","Î±-interferon"
"0031969517","Allogeneic BMT"
"0031969517","CML in chronic phase"
"0034668122","Allogeneic transplantation"
"0034668122","Chronic myelogenous leukemia"
"0034668122","Chronic myeloid leukemia"
"0034668122","Interferon"
"0034668122","Therapy"
"0034668122","Treatment"
"0023715097","Chronic granulocytic leukemia"
"0023715097","cytarabine"
"0023715097","cytogenetic remission"
"0023715097","cytosine arabinoside"
"0023715097","hydroxyurea"
"0023715097","Philadelphia chromosome"
"0031025930","CML"
"0031025930","Interferon-alpha"
"0031025930","LD ara-C"
"0027159943","Chronic myeloid leukemia"
"0027159943","Cytosine arabinoside"
"0027159943","Interferon"
"0027159943","Philadelphia chromosome"
"0030909701","CpG islands"
"0030909701","DNA methylation"
"0030909701","Leukemia"
"0030909701","Lymphoma"
"0030909701","Tumor-suppressor genes"
"16944363756","Decitabine in CML"
"16944363756","Methylation in CML"
"0031833734","Chronic myelogenous leukemia"
"0031833734","Cytogenetic response"
"0031833734","GM-CSF"
"0031833734","Interferon-alfa"
"0028227405","bcr-abl"
"0028227405","chronic myelogenous leukemia"
"0028227405","tyrosine kinase"
"0034691761","c-Kit and stem cell factor"
"0034691761","Cell motility"
"0034691761","Signal transduction in lung cancer"
"0034691761","Small cell lung cancer"
"0034691761","STI 571"
"0032556921","Apoptosis"
"0032556921","BCR-ABL oncogene"
"0035342499","COL1A1/PDGFB rearrangement"
"0035342499","Dermatofibrosarcoma protuberans"
"0035342499","PDGFB"
"0035342499","PDGFrÎ²"
"0035342499","STI571"
"0035342499","Tumor growth inhibition"
"0029897468","Chronic myeloid leukemia"
"0029897468","Cox stepwise regression model"
"0029897468","Kantarjian's staging system"
"0029897468","Prognostic factors"
"0029897468","Risk-adjusted treatment"
"0029897468","Sokal index"
"0027265468","Busulfan"
"0027265468","CML study"
"0027265468","Hydroxyurea"
"0027265468","Interferon alpha"
"0027265468","Prognostic score"
"0034895104","Chronic myeloid leukemia"
"0034895104","CML"
"0034895104","Interferon Î± and cytarabine"
"0033063104","Bcr-abl peptide"
"0033063104","CML"
"0033063104","Cytotoxic T lymphocytes"
"0033063104","Dendritic cells"
"0033063104","DLT"
"0035094066","bcr-abl"
"0035094066","Dendritic cell"
"0035094066","Peptide"
"0035094066","Vaccine"
"0033910624","Allograft"
"0033910624","Autograft"
"0033910624","Bone marrow transplantation"
"0033910624","Chronic myelogenous leukemia"
"0033910624","Management"
"0033764427","BCR-ABL"
"0033764427","BMT"
"0033764427","CML"
"0033764427","DLI"
"0033764427","PCR"
"0033764427","Relapse"
"0033519238","Abelson virus"
"0033519238","Chronic myelogenous leukemia"
"0033519238","Mouse cancer model"
"0033519238","Retrovital vector"
"2642684541","Embryonic stem cells"
"2642684541","Hemopoiesis"
"2642684541","Knockout"
"2642684541","SHIP"
"2642684541","Signal transduction"
"0031040941","BCR/ABL"
"0031040941","Leukemia"
"0031040941","Mutagenesis"
"0031040941","SH2-SH3 adaptor protein"
"0031040941","Tyrosine-phosphorylation"
"0028985012","BCR/ABL"
"0028985012","GM-CSF"
"0028985012","IL-3"
"0028985012","Vav"
"0033622043","Chronic myelogenous leukemia"
"0033622043","Ras"
"0028875460","Actin"
"0028875460","Cytoskeletal proteins"
"0028875460","p210BCR/AB1"
"0028875460","Tyrosine phosphorylation"
"0030803669","Bcr-Abl"
"0030803669","C-Abl"
"0030803669","Philadelphia chromosome"
"0030803669","SH3 binding protein"
"0030803669","Two-hybrid system"
"0034704917","Akt/PKB"
"0034704917","Crk"
"0034704917","CRKL"
"0034704917","Kinase specificity"
"0034704917","MAPK/Erk"
"0034704917","Ras"
"0029845079","BCR/ABL"
"0029845079","Leukemia"
"0029845079","Signal transduction"
"0030670095","Actin filaments"
"0030670095","ALL CML"
"0030670095","Dbl-homology"
"0030670095","Tyrosine kinase"
"0035810053","Bcr"
"0035810053","Bcr-Abl"
"0035810053","Chronic myelogenous leukemia"
"0033527057","Bcr"
"0033527057","Bcr-Abl"
"0033527057","Bcr-Abl inhibitor"
"0033527057","Tyrosine kinase"
"0032526544","Apoptosis"
"0032526544","Oncogene"
"0032526544","Phosphorylation"
"0032526544","Signal transduction"
"0030873021","Actin"
"0030873021","Cell motility"
"0030873021","Chronic myelogenic leukemia"
"0030873021","Cytoskeleton"
"0030873021","Fibronectin"
"0033959024","Bcr-Abl"
"0033959024","Chronic myelogenous leukemia"
"0033959024","Cytoskeleton"
"0033959024","Phosphatidylinositol kinase"
"0029664864","focal adhesion proteins"
"0029664864","p120(c-Cbl)"
"0029664864","p210(BCR/ABL)"
"0029664864","paxillin"
"0029664864","talin"
"0033521922","Bcr-Abl"
"0033521922","Cbl"
"0033521922","Chronic myelogenous leukemia"
"0033521922","Grb2"
"0033521922","Phosphorylation"
"0033521922","Shc"
"0027536793","C-abl"
"0027536793","Chronic myelogenous leukemia"
"0027536793","Cytoskeleton"
"0027536793","Interleukin-3"
"0027536793","Protein-tsyrosine kinase"
"15444344198","Adhesion"
"15444344198","Chronic myelogenous leukemia"
"15444344198","Integrins"
"15444344198","Intracellular signaling"
"15444344198","p210 tyrosine kinase"
"15444344198","Proliferation"
"0032870298","BCR/ABL"
"0032870298","Chronic myelogenous leukemia"
"0032870298","Cytoskeleton"
"0032870298","Hematopoietic progenitors"
"0032870298","Integrin"
"0030725775","Bcr-Abl"
"0030725775","Cell cycle"
"0030725775","Mitogenesis"
"0030725775","Tyrosine kinase"
"0031105070","BCR/ABL"
"0031105070","Hematopoietic growth factor"
"0031105070","Signal transduction"
"0029796725","BCR/abl"
"0029796725","IL-3"
"0029796725","Phosphorylation"
"0029796725","Stats"
"0029796725","Transformation"
"0027851829","IL-3"
"0027851829","Myeloid cells"
"0027851829","p210 BCR/ABL"
"0027851829","Signal transduction"
"0032953121","abl oncogene"
"0032953121","G-CSF"
"0032953121","Interleukin-3"
"0032953121","Stat"
"0035146443","Cell cycle"
"0035146443","Chronic myelogenous leukemia"
"0035146443","Hematopoietic progenitor cells"
"0035146443","Myeloproliferative disorders"
"0035146443","Protein-tyrosine kinases"
"0032841181","BCR-ABL"
"0032841181","Chronic myeloid leukemia (CML)"
"0032841181","Growth factor independence"
"0032841181","Signal transduction"
"0032546266","Apoptosis"
"0032546266","Bcl-2"
"0032546266","Bcl-X"
"0032546266","Bcr-Abl"
"0032546266","HL-60"
"0032546266","Transformation"
"0032546266","Tyrosine kinase"
"0030471795","Apoptosis"
"0030471795","BCR-ABL"
"0030471795","Ras"
"0030471795","Tyrosine phosphorylation"
"0032518910","Apoptosis"
"0032518910","BCR-ABL"
"0032518910","Ceramide"
"0032518910","CML"
"0032518910","Tyrosine phosphorylation"
"0028861070","apoptosis"
"0028861070","CML"
"0028861070","glucocorticoids"
"0028861070","growth factors"
"0028861070","Xâirradiation"
"0034039177","Apoptosis"
"0034039177","BCR-ABL"
"0034039177","CML"
"0034039177","Differentiation"
"0034039177","UT-7"
"0002223912","BCR/ABL"
"0002223912","Chronic myelogenous leukemia"
"0002223912","Leukemia"
"0002223912","Oncogenes"
"0002223912","Phosphatidyl inositol 3-kinase"
"0002223912","Signal transduction"
"0034837552","Adverse drug reaction"
"0034837552","Leukemia"
"0034837552","Tyrosine kinase inhibitor"
"0029737848","Anti-tumour antibiotics"
"0029737848","Elactocin"
"0029737848","Phase I trials"
"0034051281","BCR-ABL"
"0034051281","CML"
"0034051281","Minimal residual disease"
"0034051281","Quantitative PCR"
"0033061032","Clinical trials"
"0033061032","Drug development"
"0033061032","Proliferative diseases"
"0033061032","Protein tyrosine kinases"
"0033061032","Tyrphostin inhibitors"
"0034565927","Breast cancer"
"0034565927","CI-1033"
"0034565927","Epidermal growth factor"
"0034565927","ErbB receptor"
"0034565927","Radiation therapy"
"0029884715","Breast cancer"
"0029884715","c-erbB-2"
"0029884715","FISH"
"0029884715","Gene amplification"
"0029884715","HER-2/neu"
"0029884715","Interphase cytogenetics"
"0033902055","Allogeneic stem cell transplantation"
"0033902055","Donor leucocyte infusions"
"0033902055","Graft-versus-host disease"
"0033902055","Graft-versus-leukaemia"
"0031669128","Acyclovir-resistant herpes simplex virus infections"
"0031669128","Bone marrow transplantation"
"0031007179","leukemia"
"0031007179","oral manifestations"
"0031007179","retrospective study"
"0034050268","AML"
"0034050268","Calicheamicin immunoconjugate"
"0034050268","CD33"
"0034537334","Chronic myelogenous leukemia"
"0034537334","Differentiation"
"0034537334","Growth factors"
"0034537334","Proliferation"
"0034537334","Stem cells"
"0035038845","Acute promyelocytic leukemia"
"0035038845","Apoptosis"
"0035038845","Arsenic trioxide"
"0033779445","Acute promyelocytic leukemia"
"0033779445","Apoptosis"
"0033779445","Arsenic trioxide"
"0033779445","Caspase 8"
"0034743735","AKT"
"0034743735","AS2O3"
"0034743735","Bcl-xL"
"0034743735","Bcr-Abl"
"0034743735","STI-571"
"0032822709","Chronic myeloid leukemia"
"0032822709","Fluorescence in situ hybridization"
"0032822709","Therapy"
"7144256540","BCR-ABL gene"
"7144256540","CML"
"7144256540","Competitive RT-PCR"
"7144256540","Interphase FISH"
"7144256540","Response to interferon-Î±"
"0035132040","Chronic myelogenous leukemia"
"0035132040","Hematopoietic progenitor cells"
"0035132040","Interferon-Î±"
"0031470510","BCR- ABL"
"0031470510","Competitive RT-PCR"
"0031470510","Donor leucocyte transfusion"
"0031470510","Molecular remission"
"0031470510","Nested RT-PCR"
"10144250938","bcr-abl"
"10144250938","Chronic myelogenous leukemia"
"10144250938","Oncoprotein"
"10144250938","Philadelphia chromosome leukemias"
"10144250938","Western blotting"
"0030827311","BCR-ABL"
"0030827311","Chronic myeloid leukaemia"
"0030827311","Philadelphia chromosome"
"0030874462","BCR-ABL"
"0030874462","Chronic myeloid leukaemia"
"0030874462","Minimal residual disease"
"0030874462","Polymerase chain reaction"
"0030874462","Residual disease"
"0028307601","BCR-ABL mRNA"
"0028307601","bone marrow"
"0028307601","chronic myeloid leukaemia"
"0028307601","PCR"
"0028307601","peripheral blood"
"0031840623","Chronic myeloid leukaemia"
"0031840623","Donor leucocyte infusions"
"0031840623","Minimal residual disease"
"0031840623","Molecular diagnostics"
"0031840623","Real-time quantitation"
"0032748325","BCR- ABL"
"0032748325","Chronic myeloid leukaemia"
"0032748325","Competitive PCR"
"0032748325","Polymorphism"
"0032748325","Real-time quantitative PCR"
"0035672953","Chronic myeloid leukaemia"
"0035672953","Reverse transcription-polymerase chain reaction"
"0035672953","Stem cell transplant"
"0030766684","MAP kinase"
"0030766684","Myc"
"0030766684","P13-K"
"0030766684","Philadelphia chromosome"
"0030766684","Ras"
"0030766684","STAT"
"0030766684","Tyrosine kinase"
"0033954540","Acute lymphoblastic leukemia"
"0033954540","Adult acute leukemias"
"0033954540","Intensive chemotherapy"
"0033954540","Philadelphia chromosome"
"0033954540","Survival"
"0035080416","Chronic myelogenous leukemia"
"0035080416","Combination drug therapy"
"0035080416","Median effect method of Chou and Talalay"
"0035080416","STI571"
"0035080416","Synergism"
"0027955112","antisense"
"0027955112","growth factor receptor"
"0027955112","hematopoiesis"
"0027955112","tyrosine kinase"
"0029126850","cis/trans duplication"
"0029126850","Common ancestor gene"
"0029126850","Exon/intron structure"
"0029126850","Intron insertion"
"0029126850","Phylogenetic trees"
"0029126850","Receptor tyrosine kinase gene"
"0030986854","Digestive organ"
"0030986854","Interstitial cells of Cajal (ICC)"
"0030986854","Morphology"
"0030986854","Pacemaker"
"0030986854","Rat (Ws/Ws)"
"0026039464","Actin reorganization"
"0026039464","Chemotaxis"
"0026039464","Human c-kit product"
"0026039464","Receptor dimerization Tyrosine kinase"
"0026066984","growth factor"
"0026066984","oncogene"
"0026066984","stem cell factor"
"0026066984","tyrosine kinase"
"0033982484","Bone marrow"
"0033982484","C-KIT"
"0033982484","CD117"
"0033982484","Immunohistochemistry"
"0033982484","Mast cell"
"0033982484","Paraffin"
"0031923720","C-kit"
"0031923720","CD 117"
"0031923720","Immunohistochemistry"
"0031923720","Mast cell disease"
"0031923720","Mast cells"
"0029865054","c-kit proto-oncogene"
"0029865054","Growth stimulation"
"0029865054","Spermatogenesis"
"0029865054","Stem-cell factor (SCF)"
"0029865054","Testicular cancer"
"0028828142","c-kit proto-oncogene"
"0028828142","Germ cell tumours"
"0028828142","Seminomas"
"0028207444","carcinomaâinâsitu"
"0028207444","male germ cells"
"0028207444","protoâoncogene câkit"
"0028207444","testicular neoplasms"
"0032914890","C- kit"
"0032914890","Classical seminoma"
"0032914890","DNA ploidy"
"0032914890","Immunohistochemistry"
"0032914890","PLAP"
"0032914890","Spermatocytic seminoma"
"0030039985","Aberrant growth"
"0030039985","Acral lentiginous melanoma"
"0030039985","C-KIT"
"0030039985","Dysplastic naevus"
"0030039985","Keratinocyte-melanocyte network"
"0030039985","Tumour progression"
"0030765407","C-kit"
"0030765407","Melanoma"
"0030765407","Proto-oncogenes"
"0030765407","Tumor progression"
"0034213697","Adenoid cystic carcinoma"
"0034213697","c-kit"
"0034213697","Immunohistochemistry"
"0034213697","Salivary gland neoplasms"
"0032873349","Adenoid cystic carcinoma"
"0032873349","C-kit"
"0032873349","Head and neck"
"0032873349","Salivary gland"
"0029886011","AML"
"0029886011","c-Kit"
"0029886011","SLF"
"0031840621","Acute myeloid leukemia"
"0031840621","c-kit"
"0031840621","Soluble c-kit"
"0034083341","Genetics"
"0034083341","KIT"
"0034083341","Vascular tumors"
"0031854560","Acute lymphoblastic leukemia"
"0031854560","C-kit protooncogene"
"0031854560","Childhood"
"0031854560","Hematopoiesis"
"0031854560","Non-Hodgkin's lymphoma"
"0031854560","Stem cell factor"
"0030013525","Breast cancer"
"0030013525","c-kit proto-oncogene product"
"0030013525","Immunohistochemistry"
"0034001504","Benign prostatic hyperplasia"
"0034001504","c-Kit"
"0034001504","Immunohistochemistry"
"0034001504","Kit ligand"
"0034001504","Prostate neoplasms"
"0031133118","Antisense"
"0031133118","Autocrine"
"0031133118","c-kit"
"0031133118","Oligodeoxynucleotides"
"0031133118","Steel factor"
"0028860224","Auto-stimulation"
"0028860224","c-kit/SLF"
"0028860224","HPV16 transgenic mouse"
"0028860224","Tumorigenesis"
"0030683515","Apoptosis"
"0030683515","C-kit"
"0030683515","Neuroblastoma"
"0030683515","Stem cell factor"
"0032104728","Activating mutation"
"0032104728","C-kit"
"0032104728","Differentiation"
"0032104728","Ligand independence"
"0032104728","Mast- cells"
"0034598363","c-kit"
"0034598363","Heterozygous"
"0034598363","Mast cell"
"0034598363","Neurofibromatosis"
"0034598363","Tumor suppressor"
"0025912874","Cell-cell interaction"
"0025912874","Developmental biology"
"0025912874","Histamine"
"0025912874","Interleukin 3"
"0025912874","W and Sl loci"
"0032401747","c-kit"
"0032401747","Oncogene"
"0032401747","PDGF receptor"
"0032401747","Tyrosine kinase"
"0032401747","WW domain"
"0033557902","Dimerization"
"0033557902","Growth factor receptor"
"0033557902","Mastocytoma"
"0033557902","Pichia pastoris"
"0029907089","Mastocytosis"
"0029907089","Oncogenes"
"0029907089","Signal transduction"
"0029907089","Ubiquitin"
"0026628784","melanocytes"
"0026628784","pigmentation disorders"
"0025940323","oncogene"
"0025940323","pigmentation disorders"
"0025940323","receptor"
"0025940323","tyrosine kinase"
"0025940323","white spotting"
"0034131436","C-KIT"
"0034131436","Mastocytosis"
"0034131436","Stem cell factor"
"0034131436","Tyrosine kinase inhibitor"
"12244277954","Angiogenesis"
"12244277954","Cancer"
"12244277954","Indolinones"
"12244277954","SU5416"
"0032989226","AML"
"0032989226","c-kit"
"0032989226","CSGE"
"0032989226","Mutation"
"0032989226","Oncogene"
"0032456567","HMC-1"
"0032456567","Mast cells"
"0032456567","Stem cell factor"
"0032456567","Urticaria pigmentosa"
"0031039992","c-kit receptor"
"0031039992","mastocytosis"
"0031039992","mutation"
"0032602423","c-kit"
"0032602423","Gastrointestinal stromal tumor"
"0032602423","Immunohistochemistry"
"0032602423","Interstitial cell of Cajal"
"0032602423","Intestinal motility disorder"
"0032602423","Molecular genetics"
"0032981004","c-kit"
"0032981004","CD34"
"0032981004","Desmin"
"0032981004","Gastrointestinal stromal tumours"
"0032981004","Immunohistochemistry"
"0032981004","Ki67"
"0032981004","Statistical analysis"
"0025611985","c-kit"
"0025611985","Gonadal expression"
"0025611985","Mouse embryo"
"0025611985","Oocyte"
"0025611985","Proto-oncogene"
"0025611985","Spermatogonia"
"0025611985","W locus"
"0026355504","Cryptorchidism"
"0026355504","Mouse"
"0026355504","Orchidopexy"
"0026355504","Spermatogenesis"
"0026355504","W mutation"
"0033754885","c-kit"
"0033754885","Fertilization"
"0033754885","Oogenesis"
"0033754885","Spermatogenesis"
"0033754885","Stem cell factor"
"0344131384","C-kit"
"0344131384","Spermatozoa"
"0028784942","Apoptosis"
"0028784942","Kit Ligand"
"0028784942","Mouse"
"0028784942","Spermatogenesis"
"0030451722","Acute leukemia"
"0030451722","flt3"
"0030451722","Mutation"
"0030451722","RT-PCR"
"0032920599","Breast cancer"
"0032920599","HER2/neu"
"0032920599","RT-PCR"
"0032920599","Tumor cell detection"
"0029995607","BCR-ABL"
"0029995607","Chromosomal translocation"
"0029995607","CML"
"0029995607","PCR amplification"
"0035850870","Cancer"
"0035850870","Carcinogen"
"0035850870","Genetic instability"
"0035850870","Selection"
"0035850870","Telomerase"
"0035141317","Chronic myeloid leukemia"
"0035141317","Cytogenetic"
"0035141317","Replication error"
"0035141317","Telomerase"
"0035141317","Telomere"
"0034710536","Akt"
"0034710536","BCR/ABL"
"0034710536","Signaling"
"0034710536","STAT5"
"0034771555","Bcr-Abl"
"0034771555","Chemotherapy"
"0034771555","Cytoprotection"
"0034771555","Gendanamycin"
"0034771555","HSP90"
"0034771555","Oncogenes"
"0034668786","Cell-cycle checkpoint pathway"
"0034668786","Degradation"
"0034668786","DNA damage"
"0034668786","Transcription"
"0034704923","Apoptosis"
"0034704923","mdm2"
"0034704923","Mouse embryo fibroblasts"
"0034704923","Temperature sensitive p53"
"0033996949","Allografting"
"0033996949","Graft-versus-tumor"
"0033996949","Nonmyeloablative regimens"
"0032859309","CML treatment"
"0032859309","Mobilized peripheral blood progenitor cells"
"0032859309","Purging"
"0032859309","Stroma-dependent long-term cultures"
"0032859309","Tyrosine kinase inhibitors"
"0033814350","c-kit"
"0033814350","Gastrointestinal stromal tumor"
"0033814350","Gastrointestinal tract"
"0033814350","Interstitial cells of Cajal"
"0035014278","BCR-ABL"
"0035014278","Chronic myeloid leukaemia"
"0035014278","Philadephia chromosome"
"0035014278","STI571"
"0035014278","Telomere"
"0026348952","Abelson murine leukemia virus"
"0026348952","Bcr/abl"
"0026348952","Hematopoietic stem cell"
"0028147448","Bcr-Abl"
"0028147448","Grb2"
"0028147448","Leukemia"
"0028147448","Ras"
"0028147448","Sos"
"0027998224","AML"
"0027998224","Factor-independent and -dependent myeloid cells"
"0029952614","Bone marrow transplant"
"0029952614","Chronic myelogenous leukemia"
"0029802284","Apoptosis"
"0029802284","BCR-ABL"
"0029802284","cdc2"
"0029802284","Cell cycle"
"0029802284","Leukaemia"
"0029802284","Phosphorylation"
"0035318564","BCR/ABL"
"0035318564","Chronic myelogenous leukemia"
"0035318564","Signal transduction"
"17144463437","ETS family"
"17144463437","Leukemia"
"17144463437","Oligomerization"
"17144463437","TEL"
"17144463437","TEL-PDGFRÎ²"
"0031726412","Bovine papillomavirus E5 protein"
"0031726412","Epstein-Barr virus LMP-1"
"0031726412","Polyomavirus middle T antigen"
"0031726412","Spleen focus-forming virus gp55"
"0031726412","Viral oncogenes"
"0029804549","adenocarcinoma"
"0029804549","platelet-derived growth factor"
"0029804549","prostatic intraepithelial neoplasia"
"0034924333","Aplastic anaemia"
"0034924333","Ex vivo"
"0034924333","Expansion"
"0034924333","Haemopoiesis"
"0034924333","PBSC mobilisation"
"0034924333","Stem cell factor"
"0033625335","Leukemia"
"0033625335","Marrow cytokines"
"0033625335","Serum cytokines"
"0032828882","Cytokines"
"0032828882","Growth factors"
"0032828882","Hematopoiesis"
"0032828882","Signal transduction"
"0032828882","Stem cell factor"
"0034744915","Hematopoiesis"
"0034744915","Kit"
"0034744915","Soluble Receptor"
"0034744915","Stem cell factor"
"0033912922","Bone marrow transplantation"
"0033912922","C-kit"
"0033912922","Fas"
"0033912922","Graft-versus-host disease"
"0033912922","Growth-related oncogene protein-Î±"
"0033912922","Intercellular adhesion molecule- 1"
"0033912922","Tumor necrosis factor"
"0033912922","Tumor necrosis factor-receptor"
"0031472434","Cytokines"
"0031472434","Growth factors"
"0031472434","Hematopoiesis"
"0031472434","Signal transduction"
"0032476674","JNK"
"0032476674","Kit"
"0032476674","Phosphatidylinositol 3'-kinase"
"0032476674","Rac1"
"0032476674","Src kinase"
"0030048429","Hematopoiesis"
"0030048429","Leukemia"
"0030048429","Megakaryocytopoiesis"
"0030048429","Stem cell factor"
"0030465011","AML"
"0030465011","CFU-GM"
"0030465011","Cytosine arabinoside"
"0030465011","rh cytokines"
"0030465011","S phase"
"0345411442","AML"
"0345411442","Haemopoietic growth factor receptors"
"0345411442","Haemopoietic growth factors"
"0345411442","S phase"
"0033866047","Apoptosis"
"0033866047","Bcl-2"
"0033866047","Bcl-x(L)"
"0033866047","CD34+ cells"
"0033866047","Erythropoiesis"
"0033866047","Hematopoiesis"
"0033866047","Human"
"0035160999","Apoptosis"
"0035160999","Erythroid colony-forming cells"
"0035160999","Fas"
"0035160999","Src-family kinase"
"0035160999","Stem cell factor"
"0034633535","Cytokines"
"0034633535","IEL"
"0034633535","Stem cell factor"
"0029930378","c-kit ligand"
"0029930378","CML"
"0029930378","Normal"
"0029930378","P-tyr proteins"
"0033119490","Cell adhesion"
"0033119490","Cell migration"
"0033119490","Dok"
"0033119490","Insulin"
"0035958555","c-Kit mutation"
"0035958555","STAT3"
"0035958555","Tumorigenicity"
"0033855893","Limiting dilution analysis"
"0033855893","Mobilization"
"0033855893","Pre-CFU assay"
"0033855893","Stem cell factor"
"0033941761","Acute myeloid leukemia"
"0033941761","Cytokines"
"0033941761","Dendritic cells"
"0033941761","Differentiation"
"0034041375","Acute myeloid leukemia"
"0034041375","Costimulatory and adhesion molecules"
"0034041375","Cytokines"
"0034041375","Dendritic cells"
"0034041375","Flow cytometry"
"0343091453","Acute leukemia"
"0343091453","Chromosomal aberrations"
"0343091453","Dendritic cells"
"0343091453","Immunotherapy"
"0032577051","Phosphorylation"
"0032577051","Protein-tyrosine kinase, protein kinase, signal transduction"
"0032577051","Protein-tyrosine phosphatase"
"0033824668","ALCL"
"0033824668","ALK"
"0033824668","Cell lines"
"0033824668","Hodgkin"
"0033824668","NHL"
"0033824668","NPM"
"0033082959","Angiogenesis"
"0033082959","Eph"
"0033082959","Ephrins"
"0033082959","Receptor tyrosine kinase"
"0033082959","Vasculogenesis"
"0032774475","Achondroplasia"
"0032774475","Antley-Bixtley syndrome"
"0032774475","Apert syndrome"
"0032774475","Beare-Stevenson syndrome"
"0032774475","Craniosynostosis"
"0032774475","Crouzon syndrome"
"0032774475","FGFR1"
"0032774475","FGFR2"
"0032774475","FGFR3"
"0032774475","Hypochondroplasia"
"0032774475","Jackson- Weiss syndrome"
"0032774475","Pfeiffer syndrome"
"0032774475","Platyspon dylic lethal skeletal dysplasia"
"0032774475","Saethre-Chotzen syndrome"
"0032774475","Thanatophoric dysplasia"
"0034641890","Gastric cancer"
"0034641890","Germ line"
"0034641890","Juxtamembrane Met mutation"
"0031704545","Bone neoplasms"
"0031704545","Insulin-like growth factor"
"0031704545","Insulin-like growth factor receptor"
"0031704545","Osteosarcoma"
"0031704545","Sarcoma"
"0027359443","activation"
"0027359443","leukemia"
"0027359443","point mutation"
"0027359443","protooncogene c-kit"
"0027359443","tyrosine kinase"
"0032504757","Angiogenesis"
"0032504757","Angiopoietin"
"0032504757","Collateral vessel"
"0032504757","Endothelium"
"0032504757","Tie2"
"0025192786","Malignancy"
"0025192786","Oncogene"
"0025192786","Phosphorylation"
"0025192786","Polyps"
"0030962953","Breast cancer"
"0030962953","Gene amplification"
"0030962953","Protein kinase"
"0032100685","20q13 amplicon"
"0032100685","Centrosome"
"0032100685","Colon cancer"
"0032100685","Oncogene"
"0032100685","Serine-threonine kinase"
"0032587480","cAMP"
"0032587480","Ovarian cancer"
"0032587480","Reverse transcription polymerase chain reaction"
"0032587480","Type I-cAMP-dependent protein kinase"
"0034254157","Breast cancer"
"0034254157","Colon cancer"
"0034254157","Growth factor receptors"
"0034254157","Lung cancer"
"0034254157","Monoclonal antibody therapy"
"0034254157","Review"
"0030945060","Axl"
"0030945060","Malignant transformation"
"0030945060","Myeloid leukemia"
"0030945060","Receptor tyrosine kinase"
"0032820867","AML"
"0032820867","Axl/UFO"
"0032820867","Oncogenes"
"0032820867","Prognosis"
"0032820867","Receptor tyrosine kinase"
"0026500682","ELK-like receptor tyrosine kinase"
"0026500682","human EPH"
"0033729031","Multiple endocrine neoplasia type 2"
"0033729031","Receptor tyrosine kinase"
"0033729031","RET"
"0032078876","Breast cancer"
"0032078876","ERBB2"
"0032078876","Prognostic value"
"0032078876","Response to treatment"
"0034047441","Apoptosis"
"0034047441","FDC-P1"
"0034047441","Gas6"
"0034047441","Growth factors"
"0034047441","Tyrosine kinase"
"0034000699","Angiogenesis"
"0034000699","Tyrosine kinase inhibitors"
"0034000699","Tyrosine kinase receptors"
"0034000699","Vascular endothelial growth factor (VEGF)"
"0034235955","5- fluorouracil"
"0034235955","Epidermal growth factor receptor"
"0034235955","Monoclonal antibody"
"0034235955","Pancreatic carcinoma"
"0034235955","Xenografts"
"0033646291","Cancer"
"0033646291","Cyclin-dependent kinase"
"0033646291","Flavopiridol"
"0033646291","Inhibitor"
"0033407483","Bryostatin-1"
"0033407483","Metastatic melanoma"
"0033407483","Pharmacology"
"0033407483","Platelet activation"
"0028018343","BCR-ABL"
"0028018343","Chronic myelogenous leukemia"
"0028018343","Interferon"
"0028018343","Philadelphia chromosome"
"0028018343","Polymerase chain reaction"
"0034034921","Chimerism"
"0034034921","Engraftment"
"0034034921","GVL"
"0034034921","Low intensity conditioning"
"0031869466","Apoptosis"
"0031869466","BCR-ABL"
"0031869466","CML"
"0031869466","K562"
"0031869466","KYO-1"
"0032531929","Angiogenesis"
"0032531929","Fibroblast growth factor"
"0032531929","Tyrosine kinase inhibitor"
"0032531929","Vascular endothelial growth factor"
"0032531929","X-ray crystallography"
"0029148806","Acute lymphoblastic leukemia"
"0029148806","Adults"
"0029148806","Clinical studies"
"0029148806","Genetics"
"0029148806","Molecular"
"0030014886","CML"
"0030014886","Cytogenetics"
"0030014886","IFN-Î±"
"0030014886","Randomized trial"
"0030014886","Therapy"
"0027968212","Bone marrow transplantation"
"0027968212","Busulfan"
"0027968212","Chronic myeloid leukemia"
"0027968212","Hydroxyurea"
"0027968212","Interferon"
"18844403641","ara-G"
"18844403641","ara-GTP"
"18844403641","Leukemia"
"18844403641","Nelarabine"
"18844403641","Purine nucleoside analog"
"29244436105","Acute lymphoblastic leukaemia"
"29244436105","Acute myeloid leukaemia"
"29244436105","Clofarabine"
"0031978626","Lymphoblastic leukaemia"
"0031978626","Prognosis"
"0031978626","Treatment"
"0027202081","Arabinosyl-2-fluoradenine"
"0027202081","Cellular pharmacology"
"0027202081","Chronic lymphocytic leukemia"
"0027202081","Fludarabine"
"0036273331","Chlorambucil"
"0036273331","Cladribine"
"0036273331","Fludarabine"
"0036273331","Nucleoside analogues"
"4043137442","8-chloroadenosine"
"4043137442","BCX-1777"
"4043137442","Cancer"
"4043137442","Clofarabine"
"4043137442","Gene therapy of cancer"
"4043137442","Nelarabine"
"4043137442","Purine nucleoside"
"0036125593","2CdA"
"0036125593","AIHA"
"0036125593","CAP"
"0036125593","Chlorambucil"
"0036125593","CHOP"
"0036125593","Cladribine"
"0036125593","CLL"
"0036125593","Fludarabine"
"0036125593","PRCA"
"0036125593","Prednisone"
"0036125593","Randomized trials"
"23844481419","Cladribine"
"23844481419","Clofarabine"
"23844481419","Fludarabine"
"23844481419","Immucillin H"
"23844481419","Leukemia"
"23844481419","Lymphoma"
"23844481419","Nelarabine"
"23844481419","Pentostatin"
"18044390106","Acute leukemias"
"18044390106","Clofarabine"
"18044390106","Nucleoside analogs"
"18044390106","Solid tumors"
"6044234877","Clofarabine"
"6044234877","CNDAC"
"6044234877","Decitabine"
"6044234877","ECyD"
"6044234877","Leukemia"
"6044234877","Nelarabine"
"6044234877","Nucleoside analogs"
"6044234877","Tezacitabine"
"6044234877","Troxacitabine"
"0026533461","Chemotherapy"
"0026533461","Immunosuppression"
"0026533461","Scid mice"
"0032917771","Antimetabolite"
"0032917771","Antitumor activity"
"0032917771","Colon"
"0032917771","Oral administration"
"0032917771","Schedule"
"10344238593","AML"
"10344238593","Chloro-fluoro-ara-A"
"10344238593","Clofarabine"
"10344238593","Leukemia"
"10344238593","Nucleoside analog"
"10344238593","Pharmacology"
"0033858066","Deoxyguanosine kinase"
"0033858066","Immunofluorescence"
"0033858066","Mitochondria"
"0033858066","Submitochondrial fractionation"
"0141788217","Drug design"
"0141788217","Immucillin-H"
"0141788217","PNP"
"0141788217","Structure"
"0141788217","Synchrotron radiation"
"0031688282","Catalysis"
"0031688282","Enzymes"
"0031688282","Inhibitor"
"0031688282","Inhibitor design"
"0031688282","Isotope effects"
"0037390138","2â²-Deoxyguanosine"
"0037390138","Activated T-cell inhibition"
"0037390138","dGTP"
"0037390138","Inosine"
"0037390138","Pharmacodynamics"
"0037390138","Pharmacokinetics"
"0037390138","PNP inhibition"
"0037390138","Purine nucleoside phosphorylase"
"0038730672","Apoptosis"
"0038730672","dNTP levels"
"0038730672","T-ALL"
"0035026893","Graft vs. host disease"
"0035026893","Immunomodulators"
"0035026893","In vivo animal models"
"0035026893","T Lymphocytes"
"0030273182","BCX-34"
"0030273182","deoxyguanosine triphosphate"
"0030273182","guanosine triphosphate"
"0030273182","peldesine"
"0030273182","purine nucleoside phosphorylase"
"0030273182","T-cell proliferation"
"0033828402","Allografting"
"0033828402","CML"
"0033828402","IFN"
"0033828402","STI571"
"0033828402","Survival"
"0029348008","Abl"
"0029348008","Bcr-abl"
"0029348008","Chronic myelogenous leukemia (CML)"
"0029348008","Philadelphia chromosome"
"0029348008","Tyrosine kinase"
"0029879676","Abelson murine leukemia virus"
"0029879676","p53"
"0029879676","Retinoblastoma protein"
"0029879676","Tyrosine kinase"
"0027361837","c-Abl"
"0027361837","c-Src"
"0027361837","Nuclear tyrosine kinase"
"0028243505","c-Abl"
"0028243505","c-Crk"
"0028243505","Phosphorylation"
"0028243505","Tyrosine kinase"
"0030459950","cell cycle"
"0030459950","confocal microscopy"
"0030459950","fibronectin"
"0030459950","signal transduction"
"0029589929","chronic myelogenous leukemia"
"0029589929","mitogen-activated protein kinase"
"0030710188","ABL"
"0030710188","Activation"
"0030710188","Akt"
"0030710188","BCR"
"0030710188","Leukemogenesis"
"0030710188","PI-3k"
"0026458235","protein tyrosine kinase"
"0026458235","PTK blockers"
"0031752846","BCR/ABL"
"0031752846","Chronic myelogenous leukemia"
"0031752846","Hematopoiesis"
"0031752846","Integrins"
"0031752846","Tyrosine kinase"
"0028282865","Cell cycle"
"0028282865","Differentiation"
"0028282865","Genistein"
"0028282865","Herbimycin A"
"0028282865","K-562 cells"
"0028282865","Surface antigens"
"0025876682","Atherosclerosis"
"0025876682","c-fos mRNA"
"0025876682","Mitogenesis"
"0025876682","Platelet-derived growth factor receptor"
"0025876682","Protein-tyrosine kinase"
"0034018326","CML"
"0034018326","Interferon-Î±"
"0034018326","Progenitor amplification"
"0034018326","STI571"
"0025738186","growth factors"
"0025738186","hematopoiesis"
"0025738186","stem cells"
"0029083832","Angiogenesis"
"0029083832","Interleukin-1Î±"
"0029083832","Prostaglandin E2"
"0029083832","Rheumatoid arthritis"
"0029083832","Vascular endothelial growth factor"
"0028788710","angiogenesis"
"0028788710","human tumor xenografts"
"0028788710","renal cell carcinoma"
"0028788710","vascularization"
"0028788710","VEGF"
"0028788710","VPF"
"30944440262","Angiogenesis"
"30944440262","Cell survival"
"30944440262","Chemotherapy"
"30944440262","Hypoxia"
"30944440262","Tumour angiogenesis"
"30944440262","VEGF"
"3543002277","Angiogenesis"
"3543002277","Fibrosarcoma"
"3543002277","PDGF"
"3543002277","Stroma"
"3543002277","VEGF"
"0035895762","Angiotensin"
"0035895762","Blood flow"
"0035895762","Capillaries"
"0035895762","Electron microscopy"
"0035895762","Extracellular matrix"
"0035895762","Remodeling"
"0037280306","Angiogenesis"
"0037280306","Hematopoiesis"
"0037280306","Internal/external autocrine loop"
"6444223700","Angiogenesis"
"6444223700","Collateral circulation"
"6444223700","Genetics"
"6444223700","Ischemia"
"6444223700","Perfusion"
"32944474182","Electron microscopy"
"32944474182","Endothelial fenestration"
"32944474182","Immunohistochemistry"
"32944474182","Vascular endothelial growth factor inhibitors"
"0035053713","Adhesion"
"0035053713","Angiogenesis"
"0035053713","Embryos"
"0035053713","Transcription factors"
"0035053713","Tumours"
"33646417088","Angiogenesis"
"33646417088","Anti-angiogenic therapy"
"33646417088","Endothelial cell"
"33646417088","Fab fragment"
"33646417088","Human antibody"
"33646417088","VEGF"
"33646417088","VEGFR2/KDR"
"0032907687","Angiogenesis"
"0032907687","Cytokine"
"0032907687","Heparan-sulfate proteoglycan"
"0032907687","Hypoxia"
"0032907687","Oncogene"
"2542631833","Angiogenesis"
"2542631833","Bone development"
"2542631833","Chondrocyte survival"
"2542631833","Conditional knockout mice"
"2542631833","HIF1"
"2542631833","HIF1Î±"
"2542631833","VEGF"
"2542631833","VEGFA"
"33747058998","Cancer research"
"33747058998","Genome research"
"33747058998","Individualized therapy"
"33747058998","Molecular therapy"
"30644460519","Abscess, kidney"
"30644460519","Kidney inflammation"
"30644460519","Pyonephrosis, calculous"
"30644460519","Renal cell carcinoma, sarcomatous"
"24644519463","Diagnosis"
"24644519463","EAU guidelines"
"24644519463","Follow-up"
"24644519463","Prostate cancer"
"24644519463","Review"
"24644519463","Treatment"
"33746423135","Angiogenesis inhibitors"
"33746423135","Endothelial receptor antagonists"
"33746423135","Gene therapy"
"33746423135","Vaccines"
"3943104783","Cancer"
"3943104783","HER-2 receptor"
"3943104783","Prostate"
"3943104783","Trastuzumab"
"33748576904","Biochemical relapse"
"33748576904","Imatinib mesylate"
"33748576904","Prostate cancer"
"33644864408","Germ cell tumor"
"33644864408","Imatinib"
"33644864408","KIT"
"33746757599","Imatinib"
"33746757599","Leydig cell tumor"
"33746757599","Metastases"
"33746757599","Positron emission tomography"
"33746757599","Testicular cancer"
"33645971968","Antimitotic agents"
"33645971968","Chemotherapy"
"33645971968","COX-2"
"33645971968","Curcumin"
"33645971968","MMP-9 deficient mice"
"33645971968","VEGF isoforms"
"20844461824","Arteriosclerosis"
"20844461824","Gene therapy"
"20844461824","Growth substances"
"20844461824","Inflammation"
"20844461824","Remodeling"
"33748541956","Bcr-Abl"
"33748541956","Imatinib mesylate"
"33748541956","Kinase"
"33748541956","Leukemia"
"33748541956","Philadelphia chromosome"
"33748912840","Angiogenesis"
"33748912840","Renal cell cancer"
"33748912840","Sorafenib"
"33748912840","Tyrosine kinase inhibitors"
"33748912840","Vascular endothelial growth factor"
"33646204716","BAY 43-9006"
"33646204716","Doxorubicin"
"33646204716","Phase I"
"33646204716","Raf kinase"
"33646204716","Sorafenib"
"33748325763","Advanced melanoma"
"33748325763","Multikinase inhibitor"
"33748325763","Randomised discontinuation trial"
"33748325763","Sorafenib"
"33748325763","V600E BRAF"
"7944237784","Mitogenesis"
"7944237784","Phosphotyrosine"
"7944237784","Src"
"7944237784","Survival"
"7944237784","Ubiquitination"
"20444473802","Antiangiogenesis"
"20444473802","Colorectal"
"20444473802","Tyrosine kinase inhibitor"
"20444473802","Vascular endothelial growth factor"
"20444473802","Vatalanib"
"30944446883","Anti-vascular endothelial growth factor (anti-VEGF)"
"30944446883","Antiangiogenic"
"30944446883","Bevacizumab"
"30944446883","Multitargeted"
"30944446883","Normalization"
"20044372721","CISH"
"20044372721","Gastric carcinoma"
"20044372721","HER-2"
"20044372721","Lauren's classification"
"20044372721","Trastuzumab"
"0037714334","Î²-catenin"
"0037714334","c-erbB-2"
"0037714334","E-cadherin"
"0037714334","Gastric cancer"
"0037714334","Liver metastasis"
"33745293286","Bevacizumab"
"33745293286","Cetuximab"
"33745293286","EGFR"
"33745293286","Erlotinib"
"33745293286","Gastric carcinoma"
"33745293286","Gefitinib"
"33745293286","Imatinib"
"33745293286","Trastuzumab"
"33646746413","Estrogen receptor"
"33646746413","Lapatinib"
"33646746413","Resistance"
"33746196584","EGFR kinase inhibitors"
"33746196584","ErbB-1 tyrosine kinase inhibitors"
"33746196584","ErbB-2 tyrosine kinase inhibitors"
"33746196584","Lapatinib"
"33746196584","Quinazoline"
"33645873707","Angiogenesis"
"33645873707","EGFR"
"33645873707","Gefitinib"
"33645873707","Lung metastasis"
"33645873707","VEGFR"
"33748490710","Chemo-resistance"
"33748490710","Colon cancer"
"33748490710","Gefitinib"
"33748490710","Tyrosine kinase"
"33748490710","ZD6474"
"33750453810","Angiogenesis"
"33750453810","EGF"
"33750453810","EGF-R"
"33750453810","Thyroid cancer"
"33750453810","Tyrosine kinase inhibitor"
"33750453810","VEGF"
"33750453810","VEGF-R"
"33748169241","Cholangiocarcinoma"
"33748169241","Erlotinib"
"33748169241","Gefitinib"
"33748169241","NVP-AEE788"
"33748169241","Tyrosine kinase inhibitor"
"33745114173","AMN107"
"33745114173","BCR-ABL"
"33745114173","Dasatinib"
"33745114173","Imatinib-resistance"
"33745114173","Nilotinib"
"33646516407","AMN107"
"33646516407","Cellular kinetics"
"33646516407","Gastrointestinal stromal tumor"
"33646516407","Imatinib mesylate"
"33748114504","AMN107"
"33748114504","c-Kit kinase inhibitor"
"33748114504","Imatinib"
"33748114504","Mastocytosis"
"0034936404","AML"
"0034936404","FLT3"
"0034936404","Oncogene"
"0034936404","Prognosis"
"21844455259","Akt"
"21844455259","Multiple myeloma"
"21844455259","N-Benzoylstraurosporine"
"22844452590","EGFR"
"22844452590","ErB"
"22844452590","GSK"
"22844452590","Kinase inhibitor"
"22844452590","VEGFR"
"33747372852","Benzamides"
"33747372852","Benzamidines"
"33747372852","Inhibitor"
"33747372852","VEGFR tyrosine kinases"
"33747372852","VEGFR-1"
"33747372852","VEGFR-2"
"23644434089","Angiogenesis"
"23644434089","Drug discovery"
"23644434089","Kinase inhibitor"
"23644434089","VEGFR"
"32044458645","2-((1H-Azol-1-yl)methyl)-N-arylbenzyl amides"
"32044458645","Angiogenesis"
"32044458645","Dual kinase inhibitor"
"32044458645","Receptor tyrosine kinase"
"32044458645","Vascular endothelial growth factor receptor 2"
"32044445020","Angiogenesis"
"32044445020","Kinase inhibitor"
"32044445020","Phthalazine"
"32044445020","Vascular endothelial growth factor"
"3843140692","Isoindolinone"
"3843140692","KDR kinase"
"3843140692","Urea"
"3843140692","VEGF"
"0036242810","Angiogenesis"
"0036242810","Kinase inhibitor"
"0036242810","Platelet-derived growth factor"
"0036242810","VEGF"
"33644873854","A-431"
"33644873854","Angiogenesis"
"33644873854","Squamous cell carcinoma"
"33644873854","SU6668"
"33644873854","Xenograft model"
"30544448281","Phase I"
"30544448281","SU006668"
"30544448281","Trial"
"30544448281","Tyrosine kinase inhibitor"
"30544448281","VEGF"
"19444363120","Angiogenesis"
"19444363120","Chalcone"
"19444363120","Curcumin"
"19444363120","Enone"
"20244386849","Carcinoma, renal cell"
"20244386849","Kidney"
"20244386849","Kidney neoplasms"
"20244386849","Proteins"
"20244386849","Tumor markers, biological"
"0029655348","Carcinoma, renal cell"
"0029655348","Fluorouracil"
"0029655348","Interferon-Î±"
"0029655348","Interleukin-2"
"0029655348","Risk factors"
"18844386435","Histologic features"
"18844386435","IL-2"
"18844386435","Renal cancer"
"0036739439","Interferon"
"0036739439","Interleukin-2"
"0036739439","Metastatic renal carcinoma"
"0036739439","Prognostic factor"
"0036739439","Rapid progression"
"0036739439","Survival"
"33748976883","Angiogenesis"
"33748976883","Cancer treatment"
"33748976883","Contrast medium"
"33748976883","Doppler studies"
"33748976883","RCC"
"33748976883","Sorafenib"
"33748976883","Ultrasound (US)"
"33847288165","Chemotherapy"
"33847288165","Endocrine therapy"
"33847288165","Medical treatment"
"33847288165","Metastatic breast cancer"
"33847288165","Targeted therapy"
"0042208398","FISH"
"0042208398","IHC"
"0042208398","Prognosis"
"0042208398","Review"
"0042208398","Trastuzumab"
"0344924865","Anthracyclines"
"0344924865","Apoptosis"
"0344924865","Cardiac myocyte"
"0344924865","Neuregulin"
"0344924865","PI3-kinase, Akt, erbB2, erbB4"
"33646712747","Breast"
"33646712747","IGF-1R"
"33646712747","P27Klp1"
"33646712747","PTEN"
"33646712747","Trastuzumab"
"0032885461","Antibody-dependent cellular cytotoxicity"
"0032885461","Breast cancer"
"0032885461","Immunotherapy"
"0032885461","Interleukin 2"
"0032885461","Natural killer cell"
"0034873273","4D5 antibody"
"0034873273","Cell cycle"
"0034873273","HER2 overexpression"
"0034873273","Herceptin"
"0034873273","p27"
"0034873273","Trastuzumab"
"0032578797","Breast cancer"
"0032578797","Cisplatin"
"0032578797","Doxorubicin"
"0032578797","HER-2/neu"
"0032578797","Monoclonal antibody"
"0032578797","Ovarian cancer"
"0041696794","Cardiac toxicity"
"0041696794","Combination chemotherapy"
"0041696794","HER2"
"0041696794","Taxanes"
"0041696794","Vinorelbine"
"1642616755","Cleavage"
"1642616755","Proteases"
"1642616755","Signalling"
"0038010542","Central nervous system (CNS) metastases"
"0038010542","HER-2/neu"
"0038010542","Metastatic breast carcinoma"
"0038010542","Trastuzumab"
"1642473187","Brain"
"1642473187","Breast cancer"
"1642473187","Metastases"
"1642473187","Trastuzumab"
"4344691784","Brain metastases"
"4344691784","Breast cancer"
"4344691784","Trastuzumab"
"33748870773","Advanced breast cancer"
"33748870773","Brain metastases"
"33748870773","Systemic palliative treatment"
"33748870773","Whole brain radiotherapy"
"2942621888","Bevacizumab"
"2942621888","Breast cancer"
"2942621888","Monoclonal antibodies"
"2942621888","Vascular endothelial growth factor"
"0029870563","erbB-2"
"0029870563","neu"
"0029870563","Oncoprotein"
"0029870563","Preclinical"
"0029870563","Therapy"
"4344674482","17-Allylamino-17-demethoxygeldanamycin"
"4344674482","AKT"
"4344674482","Her-2"
"4344674482","Hsp90"
"4344674482","Raf"
"0034691674","Cell"
"0034691674","ErbB receptors"
"0034691674","Heregulin Î²1"
"0034691674","HUVEC"
"0034691674","Proliferation"
"0034691674","VEGF"
"2942682933","Angiogenesis"
"2942682933","Kidney"
"2942682933","Lung"
"2942682933","Oligodendrocyte"
"2942682933","Paracrine"
"2942682933","PDGF, Development"
"2942682933","Retina"
"0036793520","Growth factors"
"0036793520","Neovascularization"
"0036793520","Vascular smooth muscle cells"
"0036793520","VEGF"
"0035425048","Glial differentiation"
"0035425048","INK4a-ARF"
"0035425048","Oligodendroglioma"
"0035425048","PDGF"
"27144473338","Akt"
"27144473338","EGF"
"27144473338","Metastasis"
"27144473338","PDGF"
"27144473338","Prostate cancer"
"26444621412","Efficacy"
"26444621412","Glioblastoma multiforme"
"26444621412","Hydroxyurea"
"26444621412","Imatinib"
"26444621412","PDGFRs"
"26444621412","Safety"
"0037075815","Dephosphorylation"
"0037075815","Heterodimer"
"0037075815","Platelet-derived growth factor"
"0037075815","Receptor tyrosine kinase"
"0037075815","SHP-2"
"18544366585","CrexP system"
"18544366585","Diabetes"
"18544366585","Pericytes"
"18544366585","Platelet-derived growth factor"
"18544366585","Retinopathy"
"0026583942","Chemotaxis"
"0026583942","Cytoskeleton"
"0026583942","PDGF receptor"
"0026583942","Signal transduction"
"6344236867","Activation"
"6344236867","CUB"
"6344236867","PDGF"
"6344236867","Proteolysis"
"6344236867","tPA"
"0034729527","Gene targeting"
"0034729527","Leydig cell"
"0034729527","PDGF-A"
"0034729527","Spermatogenesis"
"0034729527","Testis"
"33745107179","Epithelial to mesenchymal transition"
"33745107179","Expression profiling"
"33745107179","Hepatocytes"
"33745107179","PDGF"
"0032505090","Dermatofibrosarcoma"
"0032505090","Gene rearrangement"
"0032505090","PDGFB gene"
"0032505090","Transformation"
"33746919951","CXCL12"
"33746919951","Glioblastoma multiforme"
"33746919951","Imatinib"
"33746919951","Microarray"
"33746919951","PDGF receptor"
"0028812442","fusion proteins"
"0028812442","platelet-derived growth factor receptor"
"0028812442","suramin"
"0032547385","Antagonist"
"0032547385","Cell growth"
"0032547385","Cell migration"
"0032547385","Cell transformation"
"0032547385","Kinase"
"0032547385","Platelet-derived growth factor"
"0032547385","Receptor"
"0032547385","Signal transduction"
"0035291243","Angiogenesis"
"0035291243","Blood flow"
"0035291243","Cancer detection and treatment"
"0035291243","Cell adhesion and deformation"
"0035291243","Diffusion and convection"
"0035291243","Interstitial pressure"
"0035291243","Lymphatics"
"0035291243","Receptor-ligand binding"
"0035291243","Tumor microcirculation"
"0035291243","Vascular permeability"
"12144261476","Imatinib"
"12144261476","PDGFRA"
"12144261476","PDGFRB"
"0033832891","Bone morphogenetic protein"
"0033832891","Development"
"0033832891","Epithelial-mesenchymal interaction"
"0033832891","Intestinal villus"
"0033832891","Platelet-derived growth factor"
"20044363847","Migration"
"20044363847","Platelet-derived growth factor receptor"
"20044363847","Proliferation"
"20044363847","Urokinase receptor"
"20044363847","Vascular smooth muscle cells"
"0027936261","anemia"
"0027936261","cardiac dilation"
"0027936261","erythroblastosis"
"0027936261","gene knockout"
"0027936261","glomerulus development"
"0027936261","mesangial cells"
"0027936261","PDGF"
"0027936261","thrombocytopenia"
"0037380709","Mesenchymal origin"
"0037380709","Pathophysiological process"
"0037380709","PDGF"
"33645296886","Î±V integrins"
"33645296886","Anaphylaxis"
"33645296886","Collagen gel contraction"
"33645296886","Edema"
"33645296886","Fluid homeostasis"
"0042125242","Cell retention"
"0042125242","Heparan sulphate proteoglycan"
"0042125242","Mesangial cell"
"0042125242","PDGF"
"0042125242","Pericyte"
"0042125242","Retina"
"33748068096","Dermatofibrosarcoma protuberans"
"33748068096","Imatinib"
"33748068096","Platelet-derived growth factor receptor"
"33748068096","Surgery"
"33748068096","Tyrosine kinase inhibitor"
"28944432768","Chronic eosinophilic leukemia"
"28944432768","End organ damage"
"28944432768","Hypereosinophilic syndrome"
"28944432768","Imatinib mesylate"
"28944432768","Novel treatment options"
"13444270334","Gastrointestinal stromal tumor"
"13444270334","Incidence"
"13444270334","Prevalence"
"13444270334","Prognosis"
"2942670180","Autocrine tumor growth"
"2942670180","Glivec"
"2942670180","Platelet-derived growth factor"
"2942670180","Tumor angiogenesis"
"2942670180","Tumor stroma"
"0027082937","Angiogenesis"
"0027082937","Chemotaxis"
"0027082937","Endothelial cells"
"0027082937","Platelet-derived growth factor"
"33646152550","Chronic eosinophilic leukemia"
"33646152550","Imatinib"
"33646152550","KIF5B"
"33646152550","PDGFRA"
"0034618408","Breast carcinoma"
"0034618408","c-ras(H)"
"0034618408","Desmoplasia"
"0034618408","Dominant-negative mutants"
"0034618408","Paracrine growth factors"
"0034618408","PDGF"
"0033604460","Chromosomal translocation"
"0033604460","Chronic myelomonocytic leukemia"
"0033604460","Platelet-derived growth factor"
"0033604460","TEL"
"33644504867","Cancer"
"33644504867","EBP50"
"33644504867","NHERF"
"33644504867","PDGFR"
"33644504867","PTEN"
"0041335547","Chronic myeloid leukaemia"
"0041335547","PDGFRA"
"0041335547","STI-571/Glivec"
"0035242001","Ewing family tumors"
"0035242001","Ewing's sarcoma"
"0035242001","EWS/FLI"
"0035242001","PDGF-C"
"0037198637","Ewing family tumors"
"0037198637","Ewing's sarcoma"
"0037198637","EWS/FLI"
"0037198637","PDGF-C"
"30644470953","Breast cancer"
"30644470953","Targeted therapy"
"0033500183","Breast neoplasms"
"0033500183","HER-2/neu"
"0033500183","Prognosis"
"0033500183","Proto-oncogene c-erb-B2"
"0033500183","Therapy"
"0027946003","Breast cancer"
"0027946003","erbB receptors"
"0027946003","HER-2, HER-3, HER-4"
"0027946003","Oncogenes"
"0027946003","Suppressor genes"
"0032413307","C-erbB-2/HER-2"
"0032413307","C-erbB-3/HER3"
"0032413307","C-erbB-4/HER4"
"0032413307","Epidermal growth factor receptor"
"0032413307","Type 1 growth factor receptors"
"0026610881","Antibody engineering"
"0026610881","Site-directed mutagenesis/c-erbb-2/neu"
"0034669565","Antineoplastic agents"
"0034669565","Breast neoplasms"
"0034669565","Clinical studies"
"0034669565","Combined therapy"
"0034669565","Dosage"
"0034669565","Mortality"
"0034669565","Toxicity"
"0034669565","Trastuzumab"
"11244261320","Resistance"
"11244261320","Targeted therapy"
"0033118889","Breast cancer"
"0033118889","Chemotherapy"
"0033118889","HER-2/neu (c-erbB-2)"
"0033118889","Multiple drug effects analysis"
"0033118889","Synergy"
"0034872172","Adverse events"
"0034872172","Cardiotoxicity"
"0034872172","HerceptinÂ®"
"0034872172","Metastatic breast cancer"
"0034872172","Safety"
"0034872172","Trastuzumab"
"10744229470","Metastatic breast cancer"
"10744229470","Paclitaxel"
"10744229470","Trastuzumab"
"0035695654","Chemotherapy"
"0035695654","HER-2/neu"
"0035695654","Metastatic breast cancer"
"0035695654","Paclitaxel"
"0035695654","Trastuzumab"
"12144289561","Breast neoplasm"
"12144289561","Docetaxel"
"12144289561","HER2"
"12144289561","Neoplasm metastasis"
"12144289561","Trastuzumab"
"0035015136","Breast cancer"
"0035015136","Docetaxel"
"0035015136","HER2-overexpression"
"0035015136","Herceptin"
"0035015136","Trastuzumab"
"1842530214","Chronic heart failure"
"1842530214","Epiphora"
"1842530214","Fatigue"
"1842530214","Onycholysis"
"1842530214","Taxanes"
"0035476911","Breast carcinoma"
"0035476911","Capecitabine"
"0035476911","Oral fluoropyrimidine"
"0035476911","Taxane-pretreated"
"0041508753","Capecitabine"
"0041508753","Chemotherapy"
"0041508753","Clinical trial"
"0041508753","Metastatic breast cancer"
"0041508753","Phase II"
"0041508753","Taxane failure"
"10744229320","Anthracycline"
"10744229320","Capecitabine"
"10744229320","Efficacy"
"10744229320","Fluropyrimidine"
"10744229320","Metastatic breast cancer"
"10744229320","Oral"
"10744229320","Phase II"
"10744229320","Quality of life"
"10744229320","Safety"
"10744229320","Taxane"
"0034778024","Breast cancer"
"0034778024","Capecitabine"
"0034778024","CMF"
"0034778024","First-line"
"0034778024","Oral fluoropyrimidine"
"18444417397","Anthracycline-resistant"
"18444417397","Breast cancer"
"18444417397","Capecitabine"
"18444417397","Fluoropyrimidine"
"18444417397","Paclitaxel"
"0036409086","Breast neoplasms"
"0036409086","Fluorescence"
"0036409086","Immunohistochemistry"
"0036409086","In situ hybridization"
"0036409086","Neutropenia"
"0036159859","First-line therapy"
"0036159859","Gemcitabine"
"0036159859","Metastatic breast cancer"
"0036159859","Monotherapy"
"0036159859","Phase II"
"0032999571","Advanced breast cancer"
"0032999571","First-line therapy"
"0032999571","Gemcitabine"
"17844373250","Breast cancer"
"17844373250","Gemcitabine"
"17844373250","Metastasis"
"0036072838","Combination therapy"
"0036072838","Gemcitabine"
"0036072838","HER2 overexpression"
"0036072838","Trastuzumab"
"3543111967","Breast cancer"
"3543111967","Human epidermal growth factor receptor (HER) 2 pathway"
"3543111967","Monoclonal antibody (mAb)"
"3543111967","Trastuzumab"
"33748557778","Gemcitabine"
"33748557778","Metastatic breast cancer"
"33748557778","Trastuzumab"
"33748557778","Vinorelbine"
"3843106892","Breast cancer"
"3843106892","Docetaxel"
"3843106892","Epidoxorubicin"
"3843106892","Neoadjuvant"
"3843106892","Trastuzumab"
"23644441512","Anthracyclines"
"23644441512","Breast cancer"
"23644441512","Complete response"
"23644441512","Neoadjuvant chemotherapy"
"23644441512","Pathological"
"23644441512","Taxanes"
"23644441512","Trastuzumab"
"21044436148","Cardiac toxicity"
"21044436148","Immunohistochemistry"
"21044436148","Pathologic response"
"0036784463","Anthracyclines"
"0036784463","Cardiotoxicity"
"0036784463","HER2"
"0036784463","Metastatic breast carcinoma"
"0036784463","Trastuzumab"
"11144357922","Anthracyclines"
"11144357922","Cardiotoxicity"
"11144357922","Cyclophosphamide"
"11144357922","Epirubicin"
"11144357922","HER2"
"11144357922","Metastatic breast cancer"
"11144357922","Trastuzumab"
"0031884413","Angiogenesis"
"0031884413","bFGF"
"0031884413","Breast carcinoma"
"0031884413","EGFR"
"0031884413","Growth factor receptors"
"0031884413","Growth factors"
"0031884413","Mitosis"
"0031884413","Neovascularization"
"0031884413","PDGF"
"0031884413","PDGF receptors"
"0031884413","Proliferation"
"0031884413","TGFÎ±"
"0031884413","TGFÎ²"
"0031884413","TGFÎ² receptor"
"0031884413","VEGF"
"0031884413","VEGF receptor"
"0036164390","Breast cancer"
"0036164390","EGFR"
"0036164390","ER"
"0036164390","Immunohistochemistry"
"0036164390","Prognosis"
"20844456577","Gefitinib"
"20844456577","Metastatic breast cancer"
"20844456577","Phase II"
"20844456577","Taxane-pretreated"
"28444491796","Breast cancer"
"28444491796","Epirubicin"
"28444491796","Gefitinib"
"28444491796","Phase I study"
"0037068741","AKT"
"0037068741","EGFR"
"0037068741","erbB2"
"0037068741","Erk1/2"
"0037068741","Tumor xenograft"
"0037068741","Tyrosine kinase"
"0037144359","Angiogenesis"
"0037144359","Endostatin"
"0037144359","Mammary cancer"
"0037144359","Vascular endothelial growth factor"
"0032943036","Angiogenic peptides"
"0032943036","Breast cancer"
"0032943036","Prognosis"
"0032943036","Thymidine phosphorylase"
"0032943036","Vascular endothelial growth factor"
"28444476260","Antiangiogenic therapy"
"28444476260","Bevacizumab"
"28444476260","SU11248"
"28444476260","Tyrosine kinase inhibitors"
"28444476260","VEGF"
"0000109509","Angiongenesis"
"0000109509","bcl-2"
"0000109509","c-erB-2"
"0000109509","Non-small-cell lung cancer"
"0035906852","Angiogenesis"
"0035906852","EGFR"
"0035906852","VEGF"
"9144274970","435-HAL-Luc"
"9144274970","Bioluminescence imaging"
"9144274970","Breast cancer"
"9144274970","CSF-1R"
"9144274970","Metastasis"
"9144274970","Osteoclast"
"3543067482","Chemoprevention"
"3543067482","DMBA"
"3543067482","VEGF"
"3543067482","VEGFR2"
"3543067482","ZD6474"
"0035805054","Breast cancer"
"0035805054","Females"
"0035805054","Meta-analysis"
"0035805054","NSAID"
"14044253499","Angiogenesis inhibitors"
"14044253499","Curcumin analogs"
"14044253499","Fumagillin analogs"
"14044253499","SVR assay"
"24944527548","Breast cancer"
"24944527548","Dendritic cells"
"24944527548","Epidermal growth factor"
"24944527548","HER-2/neu"
"24944527548","Immunotherapy"
"24944527548","MUC-1"
"24944527548","Vaccination"
"24944527548","VEGF"
"33745155113","Combination"
"33745155113","Development"
"33745155113","Multi-targeted"
"33745155113","Tyrosine kinase inhibition"
"21244475061","Angiogenesis"
"21244475061","Antitumour"
"21244475061","EGFR inhibitor"
"21244475061","VEGFR inhibitor"
"21244475061","ZD6474"
"23844544081","Anti-angiogenesis"
"23844544081","Dose escalation"
"23844544081","Pharmacokinetics"
"23844544081","Tolerability"
"23844544081","ZD6474"
"21144439000","Drug resistance"
"21144439000","Molecular targeted therapy"
"21144439000","Non-small cell lung cancer"
"21144439000","Tyrosine kinase inhibitor"
"33745604956","Combination therapy"
"33745604956","EGFR"
"33745604956","Monoclonal antibodies"
"33745604956","Small molecule tyrosine kinase inhibitors"
"33745604956","VEGF"
"20844437246","GW572016"
"20844437246","phase I"
"20844437246","signal transduction"
"20844437246","tyrosine kinase inhibitor"
"33144464795","EGFR mutation"
"33144464795","EKB-569"
"33144464795","Irreversible inhibitor of EGFR"
"33144464795","Non-small cell lung cancer"
"33144464795","Resistance to gefitinib"
"20344362911","BAY 43-9006"
"20344362911","Efficacy"
"20344362911","Pharmacokinetics"
"20344362911","Safety"
"20344362911","Solid tumours"
"20344362911","Targeted agent"
"0142121411","Gastrointestinal stroma tumours"
"0142121411","Imatinib mesylate"
"0142121411","Sarcoma"
"25444513214","GIST"
"25444513214","Imatinib"
"25444513214","Resection"
"12944291461","GISTs"
"33644812236","Diverticulosis"
"33644812236","Gastrointestinal stromal tumors"
"33644812236","Germline mutation"
"33644812236","Interstitial cells of Cajal"
"33644812236","KIT"
"2542520755","GIST"
"2542520755","Imatinib"
"2542520755","Kinase"
"2542520755","KIT"
"2542520755","Signal transduction"
"0042090223","GIST"
"0042090223","Mutation"
"0042090223","Receptor"
"0042090223","STI571"
"33748059560","Imatinib"
"33748059560","Kit receptor tyrosine kinase"
"33748059560","Signal transduction"
"33750076675","Gastrointestinal stromal tumor"
"33750076675","Gene expression"
"33750076675","Imatinib mesylate"
"33750076675","Insulin-like growth factor binding protein-3"
"33750076675","Positron emission tomography"
"33645807197","GIST"
"33645807197","Imatinib mesylate"
"33645807197","Mouse model"
"33645807197","Small animal PET"
"29844440422","Cell line"
"29844440422","Duodenal reflux"
"29844440422","GIST"
"29844440422","KIT"
"29844440422","STI571"
"0033978220","Carcinoma"
"0033978220","Drug therapy"
"0033978220","Interferons"
"0033978220","Interleukins"
"0033978220","Renal cell"
"12344309059","Autocrine"
"12344309059","Chemoattraction"
"12344309059","Renal epithelia"
"12344309059","Tubulogenesis"
"12344309059","VEFG"
"33748526494","Methylation"
"33748526494","Mutation"
"33748526494","Renal cell carcinoma"
"33748526494","VEGF-targeted therapy"
"33748526494","VHL"
"33646140913","CELLCYCLE"
"33646140913","DNA"
"33646140913","PROTEINS"
"19944433827","Chromosome translocation"
"19944433827","Immunohistochemistry"
"19944433827","Kidney"
"19944433827","TFEB"
"0036135224","Kidney"
"0036135224","Kidney neoplasms"
"0036135224","Neoplasm staging"
"0036135224","SEER program"
"0034966994","Abnormalities"
"0034966994","Carcinoma"
"0034966994","Neoplasms"
"0034966994","Renal cell"
"0034796962","Carcinoma, renal cell"
"0034796962","Epidemiology"
"0034796962","Kidney"
"0034796962","Therapeutics"
"8644284029","Carcinoma, renal cell"
"8644284029","Kidney"
"8644284029","Nephrectomy"
"8644284029","Survival"
"8644284029","Treatment outcome"
"4143147491","Algorithms"
"4143147491","Carcinoma, renal cell"
"4143147491","Prognosis"
"4143147491","Survival"
"0035986536","Prognosis"
"0035986536","Renal Neoplasm"
"10344224583","Carcinoma"
"10344224583","Proportional hazards models"
"10344224583","Renal cell; prognosis"
"0033179586","MN/CA9"
"0033179586","Polymerase chain reaction"
"0033179586","Renal cell carcinoma"
"0033179586","Tumor marker"
"0029760316","Chimeric bispecific monoclonal antibody"
"0029760316","G250 antigen"
"0029760316","Immunotherapy"
"0029760316","Renal cell carcinoma"
"0032514365","Allelic duplication"
"0032514365","Germline mutation"
"0032514365","MET tyrosine kinase"
"0032514365","Papillary renal cell tumours"
"14644440800","Gene"
"14644440800","Kidney cancer"
"14644440800","Met"
"14644440800","VHL"
"0033983875","Carcinoma"
"0033983875","Hereditary"
"0033983875","Kidney"
"0033983875","Neoplasms"
"0033983875","Neoplastic syndromes"
"0033983875","Papillary"
"0036892633","Birt-Hogg-DubÃ© syndrome"
"0036892633","Chromophobe renal cell carcinoma"
"0036892633","Clear cell (conventional) renal cell carcinoma"
"0036892633","Kidney cancer"
"0036892633","Oncocytosis"
"0036135236","Carcinoma, renal cell"
"0036135236","Kidney neoplasms"
"0036135236","Surgical procedures, minimally invasive"
"0036784297","Kidney"
"0036784297","Kidney neoplasms"
"0036784297","Laparoscopy"
"0036784297","Nephrectomy"
"0036784297","Nephrons"
"4143091553","Carcinoma, renal cell"
"4143091553","Kidney neoplasms"
"4143091553","Natural history, growth and development"
"0842325657","Follow-up studies"
"0842325657","Kidney"
"0842325657","Natural history"
"0842325657","Renal cell carcinoma"
"0842325657","Surveillance"
"30344458234","Kidney"
"30344458234","Kidney neoplasms"
"30344458234","Natural history"
"27544461925","Carcinoma, renal cell"
"27544461925","Kidney neoplasms"
"27544461925","Neoplasm metastasis, survival"
"24944483152","Carcinoma, renal cell"
"24944483152","Kidney"
"24944483152","Neovascularization, pathologic"
"24944483152","Receptors, vascular endothelial growth factor"
"24944483152","Vascular endothelial growth factor"
"24944515386","Adenocarcinoma, clear cell"
"24944515386","Carcinoma, renal cell"
"24944515386","Cell proliferation"
"24944515386","Kidney"
"24944515386","Ploidies"
"10844242217","Clear cell"
"10844242217","Conventional"
"10844242217","Fuhrman nuclear grading system"
"10844242217","Interobserver reproducibility"
"10844242217","Pathology"
"10844242217","Prognosis"
"10844242217","Renal cell carcinoma"
"10844242217","Therapy"
"0035862952","Neoplasm staging"
"0035862952","Renal cell carcinoma"
"0035862952","T1 subclassification"
"0035862952","TNM staging"
"17144384818","Carcinoma"
"17144384818","Kidney"
"17144384818","Neoplasm staging"
"17144384818","Renal cell"
"24644496731","Grading"
"24644496731","Histology"
"24644496731","Prognostic factors"
"24644496731","Renal cell carcinoma"
"24644496731","Staging"
"24644496731","Survival"
"27644560616","Localized renal cell carcinoma"
"27644560616","Martingale residuals analysis"
"27644560616","Nephron-sparing surgery"
"27644560616","Partial nephrectomy"
"27644560616","Radial nephrectomy"
"27644560616","TNM classification system"
"0033083830","Prognosis"
"0033083830","Renal cell carcinoma"
"0033083830","TNM staging"
"0033083830","Tumor size"
"0034934101","Carcinoma, renal cell"
"0034934101","Kidney"
"0034934101","Necrosis"
"0034934101","Survival"
"12544257520","Cancer staging"
"12544257520","Kidney neoplasms"
"12544257520","Renal cell carcinoma"
"12544257520","Survival analysis"
"23344440173","Biopsy"
"23344440173","Interventional procedures"
"23344440173","Kidney"
"23344440173","Neoplasms"
"4644251853","Biopsy, fine-needle"
"4644251853","Carcinoma, renal cell"
"4644251853","Tomography, spiral computed"
"0033880720","Computed tomography (CT), guidance"
"0033880720","Kidney neoplasms"
"0033880720","Kidney neoplasms CT"
"0033880720","Kidney neoplasms, diagnosis"
"0033880720","Kidney neoplasms, metastases"
"0033880720","Kidney, biopsy"
"0033847587","Immunotherapy"
"0033847587","Interleukin-2"
"0033847587","Renal cell carcinoma"
"23744438018","Bevacizumab"
"23744438018","Cancer"
"23744438018","Cetuximab"
"23744438018","Drugs"
"23744438018","Gefitinib"
"23744438018","Growth factor receptors"
"23744438018","Histopathology testing"
"23744438018","Imatinib mesylate"
"23744438018","Monoclonal antibodies"
"23744438018","Personalized medicine"
"23744438018","Small-molecule inhibitors"
"23744438018","Trastuzumab"
"3042634240","Cancer"
"3042634240","Clinical trials"
"3042634240","Tyrosine kinase inhibitors"
"33645092405","c-kit"
"33645092405","CD117"
"33645092405","Gastrointestinal stromal tumour"
"33645092405","KIT"
"33645092405","PDGFRA"
"20844459809","Chordoma"
"20844459809","Imatinib mesylate"
"20844459809","Platelet-derived growth factor receptor-Î² (PDGFRB)"
"20844459809","Response"
"20844459809","Tyrosine kinase inhibitor"
"2942550603","Gefitinib"
"2942550603","Interstitial lung diseases"
"2942550603","Non-small cell lung cancer"
"2942550603","Predictive factors"
"2942550603","Pulmonary fibrosis"
"2942550603","Risk factors"
"33644935076","EGFR"
"33644935076","Gefitinib"
"33644935076","Non-small cell lung cancer"
"33644935076","Tyrosine kinase inhibitor"
"33745277110","Combination therapy"
"33745277110","Metastatic breast cancer"
"33745277110","Small-molecule EGFR tyrosine kinase inhibitors"
"33745277110","Taxanes"
"30644478919","EGFR"
"30644478919","Gefitinib"
"30644478919","IRESSA"
"30644478919","Renal-cell carcinoma"
"30644478919","TKI"
"33144463758","Erlotinib"
"33144463758","Non-smal cell lung cancer"
"33144463758","Pancreatic cancer"
"33144463758","Squamous cell cancer of the head and neck"
"12744255161","Bronchoalveolar carcinoma"
"12744255161","Qualiity of life"
"12744255161","Rash"
"12744255161","Second-line therapy"
"12744261478","BR.21 study"
"12744261478","EGFR mutations"
"12744261478","TALENT trial"
"12744261478","TRIBUTE trial"
"12744261478","Tyrosine kinase inhibitors"
"33646143020","Clinical trial"
"33646143020","Colorectal cancer"
"33646143020","Correlative markers"
"33646143020","EGFR"
"33646143020","Erlotinib"
"33646143020","Phase II"
"33144481305","Breast cancer"
"33144481305","Dual tyrosine kinase inhibitor"
"33144481305","EGFR"
"33144481305","GW572016"
"33144481305","HER2"
"33144481305","Lapatinib"
"0035294634","Angiogenesis"
"0035294634","Cancer therapy"
"0035294634","Carboxyamido-triazole"
"0035294634","Endostatin"
"0035294634","IL-12"
"0035294634","Matrix metalloproteinases"
"0035294634","Sitramin"
"0035294634","Thalidomide"
"0035294634","VEGF"
"21244488907","Antitumour"
"21244488907","EGFR inhibitor"
"21244488907","Non-small-cell lung cancer"
"21244488907","VEGFR inhibitor"
"21244488907","ZD6474"
"32444439875","BAY 43-9006"
"32444439875","PDGFR inhibitor"
"32444439875","Phase I studies"
"32444439875","Pooled analysis"
"32444439875","Raf kinase inhibition"
"32444439875","Refractory solid tumours"
"32444439875","Sorafenib"
"32444439875","VEGFR inhibitor"
"20444430119","Angiogenesis"
"20444430119","Cancer"
"20444430119","Interstitial fluid pressure"
"20444430119","PDGF"
"20444430119","PDGFR"
"33645340325","Angiogenesis"
"33645340325","Radiation"
"33645340325","Vascular targeting"
"33645340325","ZD6126"
"33744805087","Combination"
"33744805087","CPT-11"
"33744805087","EGFR"
"33744805087","Gefitinib"
"33744805087","Lung cancer"
"33744805087","SN-38"
"32144441841","Chemotherapeutic agents"
"32144441841","Docetaxel"
"32144441841","Hormone refractory"
"32144441841","Quinazoline"
"32144441841","Synergism"
"33645873928","Epidermal growth factor receptor"
"33645873928","Esophageal cancer"
"33645873928","Gefitinib"
"33645873928","Radiosensitivity"
"0033063774","Angiogenesis"
"0033063774","EGFR"
"0033063774","Epidermal growth factor receptor"
"0033063774","Invasion"
"0033063774","Tyrosine kinase inhibitor"
"0035117355","Cancer therapy"
"0035117355","EGFr"
"0035117355","Human monoclonal antibody"
"0035117355","XenoMouse"
"12444251187","C225"
"12444251187","Cetuximab"
"12444251187","Monoclonal antibody"
"12444251187","Renal cell carcinoma"
"28044434622","Angiogenesis"
"28044434622","Raf/MEK/ERK pathway"
"28044434622","Renal cell carcinoma"
"28044434622","Targeted agents"
"0036568448","Oncocytoma"
"0036568448","Proximal tubulus epithelial cell"
"0036568448","PTEN"
"0036568448","Renal cell carcinoma"
"0025050735","Gene expression"
"0025050735","Hypoxia"
"0025050735","Transcriptional regulation"
"0025050735","Vascular tone"
"0025050735","Vasoconstrictor"
"0036440693","Angiogenesis"
"0036440693","Matrix metalloproteinase"
"0036440693","Microvessel density"
"0036440693","Renal cell carcinoma"
"0036440693","Vascular endothelial growth factor"
"27144527372","BAY 43-9006"
"27144527372","Pharmacokinetics"
"27144527372","Phase I"
"27144527372","Safety"
"0037379172","Kidney"
"0037379172","Metastasis"
"0037379172","Neoplasms"
"0037379172","Renal cell carcinoma"
"0037379172","Survival"
"27144468094","Antiangiogenic drugs"
"27144468094","Circulating endothelial progenitor cells"
"27144468094","Metronomic chemotherapy"
"27144468094","Targeted therapies"
"27144468094","Tumor angiogenesis"
"27144468094","VEGF"
"0345714775","Phase II trial"
"0345714775","Renal cell carcinoma"
"0345714775","ZD1839"
"0028157342","carcinoma"
"0028157342","hereditary diseases"
"0028157342","kidney neoplasms"
"0028157342","renal cell"
"33645972282","Genomics"
"33645972282","Prognostic markers"
"33645972282","Renal cell cancer"
"33645972282","Targeted therapy"
"29844445765","AG013736"
"29844445765","BAY 43-9006"
"29844445765","Renal cell carcinoma"
"29844445765","SU11248"
"29844445765","Vascular endothelial growth factor"
"29844445765","Von Hippel-Lindau"
"34250201274","AP23573"
"34250201274","Everolimus"
"34250201274","Interferon-Î±"
"34250201274","Temsirolimus"
"33748254960","p-Akt"
"33748254960","p-mTOR"
"33748254960","p-p70S6K"
"33748254960","Rapamycin"
"33748254960","Renal cell carcinoma"
"24044551995","Genomics"
"24044551995","mTOR"
"24044551995","pAKT"
"24044551995","PI3K"
"24044551995","Rapamycin"
"24044551995","Therapeutics"
"33746871442","mRNA"
"33746871442","Prognosis"
"33746871442","Renal cell carcinoma"
"33746871442","VEGF"
"33746871442","VEGF-R1"
"33746871442","VEGF-R2"
"33645737942","Isoforms"
"33645737942","Renal cell carcinoma"
"33645737942","Stage"
"33645737942","Survival"
"33645737942","VEGF"
"33645737942","Western blot"
"28344435137","Angiogenesis"
"28344435137","mRNA stability"
"28344435137","Renal cell carcinoma"
"28344435137","VHL, HuR"
"28344435137","VPF"
"28344435137","VPF/VEGF"
"1242272854","Permeability factor"
"1242272854","Regulatory pathways"
"1242272854","Tumor"
"1242272854","Vascular endothelial growth factor"
"1342288873","Prognosis"
"1342288873","Renal cell cancer"
"1342288873","Stage"
"1342288873","Survival"
"1342288873","VEGF"
"0037771137","Immunohistochemistry"
"0037771137","PDGF-Î±Î± receptor"
"0037771137","PDGF-AA"
"0037771137","Platelet-derived growth factor"
"0037771137","Prognosis"
"0037771137","Therapy"
"3342967945","G250/CAIX"
"3342967945","Gene regulation"
"3342967945","Hypoxia"
"3342967945","Renal cell carcinoma"
"3342967945","Von Hippel-Lindau"
"31544455868","bFGF"
"31544455868","COX-2"
"31544455868","Interferon alpha"
"31544455868","Renal carcinoma"
"31544455868","VEGF"
"1542327748","Immunotherapy"
"1542327748","Kidney"
"1542327748","Kidney neoplasms"
"1542327748","Neoplasm metastasis"
"1542327748","Nephrectomy"
"0036717864","Epitope"
"0036717864","Helper T lymphocyte"
"0036717864","MAGE-6"
"0036717864","Melanoma"
"0036717864","Renal cell carcinoma"
"4644288189","Aspirin"
"4644288189","Deep-vein thrombosis"
"4644288189","Fondaparinux"
"4644288189","Heparin"
"4644288189","Low-molecular-weight heparin"
"4644288189","Prophylaxis"
"4644288189","Thromboembolism"
"4644288189","Warfarin"
"0026011103","Biological response modifiers"
"0026011103","Blood flow"
"0026011103","Endothelium"
"0026011103","Flavone acetic acid"
"0026011103","Tumor response"
"0026011103","Vasculature"
"7444259131","Antiangiogenic therapy"
"7444259131","Vascular disrupting therapy"
"7444259131","Vascular targeting"
"7444259131","ZD6126"
"7444259131","ZD6474"
"0036021233","Distribution"
"0036021233","DMXXA"
"0036021233","Excretion"
"0036021233","Metabolism"
"0038575250","Antivascular"
"0038575250","DMXAA"
"0038575250","Phase I clinical trial"
"0033857963","Advanced tumor"
"0033857963","Antimicrotubule agent"
"0033857963","Tumor cell death"
"0033857963","Tumoral vascular collapse"
"0033857963","TZT-1027"
"18144432660","Dolastatins"
"18144432660","Phase I study"
"18144432660","Solid tumors"
"18144432660","TZT-1027"
"0242608613","Epithelium"
"0242608613","Gene expression"
"0242608613","Kidney"
"0242608613","Kidney neoplasms"
"0035062394","Angiogenesis"
"0035062394","Heparan sulphate proteoglycan"
"0035062394","Hypoxia"
"0035062394","Neuropilin"
"0035062394","VEGF"
"0035062394","VEGFR"
"0034979159","Angiogenesis"
"0034979159","Hyperoxia"
"0034979159","Hypoxia"
"0034979159","Vessel regression"
"0035167615","Angiogenesis"
"0035167615","Hematologic malignancy"
"0035167615","Receptor tyrosine kinase"
"0035167615","Vascular endothelial growth factor"
"0034075041","Adenoma"
"0034075041","Angiogenesis"
"0034075041","Colorectal cancer"
"0034075041","Colorectal carcinogenesis"
"0034075041","Immunohistochemistry"
"0034075041","Metastasis"
"0034075041","Vascular endothelial growth factor"
"6844237654","Colon cancer"
"6844237654","Isoform pattern"
"6844237654","Liver metastasis"
"6844237654","Vascular endothelial growth factor"
"18244364180","Angiogenesis"
"18244364180","Small cell lung cancer"
"18244364180","VEGF"
"0035800441","Metastatic lesion"
"0035800441","Ovarian cancer"
"0035800441","Patient prognosis"
"0035800441","VEGF"
"0030923795","Ovarian carcinoma"
"0030923795","Prognosis"
"0030923795","Tumor angiogenesis"
"0030923795","Vascular endothelial growth factor (VEGF)"
"0030923795","Vascular permeability factor"
"0033992036","Prognosis"
"0033992036","Renal cell carcinoma"
"0033992036","Stage"
"0033992036","VEGF"
"0033992036","Vein invasion"
"0036841072","Acute myeloid leukemia"
"0036841072","Angiogenesis"
"0036841072","Basic fibroblast growth factor"
"0036841072","Myelodysplastic syndromes"
"0036841072","Prognosis"
"0036841072","Survival"
"0036841072","Vascular endothelial growth factor"
"0032944081","Angiogenesis"
"0032944081","Ascites"
"0032944081","Cancer"
"0032944081","Effusion"
"0032944081","Metastasis"
"0032944081","Serum"
"0032944081","Vascular endothelial growth factor"
"0032768156","Angiogenesis"
"0032768156","Mouse"
"0032768156","PDGF"
"0032768156","Pericyte"
"0032768156","Vascular smooth muscle cell"
"4544290590","Angiogenesis"
"4544290590","Angiogenic switch"
"4544290590","Angiopoietins"
"4544290590","Tumour"
"14844320757","Angiopoietin"
"14844320757","Colorectal carcinoma"
"14844320757","Tie"
"20044381863","Angiogenesis"
"20044381863","Antibody"
"20044381863","Phase I clinical trial"
"20044381863","VEGF"
"23344440655","Drug resistance"
"23344440655","Gatekeeper mutation"
"23344440655","Kinase inhibitor"
"26644472169","Antivascular therapy"
"26644472169","EGF-R and VEGF-R phosphorylation"
"26644472169","Prostate cancer"
"0030016640","Gastric carcinoma"
"0030016640","Gelatinases"
"0030016640","Matrix metalloproteinase"
"0030016640","Quantitative zymography"
"27644591608","Anti-cancer"
"27644591608","Cytokine"
"27644591608","IMiDs"
"27644591608","Immunomodulatory"
"27644591608","Lenalidomide"
"27644591608","Multiple myeloma"
"27644591608","Thalidomide"
"20444427635","Angiogenesis"
"20444427635","Cancer therapy"
"20444427635","Endostatin"
"20444427635","Resistance"
"20444427635","Systems biology"
"24144461280","Cetuximab"
"24144461280","EGFR antibodies"
"24144461280","EGFR inhibitors"
"24144461280","EGFR tyrosine kinase inhibitors"
"24144461280","Erlotinib"
"24144461280","Gefitinib"
"0041844979","Biomarkers"
"0041844979","Biopsy"
"0041844979","Clinical trial"
"0041844979","Laser scanning cytometry"
"0041844979","PET"
"0033374557","Determination of angiogenesis"
"23844480769","Conventional renal cell carcinoma"
"23844480769","Localized renal cell carcinoma"
"23844480769","Nephron-sparing surgery"
"23844480769","Papillary renal cell carcinoma"
"23844480769","Partial nephrectomy"
"23844480769","Radial nephrectomy"
"23844480769","TNM staging system"
"0037407573","Chromophobe renal cell carcinoma"
"0037407573","Clear cell renal cell carcinoma"
"0037407573","Histologic subtype"
"0037407573","Papillary renal cell carcinoma"
"0037407573","Prognosis"
"0037407573","Renal cell carcinoma"
"2142853538","Histology"
"2142853538","Kidney cancer"
"2142853538","Metastases"
"2142853538","Staging"
"0024310179","Cytotoxic agents 1983-1988"
"0024310179","Monoclonal antibodies"
"0024310179","Renal cancer"
"0042839707","Allelic changes"
"0042839707","BRAF"
"0042839707","Mutation"
"0042839707","Renal cell cancer"
"0242330122","Apoptosis"
"0242330122","Cell proliferation"
"0242330122","PTEN"
"0242330122","Renal cell carcinoma"
"21344446791","Akt"
"21344446791","Bad"
"21344446791","PTEN"
"21344446791","Renal cell carcinoma"
"18144399578","Cell signal inhibitors"
"18144399578","Phase I trial"
"18144399578","Rapamycin"
"18144399578","Signal transduction inhibitors"
"18144399578","Sirolimus"
"1342330066","ALL"
"1342330066","CML blast crisis"
"1342330066","CNS leukemia"
"1342330066","Imatinib"
"0842301456","ALL"
"0842301456","CML"
"0842301456","CNS relapse"
"0842301456","Imatinib"
"0036399992","Acute lymphoblastic leukaemia"
"0036399992","Blood-brain barrier"
"0036399992","Central nervous system"
"0036399992","Imatinib mesylate"
"0036399992","Philadelphia chromosome"
"12144290456","ALL"
"12144290456","CGP74588"
"12144290456","CML"
"12144290456","Imatinib"
"12144290456","Metabolite"
"12144290456","N-Desmethyl-imatinib"
"12144290456","Pharmacokinetics"
"23644452642","Dose effects"
"23644452642","GIST"
"23644452642","Imatinib"
"23644452642","Progression"
"20144388609","Adjuvant"
"20144388609","Immunotherapy"
"20144388609","Renal cell carcinoma"
"0034071278","Carcinoma"
"0034071278","Kidney"
"0034071278","Multivariate analysis"
"0034071278","Neoplasm staging"
"0034071278","Prognosis"
"0034071278","Renal cell"
"24044439478","Adjuvant therapy"
"24044439478","Carbonic anhydrase IX"
"24044439478","Heat shock proteins"
"24044439478","Monoclonal antibodies"
"24044439478","Renal cell carcinoma"
"24044439478","Tumour-associated antigen"
"0034971244","Carcinoma"
"0034971244","Classification"
"0034971244","Kidney"
"0034971244","Neoplasm staging"
"0034971244","Renal cell"
"10744219568","Carcinoma, renal cell"
"10744219568","Prognosis, algorithms, databases"
"0242521464","Diagnosis"
"0242521464","Gene expression profiling"
"0242521464","Kidney tumor"
"0242521464","Microarray"
"0242521464","Molecular classification"
"33646349993","carcinoma"
"33646349993","complementary"
"33646349993","DNA"
"33646349993","kidney"
"33646349993","microarray analysis"
"33646349993","renal cell"
"33645807880","Gene expression profiling"
"33645807880","Prognosis"
"33645807880","Renal cell carcinoma"
"0023219487","Radiotherapy"
"0023219487","Renal adenocarcinoma"
"0023553094","Radiotherapy"
"0023553094","Renal adenocarcinoma"
"0036879921","Postoperative radiotherapy"
"0036879921","Radical nephrectomy"
"0036879921","Renal cell carcinoma"
"2942527226","Adjuvant therapy"
"2942527226","Interferon-Î±"
"2942527226","Renal cell carcinoma"
"10644258823","Carbonic anhydrase"
"10644258823","Cytokines"
"10644258823","Dendritic cells"
"10644258823","Immunotherapy"
"10644258823","Lymphocytes"
"10644258823","Renal cell carcinoma"
"10644258823","Tumor associated antigen"
"10644258823","Vaccines"
"33644868476","Angiogenesis inhibitors"
"33644868476","Neoplasm metastasis"
"33644868476","Neovascularisation"
"33644868476","Pathologic"
"33644868476","Renal cell carcinoma"
"33644868476","VEGF"
"0030006748","Active specific immunotherapy"
"0030006748","Adjuvant therapy"
"0030006748","Delayed type cutaneous hypersensitivity"
"0030006748","Renal cancer"
"0037213193","Apoptosis"
"0037213193","Heat-shock proteins"
"0037213193","Heat-shock response"
"0037213193","Urinary tract"
"0037213193","Urologic neoplasms"
"0037833596","Aurologous cancer vaccine"
"0037833596","Heat shock protiens"
"0037833596","Immunotherapy"
"0037833596","Translational medicine"
"11144354471","CA-IX"
"11144354471","Immunotherapy"
"11144354471","Monoclonal antibody"
"11144354471","Renal cell carcinoma"
"11144354471","WX-G250"
"29144503225","Cytokines"
"29144503225","Immunotherapy"
"29144503225","Kidney"
"29144503225","Kidney neoplasms"
"29144503225","Neoplasm metastasis"
"0036983115","Biomarker"
"0036983115","Extracellular signal-regulated kinase (ERK)"
"0036983115","MAPK pathways"
"0036983115","MEK"
"0036983115","Phase I studies"
"0036983115","Protein phosphorylation"
"0036983115","Raf"
"0036983115","Ras"
"0036983115","Signal transduction"
"7444253970","Bevacizumab"
"7444253970","Cyclooxygenase-2"
"7444253970","Magnetic resonance imaging"
"7444253970","Vatalanib"
"23244458246","BAY 43-9006"
"23244458246","Bevacizumab"
"23244458246","RCC"
"23244458246","SU11248"
"23244458246","VEGF"
"23244458246","VHL"
"33744941816","Cancer vaccine"
"33744941816","Dendritic cell vaccination"
"33744941816","Immunotherapy"
"33744941816","Renal cell carcinoma"
"0028216334","fibroblast growth factor"
"0028216334","rabbit cornea"
"0031171663","Angiogenesis"
"0031171663","Cornea"
"0031171663","Growth factor"
"0031171663","Neovascularization"
"0031171663","Thalidomide"
"0031171663","Tumor necrosis factor- alpha"
"19644375361","C-kit"
"19644375361","Imatinib"
"19644375361","PDGFR"
"19644375361","Receptor tyrosine kinase"
"19644375361","Sarcoma"
"11144284051","Gastrointestinal stromal tumor"
"11144284051","KIT mutations"
"11144284051","PDGFRA mutation"
"11144284051","Prognostic factors"
"4644345492","Endoscopic ultrasound-guided fine-needle aspiration biopsy"
"4644345492","Gastrointestinal stromal tumor"
"4644345492","Immunohistochemistry"
"0033976051","Gastrointestinal"
"0033976051","Recurrent"
"0033976051","Sarcoma"
"0033976051","Surgery"
"0035025460","Gastrointestinal stromal tumor"
"0035025460","Leiomyosarcoma"
"0035025460","Retroperitoneal Sarcoma"
"0028958778","chemoembolization"
"0028958778","gastrointestinal leiomyosarcoma"
"0028958778","liver metastases cisplatin"
"0028958778","polyvinyl alcohol sponge particles"
"0028958778","vinblastine"
"0035117662","Chemoembolization"
"0035117662","Chemotherapeutic infusion"
"0035117662","Hepatic arteries"
"0035117662","Liver neoplasms"
"0035117662","Sarcoma"
"0035117662","Secondary"
"0032701962","Intraperitoneal chemotherapy"
"0032701962","Recurrent abdominal sarcoma"
"2542621284","Intraoperative ultrasound"
"2542621284","Liver metastases"
"2542621284","Liver resection"
"2542621284","Radiofrequency ablation"
"0036049018","Chemotherapy"
"0036049018","Gastrointestinal stromal tumor"
"0036049018","Granulocyte macrophage colony stimulating factor"
"0036049018","Leiomyosarcoma"
"0036049018","Ovarian sarcoma"
"0036049018","Soft tissue sarcoma"
"0036305274","C-kit proto-oncogene"
"0036305274","Chemotherapy"
"0036305274","Gastrointestinal stromal tumor"
"0036305274","Radiation"
"0036305274","Sarcoma"
"0036305274","STI-571"
"0036305274","Surgery"
"0036305274","Therapy"
"0042978501","Gastrointestinal stromal tumours"
"0042978501","Imatinib"
"0042978501","KIT gene"
"0042978501","Prognosis"
"0042978501","Surgery"
"20844448396","chronic myelogenous leukemia"
"20844448396","CML"
"20844448396","gastrointestinal stromal tumors"
"20844448396","GIST"
"20844448396","PDGFR"
"20844448396","platelet-derived growth factor receptor"
"0031921287","Carcinoma, renal cell"
"0031921287","Kidney"
"0031921287","Neoplasm metastasis"
"0036893892","Carcinoma, renal cell"
"0036893892","Treatment outcome, survival, nephrectomy"
"0346749692","Carcinoma"
"0346749692","Prognosis"
"0346749692","Renal clear cell"
"0346749692","Survival"
"0030984964","Distant failure"
"0030984964","Local recurrence"
"0030984964","Renal cell carcinoma"
"24644480228","Î³-glutamyl cysteine synthetase"
"24644480228","CDDP resistance-related gene 9"
"24644480228","Cisplatin"
"24644480228","Doxorubicin"
"24644480228","Drug resistant factor"
"24644480228","Glutathione"
"24644480228","Glutathione S-transferase"
"24644480228","Multidrug resistance-associated protein"
"24644480228","Normal proximal tubule epithelial cells"
"24644480228","P-glycoprotein"
"24644480228","Renal cell carcinoma"
"0038679329","Carcinoma"
"0038679329","Catheter ablation"
"0038679329","Neoplasm metastasis"
"0038679329","Neoplasm regression"
"0038679329","Renal cell"
"0038679329","Spontaneous"
"0026730325","carcinoma"
"0026730325","kidney neoplasms"
"0026730325","lung neoplasms"
"0026730325","neoplasm metastasis"
"0026730325","renal cell"
"0038311878","Antibody"
"0038311878","Cytokines"
"0038311878","Dendritic cells"
"0038311878","Immunotherapy"
"0038311878","Kidney cancer"
"0038311878","Renal cell carcinoma"
"0033806216","Cytokine"
"0033806216","Interferon"
"0033806216","Interleukin"
"0033806216","Renal cell carcinoma"
"0033018226","Adjuvant therapy"
"0033018226","Interferon alpha"
"0033018226","Renal cell carcinoma"
"0033376181","Immunotherapy"
"0033376181","Interferon"
"0033376181","p53"
"0033376181","Renal cell carcinoma"
"0029077645","Adjuvant"
"0029077645","Immunochemotherapy"
"0029077645","Interferon"
"0029077645","Renal cell carcinoma"
"24044549635","Metastatic"
"24044549635","Novel treatments"
"24044549635","Renal cell carcinoma"
"24044549635","Systemic therapy"
"24044549635","Targeted drugs"
"0031406878","Immunotherapy"
"0031406878","Interleukin-2"
"0031406878","Renal cell carcinoma"
"0038538304","Adjuvant therapy"
"0038538304","Immunotherapy"
"0038538304","Radical nephrectomy"
"0038538304","Renal cell carcinoma"
"0038538304","Vaccine"
"1242321027","Constitution"
"1242321027","Powder in bottle formulation"
"1242321027","SU011248"
"1642556736","BAY-43-9006"
"1642556736","Kinase inhibitors"
"1642556736","MEK"
"1642556736","Raf"
"1642556736","Ras"
"0038016523","Renal cell carcinoma"
"0038016523","Thalidomide"
"0033980850","Renal cell carcinoma"
"0033980850","Thalidomide"
"0033980850","TNF-Î±"
"20444417477","Anti-angiogenic therapy"
"20444417477","New regimens"
"20444417477","Renal cancer"
"20444417477","Targeted therapies"
"33644896810","Raf kinase"
"33644896810","Renal cell carcinoma"
"33644896810","Sorafenib"
"33644896810","VEGF"
"0041691157","Antineoplastic combined chemotherapy protocols"
"0041691157","Carcinoma, renal cell"
"0041691157","Fluorouracil"
"0041691157","Kidney"
"0030449996","adoptive cellular therapy"
"0030449996","gene therapy"
"0030449996","immunotherapy"
"0030449996","interleukins"
"0030449996","renal cell cancer"
"0030449996","tumor vaccines"
"0028234853","interleukin-2"
"0028234853","renal cell carcinoma"
"0036240987","Decrescendo IL-2"
"0036240987","Interferon"
"0036240987","Kidney cancer"
"0036240987","Phase II"
"0037809210","Immunotherapy"
"0037809210","Multicentre phase II study"
"0037809210","Renal cell carcinoma"
"19244365218","Dendritic cells"
"19244365218","Immunotherapy"
"19244365218","Interleukin-2"
"19244365218","Renal cell carcinoma"
"19244365218","Tumor vaccine"
"0036448032","Dendritic cell"
"0036448032","Renal cell carcinoma"
"0036448032","Tumor lysate"
"0036448032","Vaccine"
"0036569579","Allogeneic blood stem cell transplantation"
"0036569579","Graft-versus-tumor disease"
"0036569579","Performance status"
"0036569579","Refractory malignancies"
"20844445349","Reduced intensity conditioning"
"20844445349","Solid tumor"
"20844445349","Stem cell transplantation"
"0034850652","Allogeneic stem cell transplantation"
"0034850652","Chimerism"
"0034850652","Graft-versus-leukemia"
"0034850652","Pre-emptive donor leukocyte infusions"
"0034850652","T cell depletion"
"0038507194","Carcinoma, renal cell"
"0038507194","Endothelial growth factors"
"0038507194","Gene expression"
"0038507194","Gene, tumor suppressor"
"0038507194","Kidney"
"0036668668","Ã-941"
"0036668668","Angiogenesis"
"0036668668","Anti-angiogenic agent"
"0036668668","Clinical trial"
"0036668668","Neovastat"
"0036668668","Renal cell carcinoma"
"0037352170","Akt"
"0037352170","Apoptosis"
"0037352170","Cell cycle"
"0037352170","Inhibition"
"0037352170","PI3K"
"0037352170","PTEN"
"0037352170","Targeted therapy"
"1142287363","Akt"
"1142287363","Angiogenesis"
"1142287363","EGFR"
"1142287363","erbB"
"1142287363","mTOR"
"1142287363","PI3K"
"1142287363","raf"
"1142287363","Ras"
"1142287363","Symbiosis"
"1142287363","Tyorisine kinase"
"1142287363","VEGF"
"7944223834","Akt"
"7944223834","CCI-779"
"7944223834","m-TOR"
"7944223834","pi3K pathway"
"7944223834","PTEN"
"7944223834","Rapamycin"
"0842304369","AP23573"
"0842304369","CCI-779"
"0842304369","Mammalian target of rapamycin"
"0842304369","Phosphatase and tensin homologue tumor suppressor"
"0842304369","Phosphatidylinositol 3â² kinase"
"0842304369","Protein kinase B"
"0842304369","RAD001"
"2942592008","Capecitabine"
"2942592008","EGFR"
"2942592008","HER-2"
"2942592008","Letrozole"
"2942592008","Paclitaxel"
"2942592008","Quinazoline"
"2942592008","Trastuzumab"
"2942592008","Tyrosine kinase inhibitor"
"0037102997","Breast carcinoma"
"0037102997","Mammography"
"0037102997","Metastasis"
"0037102997","Survival"
"0037102997","Tumor size"
"21844458437","Adjuvant"
"21844458437","Anthracyclines"
"21844458437","Breast cancer"
"21844458437","Capecitabine"
"21844458437","Docetaxel"
"21844458437","Gemcitabine"
"21844458437","Metastatic"
"21844458437","Paclitaxel"
"21844458437","Platinum salts"
"21844458437","Taxanes"
"0036814469","Adjuvant therapy"
"0036814469","Carbop latin"
"0036814469","Cisplatin"
"0036814469","Cycloph osphamide"
"0036814469","Docetaxel"
"0036814469","Doxorubicin"
"0036814469","Fluorescence in situ hybridization"
"0036814469","Trast uzumab"
"25144494618","Cremophor"
"25144494618","Formulation"
"25144494618","Micelles"
"25144494618","Paclitaxel"
"20244376916","BMS-247550"
"20244376916","Epothilones"
"20244376916","Ixabepilone"
"20244376916","Microtubules"
"20244376916","Taxanes"
"3242806189","Angiogenesis"
"3242806189","Prostate cancer"
"3242806189","VEGF"
"0028861231","angiogenesis"
"0028861231","flt-1"
"0028861231","kdr"
"0028861231","vascular endothelial growth factor"
"0028861231","vascular permeability factor"
"0032897455","Angiogenesis"
"0032897455","Breast"
"0032897455","Cancer"
"0032897455","VEGF"
"0032758072","Inflammatory breast cancer"
"0032758072","Lymph node metastasis"
"0032758072","VEGF-C"
"0032758072","VEGF-D"
"6444221837","Angiogenesis"
"6444221837","Breast cancer"
"6444221837","Flt-1"
"6444221837","Vascular endothelial growth factor (VEGF-A)"
"6444221837","Vascular endothelial growth factor-D (VEGF-D)"
"0034000338","Angiogenesis"
"0034000338","Breast cancer"
"0034000338","Prognosis"
"0034000338","Vascular endothelial growth factor"
"0035170092","Breast cancer"
"0035170092","Prognosis"
"0035170092","Thrombospondin"
"0346244031","Angiogenesis"
"0346244031","Breast cancer"
"0346244031","Prognosis"
"0346244031","VEGF-A"
"0346244031","VEGFR2/KDR"
"3042643346","Anti-angiogenesis"
"3042643346","Bevacizumab"
"3042643346","Colorectal cancer"
"2442701289","Bcr-Abl"
"2442701289","Breast cancer"
"2442701289","Cetuximab"
"2442701289","Chronic myelogenous leukemia"
"2442701289","Colorectal cancer"
"2442701289","CP-358, 774"
"2442701289","Epidermal growth factor"
"2442701289","Erbitux"
"2442701289","ERK"
"2442701289","Erlotinib"
"2442701289","Gefitinib"
"2442701289","Gleevec"
"2442701289","Herceptin"
"2442701289","IMC-C225"
"2442701289","Irressa"
"2442701289","K-ras"
"2442701289","MEK"
"2442701289","Monoclonal antibody"
"2442701289","Non-small cell lung cancer"
"2442701289","OSI-774"
"0037367224","Apoptosis"
"0037367224","Breast"
"0037367224","Farnesyl transferase inhibitor"
"0037367224","Ras"
"0037367224","Tamoxifen"
"21344453004","Cancer drug resistance"
"21344453004","Single nucleotide polymorphisms"
"21344453004","Toxicity"
"0032852528","Angiogenesis"
"0032852528","Retinopathy"
"0032852528","Tumor growth"
"0032852528","Tyrosine kinases"
"0032852528","Vascular endothelial growth factor"
"0025998533","Hematopoietic stem cell"
"0025998533","Protein-tyrosine kinase"
"20944441857","Angiogenesis"
"20944441857","Colorectal cancer"
"20944441857","Growth factor"
"20944441857","Signaling"
"20944441857","Tyrosine kinase"
"17744390184","Islet of Langerhans"
"17744390184","Lymphangiogenesis"
"17744390184","Tumour metastasis"
"17744390184","VEGF-C"
"20944441692","Angiogenesis"
"20944441692","Biomarker"
"20944441692","VEGF"
"20944441692","VEGF receptor inhibitor"
"0038443099","Angiogenesis"
"0038443099","Angiogenesis inhibitors"
"0038443099","Anti-angiogenic therapy"
"10244266374","antiangiogenesis"
"10244266374","pharmacodynamics"
"10244266374","pharmacokinetics"
"10244266374","Phase I trial"
"10244266374","SU6668"
"10244266374","tyrosine kinase inhibitor"
"0033920380","Cytostatic agent"
"0033920380","Paired failure times"
"0033920380","Phase II trial"
"0033920380","Time to progression"
"0027227921","Clinical trials"
"0027227921","Efficiency"
"0027227921","Epidemiology"
"0027227921","Research design"
"0027227921","Sample size"
"0027227921","Statistics"
"0037263582","Clinicopathologic study"
"0037263582","Malignant gastric GIST"
"0037263582","Multivariate analysis Immunohistochemistry"
"0037263582","Prognostic factor"
"2142747025","Gastrointestinal stromal tumor"
"2142747025","KIT"
"2142747025","PDGFRA"
"14844317303","CD117"
"14844317303","Distant metastasis"
"14844317303","Gastrointestinal stromal tumor"
"14844317303","KIT mutation"
"14844317303","Tumor recurrence"
"0035122393","Gastrointestinal stromal tumors"
"0035122393","GIST"
"0035122393","Intestinal sarcoma"
"0035122393","Small intestinal neoplasms"
"7644242712","Gene expression"
"7644242712","GIST"
"7644242712","KIT"
"7644242712","Microarray"
"7644242712","Mutations"
"7644242712","PDGFRA"
"3042646931","GIST"
"3042646931","Mutations"
"3042646931","PDGFRA"
"20944443259","Consensus"
"20944443259","ESMO"
"20944443259","GIST"
"20944443259","Imatinib"
"0036303804","Cytogenetics"
"0036303804","Gastrointestinal neoplasm"
"0036303804","KIT"
"0036303804","Mutation"
"0036303804","Oncogenic"
"0036303804","Receptor tyrosine kinase"
"0036303804","Sarcoma"
"13844294023","FDG PET"
"13844294023","GIST"
"13844294023","Image co-registration"
"13844294023","Molecular imaging"
"13844294023","Treatment response"
"12144291080","c-KIT"
"12144291080","Gastrointestinal stromal tumours"
"12144291080","Imatinib mesylate"
"12144291080","PDGFRA"
"12344335787","Bevacizumab"
"12344335787","Imatinib mesylate"
"12344335787","Renal cell carcinoma"
"12344335787","Thalidomide"
"0032323152","Carcinoma"
"0032323152","Kidney"
"0032323152","Nephrectomy"
"0032323152","Renal cell"
"0033015616","Bcl-2"
"0033015616","p53"
"0033015616","Proliferating cell nuclear antigen"
"0033015616","Renal cell carcinoma"
"0030856880","Ki-67"
"0030856880","Mitotic index"
"0030856880","Prognosis"
"0030856880","Prostate carcinoma"
"0030856880","S-phase fraction"
"0031748713","Multivariate analysis"
"0031748713","Prognostic factors"
"0031748713","Renal cell carcinoma"
"0031748713","Silver- stained nucleolar organizer regions (AgNORs)"
"0026023508","nucleolar organizer regions"
"0026023508","prognosis"
"0026023508","renal cell carcinoma"
"0035990421","Autoimmunity"
"0035990421","Interleukin-2"
"0035990421","Myasthenia gravis"
"0035990421","Renal cell cancer"
"2442490125","Carcinoma, renal cell"
"2442490125","Ki-67 antigen"
"2442490125","Kidney"
"2442490125","MN antigen, human"
"2442490125","Tumor markers, biological"
"0034905780","Clinicopathology"
"0034905780","Histology"
"0034905780","Immunohistochemistry"
"0034905780","Immunotherapy"
"0034905780","Renal cell carcinoma"
"0028006091","HLA class I"
"0028006091","Metastases"
"0028006091","Renal cell carcinoma"
"0030867401","Cytokine secretion"
"0030867401","Cytotoxic T lymphocytes"
"0030867401","Lymphocyte subsets"
"0030867401","Renal cell carcinoma"
"0030867401","Tumour-infiltrating lymphocytes"
"0030023895","clinical stage"
"0030023895","interferon-Î³"
"0030023895","renal cell carcinoma"
"0030023895","tumor infiltrating lymphocytes"
"0030000422","Immunotherapy"
"0030000422","Interleukin-2"
"0030000422","Renal cell carcinoma"
"0030000422","Tumor-infiltrating lymphocytes"
"0030449573","DNA ploidy"
"0030449573","HLA-II"
"0030449573","IL-2 immunotherapy"
"0030449573","macrophages"
"0030449573","renal cell carcinoma"
"0032999409","Organogenesis"
"0032999409","Receptor protein tyrosine kinase (RPTK)"
"0032999409","Signaling pathways"
"0032999409","Tumor invasion"
"0032999409","Wound healing"
"0030271724","Adhesion"
"0030271724","EGF"
"0030271724","Invasion"
"0030271724","Metalloproteinase"
"0030271724","Metastasis"
"0030271724","Motility"
"0030271724","Renal carcinoma"
"16244379522","BAY 43-9006"
"16244379522","Bevacizumab"
"16244379522","RCC"
"16244379522","SU11248"
"16244379522","VEGF"
"16244379522","VHL"
"0036738403","Endothelial cell function"
"0036738403","Hemostasis"
"0036738403","SU5416"
"0036738403","Vascular endothelial growth factor"
"0034101808","Microvessel density"
"0034101808","Renal cell carcinoma"
"0034101808","VEGF expression"
"0036362221","Cancer therapy"
"0036362221","EGFR-TKI"
"0036362221","Predictive factor"
"0036362221","Prognostic factor"
"0036362221","ZD1839 (Iressaâ¢)"
"0038354561","Angiogenesis"
"0038354561","Bladder cancer"
"0038354561","Epidermal growth factor receptor family"
"0038354561","Her2/neu"
"0038354561","IMC-C225"
"0038354561","Tyrosine kinase inhibitors"
"10744221013","ABX-EGF"
"10744221013","EGFR"
"10744221013","Epidermal growth factor"
"10744221013","Epidermal growth factor receptor"
"10744221013","Transforming growth factor-Î±"
"0035048096","Cytokine therapy"
"0035048096","Renal cell carcinoma"
"0037303885","Angiogenesis"
"0037303885","Chemotherapy"
"0037303885","Clinical trial"
"0037303885","Monoclonal antibody"
"0037303885","Vascular endothelial growth factor"
"0035116613","EGF"
"0035116613","FGF"
"0035116613","Growth factors"
"0035116613","PDGF"
"0035116613","Signal transduction"
"0035116613","VEGF"
"0242386261","AML"
"0242386261","c-Kit"
"0242386261","FLT3"
"0242386261","Mutations"
"0242386261","Pathogenesis"
"0242386261","Prognosis"
"0242386261","RTKs"
"0026846928","6FGF"
"0026846928","Angiogenesis"
"0026846928","Angiogenic phenotype"
"0026846928","Antiangiogenesis"
"0031870786","Angiogenesis"
"0031870786","Collagenase"
"0031870786","Gelatinase"
"0031870786","Metalloproteinases"
"0031870786","VEGF"
"0029953671","Angiogenesis"
"0029953671","Extracellular matrix"
"0029953671","Plasminogen activator inhibitor-1"
"0029953671","Polyoma virus middle-T oncogene"
"0029953671","Tissue-type plasminogen activator"
"0029953671","Urokinase-type plasminogen activator"
"0029988680","Angiogenesis"
"0029988680","Lung carcinoma"
"0029988680","Proliferation"
"0029988680","Vascular endothelial growth factor (VEGF)"
"1542426623","Biomarker"
"1542426623","Immunohistochemistry"
"1542426623","in vivo"
"1542426623","Microarray"
"1542426623","SU11248"
"1542315370","GIST"
"1542315370","Imatinib"
"1542315370","KIT"
"1542315370","PDGF-RÎ±"
"1542315370","RTK inhibitor"
"1542315370","Targeted therapy"
"2342557044","Epidermal growth factor receptor (EGFR)"
"2342557044","Non-small-cell lung cancer (NSCLC)"
"2342557044","Targeted therapy"
"27644557532","Blood vessels"
"27644557532","Pathologic neovascularization"
"27644557532","Vascular endothelium"
"0034693757","MEN 2"
"0034693757","Papillary thyroid carcinomas"
"0034693757","RET"
"0034693757","Signal transduction"
"0347133261","Breast cancer"
"0347133261","C-fms"
"0347133261","Growth factor"
"0347133261","Lactogenesis"
"0347133261","Macrophage"
"33646108821","Food"
"33646108821","Pharmacokinetics"
"33646108821","SU11248"
"33646108821","SU12662"
"33646108821","Sunitinib malate"
"23744445106","Anti-angiogenesis"
"23744445106","Cancer"
"23744445106","Carbonic anhydrase IX"
"23744445106","Kidney"
"23744445106","Metastases"
"23744445106","Small molecule inhibitors"
"23744445106","Therapy"
"23744431849","Chemotherapy"
"23744431849","Cytokines"
"23744431849","Drug resistance"
"23744431849","Renal cell cancer"
"23744456812","5-Fluorouracil"
"23744456812","Immunotherapy"
"23744456812","Interferon-alpha"
"23744456812","Interleukin-2"
"23744456812","Metastases"
"23744456812","Renal cell cancer"
"20044362947","Gastrointestinal stromal tumor"
"20044362947","GIST"
"20044362947","Imatinib mesylate"
"20044362947","Targeted therapy"
"0031910169","Breast carcinoma"
"0031910169","Growth factor receptors"
"0031910169","Growth factors"
"0031910169","Immunohistochemistry"
"0031906775","Carcinoid"
"0031906775","Neuroendocrine"
"0031906775","Tumours"
"0031906775","Vascular endothelial growth factor"
"20944442418","Gastrointestinal stromal tumor"
"20944442418","Gene expression"
"20944442418","KIT mutation"
"20944442418","Pediatric"
"20944442418","Receptor tyrosine kinase"
"20344371928","Gastrointestinal"
"20344371928","Pediatric"
"20344371928","Stromal"
"20344371928","Tumors"
"1642442499","Epidermal growth factor receptor"
"1642442499","Lung cancer"
"1642442499","Monoclonal antibodies"
"1642442499","Non-small-cell lung cancer"
"1642442499","Tyrosine-kinase inhibitors"
"21244457921","Antitumour"
"21244457921","Combination therapy"
"21244457921","Monotherapy"
"21244457921","Patient selection"
"21244457921","Targeted therapy"
"0032169018","Permeability"
"0032169018","Vascular density"
"0032169018","Vascular regression"
"0030999445","Cell cycle"
"0030999445","Endothelial cells"
"0030999445","Senescence"
"0030999445","VPF/VEGF"
"84918815964","Cancer"
"84918815964","Global estimates"
"84918815964","GLOBOCAN"
"84918815964","Incidence"
"84918815964","Mortality"
"33645659233","Gastric cancer"
"33645659233","Gastric cancer screening"
"33645659233","Japan"
"33645659233","Prospective study"
"84884705232","Dihydropyrimidine dehydrogenase"
"84884705232","Excision repair cross-complementing gene 1"
"84884705232","Gastric cancer"
"84884705232","Prognostic factor"
"84884705232","Thymidylate synthase"
"84884705232","Vascular endothelial growth factor"
"0032921628","Cancer"
"0032921628","Chemotherapy"
"0032921628","ECF"
"0032921628","FAMTX"
"0032921628","Gastric"
"0032921628","Oesophagogastric"
"63749096474","5-fluorouracil"
"63749096474","Capecitabine"
"63749096474","Fluoropyrimidine"
"63749096474","Oesophago-gastric cancer"
"63749096474","Overall survival"
"58149383761","5-FU (5-fluorouracil)"
"58149383761","Alternate-day S-1 regimen"
"58149383761","Balancing efficacy and toxicity"
"58149383761","S-1 (TS-1Â®)"
"58149383761","S-1 and low-dose CDDP therapy"
"84886788915","5-Fluorouracil"
"84886788915","Cisplatin"
"84886788915","FLAGS"
"84886788915","Gastric"
"84886788915","Phase 3"
"84886788915","S-1"
"64949201263","Advanced gastric cancer"
"64949201263","Depth of invasion"
"64949201263","Diffuse type"
"64949201263","Peritoneal free cancer cell"
"64949201263","Prognosis"
"80054057131","EGFR"
"80054057131","Gastric cancer"
"80054057131","HER2"
"80054057131","Lapatinib"
"58749089260","Cetuximab"
"58749089260","Chemotherapy"
"58749089260","Epidermal growth factor"
"58749089260","Epidermal growth factor receptor"
"58749089260","Gastric cancer"
"58749089260","Transforming growth factor-Î±"
"79957864676","Biomarkers"
"79957864676","Cetuximab"
"79957864676","EGFR-1"
"79957864676","Gastric cancer"
"79957864676","Irinotecan"
"79957864676","PTEN"
"76349109904","Antibody"
"76349109904","Cetuximab"
"76349109904","Chemotherapy"
"76349109904","EGFR"
"76349109904","Gastric cancer"
"76349109904","KRAS mutation"
"79957539777","Capecitabine"
"79957539777","Cetuximab"
"79957539777","Gastric cancer"
"79957539777","Oxaliplatin"
"79957539777","Targeted therapy"
"84866529371","Cetuximab"
"84866529371","Chemotherapy"
"84866529371","Colorectal cancer"
"84866529371","Fluoropyrimidine"
"84866529371","Meta-analysis"
"84906803582","Advanced gastric cancer"
"84906803582","Anti-EGFR"
"84906803582","Irinotecan"
"84906803582","Nimotuzumab"
"84906803582","Second-line therapy"
"84875796932","FISH"
"84875796932","Gastric cancer"
"84875796932","Gene amplification"
"84875796932","MET"
"84875796932","PCR"
"80053341349","Best supportive care"
"80053341349","Gastric cancer"
"80053341349","Irinotecan"
"80053341349","Phase III study"
"80053341349","Second-line"
"84917670422","Autophagy"
"84917670422","Cisplatin resistance"
"84917670422","mTOR"
"84917670422","NSCLC"
"84917670422","Radiosensitization"
"26444503696","AKT"
"26444503696","Chemoresistance"
"26444503696","Gastric cancer"
"26444503696","Loss of heterozygosity"
"26444503696","Phosphorylation"
"26444503696","PTEN"
"33947099498","Angiogenesis"
"33947099498","Gastric cancer"
"33947099498","Mammalian target of rapamycin"
"33947099498","Rapamycin"
"33947099498","Tumor growth"
"77957891539","Gastric cancer"
"77957891539","MTOR"
"77957891539","RAD001"
"77957891539","Thymidylate synthase"
"84885926936","Antiangiogenesis"
"84885926936","HCC"
"84885926936","MET"
"84885926936","Sorafenib"
"84885926936","TACE"
"84861038995","Colorectal cancer"
"84861038995","Combination treatment"
"84861038995","GIST"
"84861038995","Regorafenib"
"84861038995","Renal cell cancer"
"84861038995","Tyrosine kinase inhibitor"
"84885173677","Hepatocellular carcinoma"
"84885173677","Receptor kinase inhibition"
"84885173677","Regorafenib"
"84885173677","Safety Second line"
"84885173677","Tolerability"
"34248591612","Epidermal growth factor receptor"
"34248591612","ERK"
"34248591612","Mitogen-activated protein kinases"
"34248591612","Monoclonal antibodies"
"34248591612","Ras"
"34248591612","Small molecule inhibitors"
"84880917333","Amplification"
"84880917333","c-Met"
"84880917333","Hepatocellular carcinoma"
"84880917333","Recurrence"
"62349137063","Hepatocellular carcinoma"
"62349137063","Liver cancer"
"62349137063","Meta-analysis"
"62349137063","Spontaneous regression"
"84922544747","CD163"
"84922544747","CD68"
"84922544747","Hepatocellular carcinoma"
"84922544747","Macrophages"
"84922544747","Spontaneous regression"
"84879141840","CTLA-4"
"84879141840","Immunotherapy"
"84879141840","Liver cancer"
"84879141840","Treg"
"0036224309","Adenovirus"
"0036224309","Dl1520"
"0036224309","Hepatocellular carcinoma"
"0036224309","P53"
"0036224309","Tumor"
"84920837701","cancer cases"
"84920837701","cancer statistics"
"84920837701","death rates"
"84920837701","incidence"
"84920837701","mortality"
"84920837701","survival"
"84920837701","trends"
"84894420746","Bladder cancer"
"84894420746","Bladder sparing treatments"
"84894420746","Chemotherapy"
"84894420746","Cisplatin-based"
"84894420746","Comorbidities"
"84894420746","Cystectomy"
"84894420746","EAU guidelines"
"84894420746","Infiltrative"
"84894420746","Invasive"
"84894420746","Quality of life"
"84876305104","Incidence"
"84876305104","Neoplasm staging"
"84876305104","SEER program/statistics &amp; numerical data"
"84876305104","Survival analysis"
"84876305104","Urinary bladder neoplasms/mortality"
"20444453658","Bladder"
"20444453658","Bladder neoplasms"
"20444453658","Cisplatin"
"20444453658","Drug therapy"
"84898978284","circulating tumor cells"
"84898978284","early bladder cancer"
"84898978284","micrometastatic disease"
"84898978284","prognosis"
"53149143875","Bladder cancer"
"53149143875","Second-line"
"53149143875","Transitional cell carcinoma of the urothelium"
"53149143875","Urothelial carcinoma"
"29144434734","Bladder cancer"
"29144434734","EORTC"
"29144434734","M-VAC chemotherapy"
"29144434734","Randomized trial"
"29144434734","Transitional cell carcinoma"
"33746298622","Adjuvant chemotherapy"
"33746298622","Aged"
"33746298622","Bladder neoplasms"
"33746298622","Creatinine/blood"
"33746298622","Cystectomy"
"33746298622","Glomerular filtration rate"
"33746298622","Kidney function tests"
"79955629384","Bladder cancer"
"79955629384","Chemotherapy"
"79955629384","Cystectomy"
"79955629384","EAU guidelines"
"79955629384","Multidisciplinary management"
"79955629384","Muscle-invasive"
"79955629384","Quality of life"
"79955629384","Radiation therapy"
"33646844469","Phase II"
"33646844469","Transitional cell carcinoma (TCC) of the bladder"
"33646844469","Vinflunine"
"84878442860","Antineoplastic"
"84878442860","Bladder neoplasms"
"84878442860","Survival analysis"
"84878442860","Transitional cell carcinoma"
"84878442860","Urologic tumor"
"0037103074","Advanced urothelial tumors"
"0037103074","Chemotherapy"
"0037103074","Cisplatin"
"0037103074","Gemcitabine"
"0037103074","Paclitaxel"
"0037103074","Prognostic factors"
"0037103074","Transitional cell carcinoma"
"78650046514","Angiogenesis"
"78650046514","Bevacizumab"
"78650046514","Bladder cancer"
"78650046514","Sorafenib"
"78650046514","Sunitinib"
"78650046514","Urothelial carcinoma"
"84866455864","Angiogenesis"
"84866455864","FGF2"
"84866455864","OPN"
"84866455864","RHOC"
"84866455864","Urinary bladder"
"84866455864","VEGFA"
"0030974548","bladder carcinoma"
"0030974548","platelet-derived endothelial cell growth factor (PDECGF)"
"0030974548","prognosis"
"0030974548","thymidine phosphorylase"
"0034791795","CD34"
"0034791795","Immunohistochemistry"
"0034791795","Platelet-derived endothelial cell growth factor/thymidine phosphorylase"
"0034791795","pT1 G3 bladder cancer"
"84862165679","Bladder cancer"
"84862165679","Diagnosis"
"84862165679","Gene expression"
"84862165679","Matrix metalloproteinase"
"84862165679","Prognosis"
"84889856078","Angiogenesis"
"84889856078","Bladder cancer"
"84889856078","Sunitinib"
"84889856078","Urothelial carcinoma"
"84877613151","Bladder cancer"
"84877613151","Diabetic retinopathy"
"84877613151","Progression"
"84877613151","Vascular endothelial growth factor (VEGF)"
"0034827699","Biological"
"0034827699","Bladder"
"0034827699","Bladder neoplasms"
"0034827699","Endothelial growth factors"
"0034827699","Prognosis"
"0034827699","Tumor markers"
"47949128768","Angiogenesis"
"47949128768","Bevacizumab (avastin)"
"47949128768","Urethra"
"47949128768","Urothelial cancer"
"47949128768","Vascular endothelial growth factor"
"84926219735","Guideline"
"84926219735","Meta-analysis"
"84926219735","Renal cell carcinoma"
"84926219735","Systematic review"
"67649354223","Cisplatin"
"67649354223","Sunitinib malate"
"67649354223","Urothelial carcinoma"
"84923130166","Advanced urothelial tract"
"84923130166","Clinical trial"
"84923130166","First-line treatment"
"84923130166","Phase 2"
"84923130166","Sunitinib"
"84923130166","transitional cell carcinoma"
"84876982362","Antiangiogenic therapy"
"84876982362","Chemotherapy"
"84876982362","Hematologic toxicity"
"84876982362","Neoadjuvant"
"84876982362","Phase II"
"80053270703","Biomarkers"
"80053270703","Interleukin-8"
"80053270703","Sunitinib"
"80053270703","Urothelial carcinoma"
"84896703767","angiogenesis"
"84896703767","bladder cancer"
"84896703767","chemotherapy"
"84896703767","maintenance therapy"
"84896703767","sunitinib"
"84896703767","urothelial carcinoma"
"79959571422","Biomarkers"
"79959571422","Predictive"
"79959571422","Sunitinib"
"79959571422","Transitional cell carcinoma"
"79959571422","Urothelial cancer"
"84910145396","Apoptosis"
"84910145396","Mitogen activated protein kinase (MAPK) signaling"
"84910145396","Tyrosine kinase inhibitor"
"84910145396","Urothelial cancer"
"77954324477","bladder cancer"
"77954324477","ERK"
"77954324477","sorafenib"
"77954324477","urothelial cancer"
"77954149972","Doxorubicin"
"77954149972","eIF2Î±"
"77954149972","PERK"
"77954149972","Sorafenib"
"77954149972","Urothelial cancer"
"84856071311","First-line"
"84856071311","Metastatic urothelial cancer"
"84856071311","Phase II"
"84856071311","Sorafenib"
"84896694547","advanced urothelial cancer"
"84896694547","chemotherapy"
"84896694547","tyrosine-kinase-inhibitors"
"84896694547","VEGFR-overexpression"
"84878949540","advanced urothelial carcinoma"
"84878949540","platelet-derived growth factor receptor Î²"
"84878949540","sorafenib"
"84878949540","vascular endothelial growth factor receptor 2"
"70149124507","Cisplatin"
"70149124507","Sorafenib"
"70149124507","Tyrosine kinase inhibitors"
"70149124507","Urothelial cancer"
"84887993264","Pazopanib"
"84887993264","Urothelial cancer"
"84887993264","VEGF tyrosine kinase inhibitors"
"84891851601","angiogenesis"
"84891851601","biomarkers"
"84891851601","pazopanib"
"84891851601","transitional cell carcinoma"
"84891851601","urothelial cancer"
"84875055446","clinical trial"
"84875055446","pazopanib"
"84875055446","phase I study"
"84875055446","second line"
"84875055446","urothelial carcinoma"
"84875055446","vinflunine"
"84905175125","C-Met"
"84905175125","Clinical trial"
"84905175125","Receptor tyrosine kinase"
"84905175125","Renal cancer"
"84905175125","Vegfr-2"
"84925449125","Bladder cancer"
"84925449125","Hepatocyte growth factor"
"84925449125","Met"
"84925449125","Tumor cell invasion"
"84925449125","Tumor growth"
"84925449125","Urothelial carcinoma"
"84899049029","Elderly"
"84899049029","Gemcitabine"
"84899049029","Non-small-cell lung cancer"
"84899049029","Vandetanib"
"84904578792","Bicalutamide"
"84904578792","Castration-resistant prostate cancer"
"84904578792","EGFR"
"84904578792","Vandetanib"
"84904578792","VEGFR-2"
"84903576582","Chemotherapy"
"84903576582","Cisplatin"
"84903576582","Metastatic bladder cancer"
"84903576582","Targeted biological therapy"
"67651087280","Anti-angiogenesis"
"67651087280","Bevacizumab"
"67651087280","Bladder cancer"
"67651087280","Prostate cancer"
"67651087280","Renal cell cancer"
"67651087280","Sorafenib"
"67651087280","Sunitinib"
"84925384532","Biomarker"
"84925384532","Bladder cancer"
"84925384532","HGF receptor"
"84925384532","Met"
"84925384532","Urine"
"84925384532","Urothelial carcinoma"
"79955122447","AxlPDGFR-Î±C-Met"
"79955122447","Bladder cancer"
"84872245627","Aflibercept"
"84872245627","Bevacizumab"
"84872245627","Bladder cancer"
"84872245627","Everolimus"
"84872245627","Gefitinib"
"84872245627","Lapatinib"
"84872245627","Sorafenib"
"84872245627","Sunitinib"
"84872245627","Targeted therapy"
"84872245627","Trastuzumab"
"84888015098","Advanced urothelial carcinoma"
"84888015098","Prognostic factors"
"84888015098","Response to prior chemotherapy"
"84888015098","Second-line therapy"
"84926168799","Active targeting"
"84926168799","Cancer"
"84926168799","Chemotherapy"
"84926168799","Clinical status"
"84926168799","Nanocarriers"
"84926168799","Passive targeting"
"84926168799","Polymeric nanoparticles"
"84926168799","Targeted therapy"
"84906691195","axitinib"
"84906691195","cediranib"
"84906691195","hypothyroidism"
"84906691195","meta-analysis"
"84906691195","sunitinib"
"0022992740","covariate information"
"0022992740","distribution of treatment effects"
"0022992740","heterogeneity of treatment effects"
"0022992740","random effects model"
"84924207092","Non-small cell lung cancer (NSCLC)"
"84924207092","Nonsquamous"
"84924207092","Pemetrexed"
"84924207092","Platinum"
"84924207092","Ramucirumab"
"84924207092","Vascular endothelial growth factor (VEGF)"
"84920948299","Bevacizumab"
"84920948299","Neuroendocrine neoplasms"
"84920948299","Sunitinib"
"84920948299","VEGF"
"84912532971","Cardiovascular toxicities"
"84912532971","Hypertension"
"84912532971","Left ventricular dysfunction"
"84912532971","Meta-analysis"
"84912532971","Sunitinib"
"84919821838","hand-foot skin reaction"
"84919821838","meta-analysis"
"84919821838","mucocutaneous toxicities"
"84919821838","skin rash"
"84919821838","stomatitis"
"84919821838","sunitinib"
"84919821838","tyrosine kinase inhibitors"
"84923372373","antiangiogenic drugs"
"84923372373","breast cancer"
"84923372373","monoclonal antibodies"
"84923372373","tyrosine kinases inhibitors"
"84923372373","VEGF"
"84923372373","VEGFR"
"84881544724","Anemia"
"84881544724","Hematologic toxicities"
"84881544724","Meta-analysis"
"84881544724","Neutropenia"
"84881544724","Sunitinib"
"84881544724","Thrombocytopenia"
"79955548077","Anaemia"
"79955548077","Bevacizumab"
"79955548077","Bone marrow toxicities"
"79955548077","Febrile neutropenia"
"79955548077","Haematologic toxicities"
"79955548077","Meta-analysis"
"79955548077","Neutropenia"
"79955548077","Thrombocytopenia"
"84930472517","Bevacizumab"
"84930472517","Cancer"
"84930472517","Febrile neutropenia"
"84930472517","Meta-analysis"
"84930472517","Neutropenia"
"84928828651","Bevacizumab"
"84928828651","Cancer"
"84928828651","Infections"
"84928828651","Meta-analysis"
"80053973209","Anemia"
"80053973209","Bone marrow toxicities"
"80053973209","Hematologic toxicities"
"80053973209","Lymphopenia"
"80053973209","Meta-analysis"
"80053973209","Neutropenia"
"80053973209","Sorafenib"
"80053973209","Targeted therapy"
"80053973209","Thrombocytopenia"
"80053973209","Tyrosine kinase inhibitors"
"80053973209","Vascular endothelial growth factor receptor"
"34250365240","Angiogenesis inhibitors"
"34250365240","Capillaries"
"34250365240","VEGF signalling"
"14744294346","Clonogenic assay"
"14744294346","Hematotoxicity"
"14744294346","Myelotoxicity: BFU-E/CFU-E, CFU-GM, CFU-Mk prediction model validation"
"34548415059","CEP-701"
"34548415059","FL"
"34548415059","FLT3"
"34548415059","Hematopoietic stem cells"
"34548415059","Signal trasduction"
"84896716303","Angiogenesis inhibitors"
"84896716303","Bevacizumab"
"84896716303","Drug therapy"
"84896716303","Endostatin"
"84896716303","Monoclonal antibodies"
"84896716303","Protein-tyrosine kinases"
"84896716303","Sunitinib"
"84896716303","Vascular endothelial growth factor"
"0037137903","Angiogenesis"
"0037137903","Fab fragment"
"0037137903","Human antibodies"
"0037137903","Phage display library"
"0037137903","VEGF/KDR"
"84903901177","Blood flow"
"84903901177","Intussusceptive angiogenesis"
"84903901177","Microcirculation"
"84903901177","Microscopy"
"84903901177","Pillars"
"84868301370","Angiogenesis"
"84868301370","Endothelial cell"
"84868301370","Sprouting"
"84868301370","Stalk cell"
"84868301370","Tip cell"
"84868301370","Vascular system"
"0033047875","Angiogenesis"
"0033047875","Endothelial cells"
"0033047875","Lymphatic vasculature"
"0033047875","VEGF family"
"0033047875","VEGF receptors"
"84872553104","Angiogenesis"
"84872553104","Signal transduction"
"84872553104","Tumours"
"84872553104","Vascular permeability"
"84872553104","VEGFA"
"84872553104","VEGFR2"
"84902070174","6p12"
"84902070174","FISH"
"84902070174","Gene amplification"
"84902070174","TMA"
"84902070174","VEGFA"
"84868616455","Anegiogenesis"
"84868616455","Cancer stem cell"
"84868616455","Growth factor"
"84868616455","Neuropilin"
"84868616455","Semaphorin"
"84868616455","TGF-beta"
"84868616455","VEGF"
"84871633270","hypoxia"
"84871633270","preeclampsia"
"84871633270","tumor angiogenesis"
"84871633270","VEGF"
"84871633270","VEGFR"
"33646021965","Angiogenesis"
"33646021965","FLT-1"
"33646021965","Quantitative image analysis"
"33646021965","Tissue microarray"
"80053189056","Metastasis"
"80053189056","Signal pathway"
"80053189056","Vascular endothelial growth factor"
"80053189056","VEGFR"
"0034255151","Angiogenesis"
"0034255151","Antibodies"
"0034255151","Apoptosis"
"0034255151","Colon carcinoma"
"0034255151","Endothelial cells"
"0034255151","Immunohistochemistry"
"0034255151","Metastasis"
"0034255151","Receptor"
"0034255151","Vascular endothelial growth factor"
"0034255151","Vascular endothelial growth factor receptor-2"
"9744253054","Angiogenesis"
"9744253054","Autocrine growth"
"9744253054","ERK"
"9744253054","Flk"
"9744253054","KDR"
"9744253054","Melanoma"
"9744253054","Metastasis"
"9744253054","NRP-1"
"9744253054","Proliferation"
"9744253054","VEGF"
"9744253054","VEGFR"
"0036826999","Antigen-antibody clearance"
"0036826999","Bevacizumab"
"0036826999","Monoclonal antibody"
"0036826999","Pharmacokinetics"
"0036826999","VEGF"
"65349186800","Aflibercept (VEGF trap)"
"65349186800","Angiogenesis"
"65349186800","Cancer"
"65349186800","Vascular endothelial growth factor (VEGF)"
"84929992673","Neuropilin"
"84929992673","Osteosarcoma"
"84929992673","Tissue microarray"
"84929992673","VEGF"
"84907591274","Anti-angiogenesis"
"84907591274","Bevacizumab"
"84907591274","Genetic variant"
"84907591274","Predictive and prognostic biomarker"
"84907591274","Treatment outcome"
"84897904203","Angiotensin II - diagnostic use"
"84897904203","Bevacizumab"
"84897904203","Colorectal neoplasms"
"84897904203","Nitric oxide - diagnostic use"
"84897904203","Vascular endothelial growth factors"
"84889027175","Angiogenesis"
"84889027175","Tumor vascularization"
"84889027175","Tumor-associated macrophages"
"84901493119","Cancer associated fibroblasts"
"84901493119","Interstitial fluid pressure"
"84901493119","Solid stress"
"84901493119","Therapy resistance"
"84901493119","Tumor microenvironment"
"35548982639","CELLIMMUNO"
"35548982639","HUMDISEASE"
"84883490063","breast cancer"
"84883490063","extravasation"
"84883490063","intravasation"
"84883490063","lung metastasis"
"84883490063","lymph node"
"84883490063","lymphatic metastasis"
"84883490063","metastatic niche formation"
"84857407549","Antiangiogenesis"
"84857407549","HIF-1Î±"
"84885106382","angiogenesis inhibitors"
"84885106382","cancer therapy"
"84885106382","tumour micro-environment"
"84886813161","Aflibercept"
"84886813161","Antiangiogenic"
"84886813161","Metastatic colorectal cancer"
"78449253608","Gastrointestinal stromal tumors"
"78449253608","Hepatocellular carcinoma"
"78449253608","Multitargeted anticancer oral therapies"
"78449253608","Renal cell carcinoma"
"78449253608","Sorafenib"
"78449253608","Sunitinib"
"78449253608","Tyrosine kinase inhibitors"
"84938079692","Phase I study"
"84938079692","Ramucirumab"
"84938079692","Solid tumors"
"84938079692","Vascular endothelial growth factor"
"84938079692","VEGFR-2"
"84925706983","Angiogenesis"
"84925706983","Carboplatin"
"84925706983","Lung cancer"
"84925706983","Paclitaxel"
"84925706983","Ramucirumab"
"33747481634","Angiogenesis"
"33747481634","Bevacizumab"
"33747481634","Vascular Endothelial Growth Factor"
"33747481634","VEGF"
"84887029479","Anti-angiogenesis"
"84887029479","Bevacizumab"
"84887029479","First-line therapy"
"84887029479","Metastatic breast cancer"
"84887029479","Triple-negative breast cancer"
"84887029479","Vascular endothelial growth factor"
"84896941352","advanced gastric cancer"
"84896941352","angiogenesis"
"84896941352","breast cancer"
"84896941352","cost-benefit"
"84896941352","IMC-1121B"
"84896941352","ramucirumab"
"84896941352","VEGF"
"84896738934","Alpha-fetoprotein (AFP)"
"84896738934","Blood-borne gene signature"
"84896738934","C-C chemokine receptor type 2 (CCR2)"
"84896738934","Chemokine (C-X-C motif) receptor 2 (CXCR2)"
"84896738934","Chronic hepatitis B (CHB)"
"84896738934","E1A-Binding Protein P400 (EP400)"
"84896738934","Human hepatocellular carcinoma (HCC)"
"84896738934","Multivariate logistic regression"
"84896738934","Peripheral blood mononuclear cells (PBMC)"
"84892805731","cancer"
"84892805731","epidemiology"
"84892805731","health disparities"
"84892805731","incidence"
"84892805731","survival"
"84892805731","trends"
"77955174673","Chemotherapy"
"77955174673","Gastric cancer"
"77955174673","Molecular targets"
"77955174673","Prognostic index"
"77955174673","Salvage"
"77955174673","Second-line treatment"
"63749118193","5-fluorouracil"
"63749118193","Advanced gastric cancer"
"63749118193","Capecitabine"
"63749118193","Cisplatin"
"63749118193","Phase III"
"80054071524","Gastric cancer"
"80054071524","Molecularly targeted agents"
"80054071524","Target therapy"
"84866759547","Anti-EGFR drugs"
"84866759547","Antiangiogenesis drugs"
"84866759547","Gastric cancer"
"84866759547","Targeted therapy"
"84875521549","Drug therapy"
"84875521549","Stomach neoplasms"
"84875521549","Targeted agents"
"84897471433","Gastroesophageal"
"84897471433","Junction"
"84897471433","Oesophagus"
"36849066978","Angiogenesis"
"36849066978","Autophagy"
"36849066978","Bcl-2/adenovirus EIB 19 kDa-interacting protein 3"
"36849066978","Cancer"
"36849066978","Carbonic anhydrase"
"36849066978","Hypoxia"
"36849066978","Hypoxia-inducible factor"
"36849066978","Oxygen-sensor"
"36849066978","pH regulation"
"36849066978","Tumour metabolism"
"76349095132","Angiogenesis"
"76349095132","Chemotherapy"
"76349095132","Metabolism"
"76349095132","Oxygen"
"76349095132","Radiation therapy"
"76349095132","Transcription"
"78149281188","angiogenesis"
"78149281188","coronary disease"
"78149281188","hypertrophy"
"84883359165","Decidual angiogenesis"
"84883359165","Pregnant uterus"
"84883359165","Vascular regression"
"84883359165","Vascular sinus folding"
"84883359165","VEGF-A"
"0035355472","Binding site"
"0035355472","Flk-1"
"0035355472","KDR"
"0035355472","PLC-Î³"
"0035355472","Tyrosine kinase receptor"
"0035355472","Vascular endothelial growth factor-A"
"36148937125","Angiogenesis inhibition"
"36148937125","Endothelial progenitor cells (EPCs)"
"36148937125","Intussusceptive angiogenesis"
"36148937125","Lymphangiogenesis"
"36148937125","Sprouting angiogenesis"
"36148937125","Vasculogenic mimicry"
"36148937125","Vessel co-option"
"84896989902","Angiogenesis"
"84896989902","Antibacterial therapy"
"84896989902","Clinical significance"
"84896989902","Gastric cancer"
"84896989902","Vessels morphology"
"60649106195","CELLCYCLE"
"0030198988","Angiogenesis"
"0030198988","Blood flow"
"0030198988","Cancer detection and treatment"
"0030198988","Cell adhesion and deformation"
"0030198988","Diffusion and convection"
"0030198988","Interstitial pressure"
"0030198988","Lymphatics"
"0030198988","Receptor-ligand binding"
"0030198988","Tumor microcirculation"
"0030198988","Vascular Permeability"
"0028307739","drug resistance"
"0028307739","hypoxia"
"0028307739","hypoxic cell selective agents"
"0028307739","physiological drug resistance"
"0028307739","radiation sensitizers"
"0028307739","tumor oxygenation"
"0029084797","Angiogenesis"
"0029084797","Cell proliferation"
"0029084797","Gastric carcinoma"
"0029084797","Prognosis"
"33947714052","Angiogenesis"
"33947714052","Gastric carcinoma"
"33947714052","Lymphangiogenesis"
"33947714052","VEGF-A"
"33947714052","VEGF-C"
"34447295882","Gastric cancer"
"34447295882","Gene"
"34447295882","Polymorphism"
"34447295882","Prognosis"
"34447295882","VEGF"
"77957160694","Bevacizumab"
"77957160694","Docetaxel"
"77957160694","Gastric cancer"
"77957160694","Oxaliplatin"
"60549118166","Arterial hypertension"
"60549118166","Bevacizumab"
"60549118166","Colorectal cancer"
"79951673901","bevacizumab"
"79951673901","hypertension"
"79951673901","predictive factor"
"82455166762","Arterial hypertension"
"82455166762","Bevacizumab"
"82455166762","Metastatic colorectal cancer"
"82455166762","Predictive marker"
"84875409996","Bevacizumab"
"84875409996","Clinical outcome"
"84875409996","Hypertension"
"84875409996","Predictive factor"
"84875409996","Prognostic factor"
"79959621928","Angiogenesis"
"79959621928","Bevacizumab"
"79959621928","Biomarkers"
"79959621928","Esophageal cancer"
"79959621928","Gastric cancer"
"79959621928","VEGF"
"84916196944","Bevacizumab"
"84916196944","Gastric adenocarcinoma"
"84864390180","Chemotherapy"
"84864390180","Esophageal cancer"
"84864390180","Radiation therapy"
"84864390180","Targeted therapy"
"82955241985","Gastric cancer"
"82955241985","Pharmacodynamics"
"82955241985","Pharmacokinetics"
"82955241985","Sunitinib"
"82955241985","Tyrosine kinase inhibitor"
"79958803154","Advanced gastric cancer"
"79958803154","Biomarkers"
"79958803154","Objective response"
"79958803154","Sunitinib"
"79958803154","Tyrosine kinase inhibitor"
"84860234330","docetaxel"
"84860234330","Gastric cancer"
"84860234330","second-line chemotherapy"
"84860234330","sunitinib"
"84896405203","Dose-finding"
"84896405203","Gastric cancer"
"84896405203","Phase I"
"84896405203","Sunitinib"
"84888588300","Advanced gastric cancer"
"84888588300","Capecitabine"
"84888588300","Cisplatin"
"84888588300","Oxaliplatin"
"84888588300","Phase I"
"84888588300","Sunitinib"
"84891628705","Cisplatin"
"84891628705","Gastric adenocarcinoma"
"84891628705","Phase I"
"84891628705","S-1"
"84891628705","Sorafenib"
"84856524126","Capecitabine"
"84856524126","Cisplatin"
"84856524126","Gastric cancer"
"84856524126","Phase I study"
"84856524126","Sorafenib"
"84856736532","Cediranib"
"84856736532","Gastric cancer"
"84856736532","Japanese"
"84856736532","Phase I"
"84856736532","VEGF signalling"
"84919471164","Ascites"
"84919471164","Cediranib"
"84919471164","Palliation"
"84919471164","Pleural effusion"
"84919471164","Puncture-free survival"
"84919471164","VEGFR TKI"
"84892921370","CellSearch system"
"84892921370","circulating tumour cells"
"84892921370","immunohistochemical subtypes"
"84892921370","metastatic breast cancer"
"84892921370","prognostic significance"
"84862275233","AMG 386"
"84862275233","Exposure-response analysis"
"84862275233","Ovarian cancer"
"84862275233","Paclitaxel"
"84862275233","Pharmacokinetics"
"84862275233","Population pharmacokinetic/pharmacodynamic modeling"
"84870659220","AMG 386"
"84870659220","clear cell renal cell carcinoma"
"84870659220","phase 2 clinical trial"
"84870659220","randomized controlled trial"
"84870659220","sorafenib"
"84874566567","Amg 386"
"84874566567","Angiogenesis"
"84874566567","Angiopoietin"
"84874566567","Metastatic gastric cancer"
"84874566567","Peptibody"
"84874566567","Tie2 receptor"
"84888264541","Gene Regulation"
"84888264541","Mouse Model"
"84888264541","Stomach Cancer"
"84888264541","TNF-Î±"
"82855170849","Apoptosis"
"82855170849","Caspase 2"
"82855170849","Foretinib"
"82855170849","Mitotic catastrophe"
"82855170849","Plk1"
"84866738718","Crosstalk"
"84866738718","FGFR2"
"84866738718","Gastric cancer"
"84866738718","MET. Foretinib"
"79953803472","Advanced HCC"
"79953803472","Angiogenesis"
"79953803472","Liver function"
"79953803472","Pharmacokinetics"
"79953803472","Tolerability"
"79953803472","TSU-68"
"84858334676","Angiogenesis"
"84858334676","Non-small cell lung cancer"
"84858334676","Phase I"
"84866735754","Colorectal Cancer"
"84866735754","Oxaliplatin"
"84866735754","Phase I"
"84866735754","S-1"
"84866735754","TSU-68"
"84891557710","Anthracycline-resistant breast cancer"
"84891557710","Phase II study"
"84891557710","Receptor tyrosine kinase inhibitor"
"84881104603","factor"
"84881104603","Hepatocellular carcinoma"
"84881104603","Platelet-derived growth"
"84881104603","Transarterial chemoembolisation"
"84881104603","TSU-68"
"84885919561","advanced gastric cancer"
"84885919561","S-1 plus cisplatin therapy"
"84885919561","TSU-68"
"84896039635","Japanese patients"
"84896039635","Ombrabulin"
"84896039635","Pharmacokinetic"
"84896039635","Phase I"
"84896039635","Vascular disrupting agent"
"0035871403","Angiogenesis"
"0035871403","CD34"
"0035871403","Chalkley"
"0035871403","Microvessel count"
"0035871403","Nonsmall-cell lung carcinoma"
"0035871403","Prognosis"
"0035871403","Vascular endothelial cell growth factor"
"0035871403","Vascular pattern"
"33845966075","Angiogenesis"
"33845966075","Angiopoietins"
"33845966075","Coopted vessels"
"33845966075","Pericytes"
"33845966075","Vascular stability"
"33845966075","VEGF"
"84871538217","Bevacizumab"
"84871538217","Carcinoma"
"84871538217","Efficacy"
"84871538217","Meta-analysis"
"84871538217","Non-small-cell lung"
"84871538217","Safety"
"84906242661","Bevacizumab"
"84906242661","Chemotherapy"
"84906242661","Non-small-cell lung cancer"
"84860491472","Bevacizumab"
"84860491472","Carcinoma"
"84860491472","Haemoptysis"
"84860491472","Haemorrhage"
"84860491472","Non-small-cell lung cancer"
"84860491472","Safety"
"84901595989","Bevacizumab"
"84901595989","Biomarker"
"84901595989","Non-small-cell lung cancer"
"84901595989","Vascular endothelial growth factor"
"84866520947","Anti-angiogenic agents"
"84866520947","Fibroblast growth factor (FGF)"
"84866520947","Multitargeted kinase inhibitors"
"84866520947","Non-small cell lung cancer (NSCLC)"
"84866520947","Platelet-derived growth factor (PDGF)"
"84866520947","Vascular endothelial growth factor (VEGF)"
"84864955678","Angiogenesis"
"84864955678","BIBF 1120"
"84864955678","Chemotherapy"
"84864955678","NSCLC"
"84864955678","Pharmacokinetics"
"84864955678","Phase I"
"79957452054","Angiokinase inhibitor"
"79957452054","BIBF 1120"
"79957452054","Non-small cell lung cancer"
"79957452054","Pharmacokinetics"
"79957452054","Phase II"
"84897048556","Biomarkers"
"84897048556","Gastric cancer"
"84897048556","Patient stratification"
"84897048556","Predictive"
"84897048556","Prognostic"
"84897048556","Targeted therapy"
"84869097283","Advanced gastric cancer"
"84869097283","Best supportive care"
"84869097283","Chemotherapy"
"84869097283","Prognostic factors"
"84869097283","Targeted therapy"
"75549083827","Drug discovery"
"75549083827","Epidermal growth factor receptor"
"75549083827","Monoclonal antibodies"
"75549083827","Receptor targeting"
"75549083827","Tyrosine kinase inhibitors"
"78249282604","Experimental models"
"78249282604","Molecular alterations"
"78249282604","Single nucleotide polymorphism"
"84860487790","gastric cancer"
"84860487790","guidance"
"84860487790","HER2 testing"
"84860487790","immunohistochemistry"
"84860487790","in situ hybridization"
"84860487790","quality assurance"
"84860487790","trastuzumab"
"84868630658","CISH"
"84868630658","FISH"
"84868630658","Gastric cancer"
"84868630658","HER2"
"84868630658","IHC"
"84868630658","Prognostic marker"
"84902318168","Educational quality assurance/quality control program"
"84902318168","Gastric carcinoma"
"84902318168","HER2"
"84902318168","Immunohistochemistry"
"84902318168","Ring study"
"84904751533","Gastric cancer"
"84904751533","HER2"
"84904751533","Human epidermal growth factor receptor"
"84904751533","Meta-analysis"
"84904751533","Prognosis"
"84899645435","Ado-trastuzumab emtansine"
"84899645435","Companion diagnostics"
"84899645435","Gastric cancer"
"84899645435","Human epidermal growth factor receptor 2"
"84899645435","Lapatinib"
"84899645435","Pertuzumab"
"84899645435","Prognostic"
"84899645435","Trastuzumab"
"84901516142","Esophageal cancer"
"84901516142","Gastric cancer"
"84901516142","Gastroesophageal junction"
"84901516142","HER2 positive"
"84901516142","Treatment"
"42649133793","Epidermal growth factor receptor"
"42649133793","Gene amplification"
"42649133793","Stomach neoplasm"
"42649133793","Survival analysis"
"42649133793","Tissue array analysis"
"84883401358","EGFR"
"84883401358","Gastric cancer"
"84883401358","HER2"
"84883401358","Human epidermal growth factor receptor"
"84883401358","Meta-analysis"
"77649085714","EGFR inhibition"
"77649085714","Esophageal cancer"
"77649085714","Gastroesophageal cancer"
"77649085714","Multimodality therapy"
"80052439302","EGFR"
"80052439302","erlotinib"
"80052439302","FOLFOX"
"80052439302","oesophagogastric cancer"
"0036252329","Angiogenesis"
"0036252329","EGF"
"0036252329","Gastric cancer"
"0036252329","Growth factors"
"0036252329","VEGF"
"84876378081","Galectin-1"
"84876378081","Gastric cancer"
"84876378081","Prognosis"
"84876378081","Vascular endothelial growth factor"
"58149158076","HIF-1Î±"
"58149158076","Hypoxia"
"58149158076","Metronomic"
"58149158076","mTORC1"
"58149158076","RAD001"
"0342858949","4E-BP1 (PHAS-I)"
"0342858949","eIF4E"
"0342858949","Gastrointestinal cancer"
"0342858949","Translation initiation"
"0342858949","Tumour"
"74949131430","Everolimus"
"74949131430","mTOR"
"74949131430","Pharmacokinetics"
"74949131430","Phase I study"
"74949131430","RAD001"
"84881542709","ARQ 197"
"84881542709","HGF receptor"
"84881542709","MET protooncogene"
"84881542709","Receptor tyrosine kinase"
"84881542709","Tivantinib"
"84881542709","Tyrosine kinase inhibitor"
"84887617202","Chemotherapy"
"84887617202","Lung cancer"
"84887617202","Maintenance"
"84887617202","Progression-free survival"
"84887617202","Target therapy"
"84887617202","Vandetanib"
"84880923313","Maintenance therapy"
"84880923313","Non?small-cell lung cancer"
"84880923313","Vandetanib"
"44149090296","Cancer"
"44149090296","Development"
"44149090296","Fibrosis"
"44149090296","PDGF receptor"
"44149090296","Platelet-derived growth factor"
"84875008449","Bevacizumab"
"84875008449","Epidermal growth factor receptor"
"84875008449","Erlotinib"
"84875008449","Non-small cell lung cancer"
"84875008449","Vascular endothelial growth factor"
"84866856702","Antiangiogenic therapy"
"84866856702","Cancer spread"
"84866856702","Growth factors"
"84866856702","Neovascularization"
"84866856702","Signaling interplay"
"84883360843","Combination therapy"
"84883360843","Efficacy"
"84883360843","Erlotinib"
"84883360843","Non-small-cell lung cancer"
"84883360843","Safety"
"84883360843","Sunitinib"
"84893413347","CALGB 30704"
"84893413347","Lung cancer"
"34548443831","Angiogenesis"
"34548443831","Endothelial"
"34548443831","Inhibitors"
"34548443831","Signal transduction"
"34548443831","VEGF"
"34548443831","VEGFR-2"
"84893352389","Asia"
"84893352389","Carboplatin"
"84893352389","Motesanib"
"84893352389","NSCLC"
"84893352389","Paclitaxel"
"84860505684","Advanced lung cancer"
"84860505684","Bevacizumab"
"84860505684","Carboplatin"
"84860505684","ChemonaÃ¯ve"
"84860505684","Non-small cell lung cancer"
"84860505684","Paclitaxel"
"33747810445","Angiogenesis"
"33747810445","Immunohistochemistry"
"33747810445","Prognosis"
"79955943755","Cytokine Networks"
"79955943755","Review"
"79955943755","Tumor Angiogenesis"
"79955943755","Tumor Lymphangiogenesis"
"79955943755","Tumor Microenvironment"
"84880212274","Anti-angiogenesis"
"84880212274","BIBF 1120"
"84880212274","Nintedanib"
"84880212274","Non-small cell lung cancer"
"84880212274","Vascular endothelial growth factor"
"79952943038","BIBF 1120"
"79952943038","metabolism"
"79952943038","pharmacokinetic profile"
"80155191242","DNA damage"
"80155191242","Drug development"
"80155191242","Oncogene addiction"
"80155191242","Targeted therapies"
"80155191242","Tyrosine kinases"
"84866625336","Non-small-cell lung cancer"
"84866625336","Randomized discontinuation trial"
"84866625336","Sorafenib"
"84872967522","cancer"
"84872967522","deaths averted"
"84872967522","incidence"
"84872967522","mortality"
"84872967522","survival"
"84872967522","trends"
"83655163939","fluorescence in situ hybridization"
"83655163939","gastric adenocarcinoma"
"83655163939","gastroesophageal junction adenocarcinoma"
"83655163939","HER2"
"83655163939","immunohistochemistry"
"79960088597","hepatocyte growth factor"
"79960088597","kinase inhibitors"
"79960088597","MET"
"79960088597","targeted therapy"
"0036145250","Gastric cancer"
"0036145250","Helicobacter pylori"
"0036145250","p53 mutations"
"0036145250","Prognostic factor"
"0033135820","C-erb B-2"
"0033135820","C-met"
"0033135820","Gastric carcinoma"
"0033135820","Gene amplification"
"0033135820","Immunohistochemistry"
"0033135820","Overexpression"
"0033135820","Prognosis"
"0031858312","c-erbB-2"
"0031858312","c-met"
"0031858312","Epidermal growth factor receptor"
"0031858312","Gastric cancer"
"0031858312","Oncogene amplification"
"79954471845","Gastric cancer"
"79954471845","MET amplification"
"79954471845","MET kinase inhibitors"
"84863719409","gene amplification"
"84863719409","immunohistochemistry"
"84863719409","MET"
"84863719409","silver in-situ hybridisation"
"84863719409","stomach neoplasm"
"84896734688","gastric cancer"
"84896734688","gene amplification"
"84896734688","MET"
"84896734688","metastatic"
"84896734688","prognosis"
"84896734688","protein expression"
"84896734688","recurrent"
"84863229341","EGFR"
"84863229341","FISH"
"84863229341","Gene copy number"
"84863229341","MET"
"84863229341","Non-small cell lung cancer"
"84859889031","c-Met"
"84859889031","epithelial mesenchymal transition"
"84859889031","gastric cancer"
"84859889031","hepatocyte growth factor"
"84859889031","peritoneal metastasis"
"84871592260","Inhibitors"
"84871592260","MET"
"84871592260","MET receptor"
"84871592260","Molecule-targeted treatment"
"84871592260","Target"
"84875241735","Angiogenesis"
"84875241735","Apoptosis"
"84875241735","Gastric cancer"
"84875241735","KRC-408"
"84863838764","c-Met"
"84863838764","NSCLC"
"84863838764","Radiosensitivity"
"33646889748","Cyclooxygenase-2"
"0025828180","Polymerase chain reaction"
"0025828180","RAS gene mutation"
"0025828180","Restriction fragment length polymorphism"
"0025828180","Solution hybridization"
"0025828180","Transcript amplification"
"84895807143","Gastric cancer"
"84895807143","Growth factor receptors"
"84895807143","Personalised medicine"
"84895807143","Predictive markers"
"84895807143","Targeted therapies"
"78650865669","cancer"
"78650865669","esophagus"
"78650865669","gastroesophageal junction"
"78650865669","staging"
"78650865669","stomach"
"84861428324","C-met"
"84861428324","Gastric carcinoma"
"84861428324","Tissue microarray"
"84891060305","Angiogenesis inhibitors"
"84891060305","Combination therapies"
"84891060305","Drug delivery"
"84891060305","Paclitaxel"
"84891060305","Tumor microenvironment"
"84891060305","Tyrosine kinase receptor inhibitors"
"84891060305","Vascular disrupting agents"
"84871977845","Carboplatin"
"84871977845","Cediranib"
"84871977845","Gemcitabine"
"0029914622","health technology assessment"
"0029914622","meta-analysis"
"0029914622","pain"
"0029914622","quality"
"0029914622","randomized controlled trials"
"84863867875","Angiogenesis"
"84863867875","Anti-angiogenic therapy"
"84863867875","Macrophage"
"84863867875","Tumor angiogenesis"
"84863867875","VEGF"
"84894041073","Angiogenesis inhibitor"
"84894041073","Non-small cell"
"84894041073","Phase III"
"84894041073","Systemic therapy"
"84902297551","Advanced lung cancer"
"84902297551","Bevacizumab"
"84902297551","Chemotheraphy"
"84902297551","Cost-effectiveness analysis"
"84902297551","Lung cancer"
"84902297551","Metastatic lung cancer"
"84902297551","Review"
"84902297551","Targeted therapy"
"84870931206","Antiangiogenic drug"
"84870931206","Bevacizumab"
"84870931206","Biomarker"
"84870931206","Glioblastoma"
"84870931206","Hypertension"
"84870931206","Sorafenib"
"80052199468","Emerging targeted therapies"
"80052199468","Kidney cancer"
"80052199468","Metastatic renal cell carcinoma"
"80052199468","Novel agents"
"80052199468","Novel immunologic treatments"
"80052199468","Tyrosine kinase inhibitors"
"84905642208","Biomarkers"
"84905642208","EGFR"
"84905642208","HER2"
"84905642208","Non-small cell lung cancer"
"84905642208","Targeted therapy"
"77951473661","Bevacizumab"
"77951473661","Chemotherapy"
"77951473661","NSCLC"
"77951473661","Overall survival"
"77951473661","Vascular endothelial growth factor"
"12444304260","Angiogenesis"
"12444304260","Hypertension"
"12444304260","Pre-eclampsia"
"12444304260","Rarefaction"
"12444304260","Vascular endothelial growth factor"
"84892165925","Cisplatin"
"84892165925","Non-small-cell lung cancer"
"84892165925","Pazopanib"
"84892165925","Pemetrexed"
"84864879887","Angiogenesis"
"84864879887","Neovascularization"
"84864879887","Normalization"
"84864879887","Traditional chinese medicine"
"84864879887","Tumor"
"84864879887","Vasculature"
"84864879887","Vasculogenesis"
"84866155376","Bevacizumab"
"84866155376","Carboplatin"
"84866155376","Ixabepilone"
"84866155376","Non-small-cell lung cancer"
"65349124698","Chemotherapy"
"65349124698","Elderly"
"65349124698","Never smoking"
"65349124698","Poor performance status"
"65349124698","Targeted therapy"
"84873713565","Chemotherapy"
"84873713565","Meta-analysis"
"84873713565","Multitargeted antiangiogenic TKI"
"84873713565","Non-small-cell lung cancer"
"84873713565","RCTs"
"0031969264","Angiogenesis inhibitors"
"0031969264","Blood vessels"
"0031969264","Cancer therapy"
"0031969264","Invasion"
"0031969264","Tumor dormancy"
"84883875530","Anti GD2"
"84883875530","Ch14.18/CHO"
"84883875530","Immunotherapy"
"84883875530","Monoclonal antibody"
"84883875530","Neuroblastoma"
"84906323762","Alirocumab"
"84906323762","Cholesterol-lowering drugs"
"84906323762","Hypercholesterolemia"
"84906323762","LDL-C"
"84906323762","Monoclonal antibodies"
"84906323762","PCSK9"
"84897146802","gene expression"
"84897146802","guselkumab"
"84897146802","Histology"
"84897146802","IL-23"
"84897146802","psoriasis"
"84897146802","Psoriasis Area and Severity Index"
"84897146802","serum"
"84897146802","skin"
"84897146802","T cell"
"84894291466","ALLEVIATE"
"84894291466","CD22"
"84894291466","Clinical trial"
"84894291466","Corticosteroids"
"84894291466","Epratuzumab"
"84894291466","HRQOL"
"84894291466","Lupus"
"84894291466","Monoclonal antibody"
"84894291466","SF-36"
"84894291466","SLE"
"84887711873","Clivatuzumab"
"84887711873","Early detection"
"84887711873","Enzyme immunoassay"
"84887711873","MUC5AC"
"84887711873","PAM4"
"84887711873","Pancreatic cancer"
"84903581591","Cancer"
"84903581591","Clinical studies"
"84903581591","European Medicines Agency"
"84903581591","Food and Drug Administration"
"84903581591","Immune-mediated disorders"
"84903581591","Monoclonal antibodies"
"84892590856","Cancer"
"84892590856","Clinical studies"
"84892590856","European Medicines Agency"
"84892590856","Food and Drug Administration"
"84892590856","Immune-mediated disorders"
"84892590856","Monoclonal antibodies"
"84872858296","Cancer"
"84872858296","Clinical studies"
"84872858296","Monoclonal antibodies"
"78049485263","Cancer"
"78049485263","Global estimates"
"78049485263","Incidence"
"78049485263","Mortality"
"0025029130","anterior CisâDDP"
"0025029130","response"
"0025029130","survival"
"4644271767","Capecitabine"
"4644271767","Gastric cancer"
"4644271767","Metastatic"
"4644271767","Untreated"
"0037265616","Capecitabine"
"0037265616","Gastric cancer"
"0037265616","Phase II study"
"0038579652","Adenocarcinoma"
"0038579652","Gastric cancer"
"0038579652","Gimeracil"
"0038579652","Oral fluoropyrimidines"
"0038579652","Oteracil"
"0038579652","Palliative chemotherapy"
"0038579652","Tegafur"
"0032189218","Chemotherapy"
"0032189218","Fluoropyrimidine"
"0032189218","Gastric cancer"
"0032189218","S-1"
"34447323322","Adenocarcinoma"
"34447323322","Esophageal cancer"
"34447323322","Squamous cell carcinoma"
"34447323322","Weekly paclitaxel"
"0141676699","96-Hour infusion"
"0141676699","Esophageal cancer"
"0141676699","Paclitaxel"
"0030451795","adenocarcinoma of upper gastrointestinal tract"
"0030451795","docetaxel"
"0036203194","Cancer of the esophagus"
"0036203194","Chemotherapy"
"0036203194","Docetaxel"
"0036203194","Paclitaxel"
"3442902880","Docetaxel"
"3442902880","Esophageal cancer"
"3442902880","Phase II study"
"3442902880","RECIST"
"3442902880","Single agent"
"30844449923","Chemotherapy"
"30844449923","Esophageal adenocarcinoma"
"30844449923","Gastric adenocarcinoma"
"30844449923","Irinotecan"
"30844449923","Phase II trial"
"0028023741","DNA amplification"
"0028023741","epidermal growth factor receptor"
"0028023741","esophageal squamous cell carcinoma"
"0028023741","immunohistochemistry"
"23044479392","ckit"
"23044479392","EGFR"
"23044479392","HER-2"
"23044479392","Immunohistochemistry"
"23044479392","Oesophageal cancer"
"23044479392","VEGF"
"2342437556","epidermal growth factor receptor"
"2342437556","Esophageal adenocarcinoma"
"2342437556","immunohistochemical analysis"
"2342437556","tyrosine kinase receptors"
"46749126147","Cetuximab"
"46749126147","Colorectal cancer cells"
"46749126147","Epidermal growth factor receptor"
"46749126147","Thymidylate synthase"
"84877721344","Adenocarcinoma"
"84877721344","Biomarker"
"84877721344","Chemotherapy"
"84877721344","EGFR"
"84877721344","Gastric"
"84877721344","Oesophageal"
"84877721344","Oesophagogastric"
"84877721344","Palliative"
"84877721344","Panitumumab"
"84877721344","Peri-operative"
"70349641356","Cetuximab"
"70349641356","Chemotherapy"
"70349641356","Esophageal cancer"
"70349641356","KRAS mutation"
"70349641356","Squamous cell carcinoma"
"77958496605","Advanced"
"77958496605","Anti-EGFR"
"77958496605","Chemotherapy"
"77958496605","Oesophago-gastric cancer"
"77958496605","Randomised"
"77958496605","Treatment"
"0034929997","Fluorescence in situ hybridization (FISH)"
"0034929997","Gastrointestinal tumors"
"0034929997","HER-2/neu"
"0034929997","Immunohistochemistry (IHC)"
"84866565407","HER2 protein"
"84866565407","Oesophageal neoplasms"
"84866565407","Prognosis"
"84866565407","Survival"
"0033963379","Esophageal adenocarcinoma"
"0033963379","FISH"
"0033963379","HER-2/neu"
"84859903908","gastric cancer"
"84859903908","HER2/neu"
"84859903908","trastuzumab"
"84867131579","Esophagogastric cancer"
"84867131579","Gastric cancer"
"84867131579","Gastroesophageal cancer"
"84867131579","Human epidermal growth factor receptor 2 (HER2)"
"84877103264","Adenocarcinoma"
"84877103264","Gastric"
"84877103264","HER2"
"84877103264","Immunohistochemistry"
"84877103264","In situ hybridisation"
"84877103264","Oesophageal"
"84906092045","advanced gastric cancer"
"84906092045","HER2"
"84906092045","pertuzumab"
"84906092045","pharmacokinetics"
"84906092045","trastuzumab"
"33845313345","Angiogenesis inhibitors"
"33845313345","Antibodies"
"33845313345","Side-effects"
"33845313345","Treatment"
"33845313345","Tyrosine kinase inhibitors"
"33845313345","VEGF"
"0031024216","angiogenesis"
"0031024216","esophageal carcinoma"
"0031024216","microvessel density"
"0031024216","vascular endothelial growth factor (VEGF)"
"3843150503","Anti-angiogenic therapy"
"3843150503","Barrett's disease"
"3843150503","Esophagus"
"3843150503","Lymphangiogenesis"
"3843150503","VEGF"
"3843150503","VEGF-C"
"0036206713","Neoadjuvant therapy"
"0036206713","Oesophageal cancer"
"0036206713","Predictive factors"
"18244392740","Chemoradiotherapy"
"18244392740","Oesophageal cancer"
"18244392740","Thymidine phosphorylase"
"18244392740","Treatment response"
"18244392740","Vascular endothelial growth factor"
"0344307598","Adenocarcinoma"
"0344307598","Esophageal"
"0344307598","Metaplasia"
"0030066037","gastric carcinoma"
"0030066037","hepatic recurrence"
"0030066037","metastasis"
"0030066037","prognosis"
"0030066037","vascular endothelial growth factor"
"0034729146","Basic fibroblast growth factor"
"0034729146","Gastric cancer"
"0034729146","Prognostic factor"
"0034729146","Vascular endothelial growth factor"
"40849119954","COX-2"
"40849119954","HGF receptor"
"40849119954","Met"
"40849119954","Oesophageal adenocarcinoma"
"40849119954","Prognosis"
"34447102329","Angiogenesis"
"34447102329","Gastric cancer"
"34447102329","Genetic alterations"
"34447102329","Molecular markers"
"79958192767","Apoptosis"
"79958192767","BCL-2"
"79958192767","Breast cancer"
"79958192767","Fas"
"79958192767","PARP inhibitors"
"79958192767","TNF-alpha"
"79958192767","TRAIL"
"69149089384","Angiogenesis"
"69149089384","Angiogenesis-inhibitor"
"69149089384","Cancer"
"69149089384","Endothelial cell"
"69149089384","Receptor"
"69149089384","Signaling"
"69149089384","VEGF"
"69149089384","Vessels"
"84877354216","Anti-angiogenic therapy"
"84877354216","Biomarkers"
"84877354216","Cancer"
"84877354216","VEGF"
"79957921039","Angiogenesis"
"79957921039","Anti-angiogenic therapy"
"79957921039","Bevacizumab"
"79957921039","Cancer"
"79957921039","VEGF"
"77956903170","Molecular imaging"
"77956903170","Targeted therapy"
"77956903170","Vascular endothelial growth factor"
"77956903170","VEGF"
"0036033456","Co-option"
"0036033456","Magnetic resonance imaging"
"0036033456","Melanoma"
"0036033456","Vascular endothelial growth factor"
"34548473120","ACE-inhibition"
"34548473120","IGF-1"
"34548473120","Ischemia"
"34548473120","Myocardium"
"34548473120","Receptor"
"34548473120","Reperfusion"
"34548473120","VEGF"
"20644450138","Anastomosis"
"20644450138","Collagen"
"20644450138","Endothelium"
"20644450138","Extracellular matrix"
"20644450138","Vascular endothelial growth factor"
"2442610956","ARDS"
"2442610956","Burn"
"2442610956","Edema"
"2442610956","VEGF"
"52649150833","Bevacizumab"
"52649150833","Endothelial cells"
"52649150833","Ligand"
"52649150833","Predictive factor"
"52649150833","Signal transduction"
"52649150833","Vascular endothelial growth factor"
"73349135923","Angiogenesis inhibitor"
"73349135923","Bevacizumab"
"73349135923","Ramucirumab"
"73349135923","Vascular endothelial growth factor receptor"
"84866318108","Angiogenesis"
"84866318108","Breast cancer"
"84866318108","Neoangiogenesis inhibition"
"84866318108","Tyrosine kinase inhibitor"
"84866318108","Vascular endothelial growth factor"
"84859105892","Bevacizumab"
"84859105892","Breast cancer"
"84859105892","Cost-benefit analysis"
"84859105892","Economics"
"84859105892","Metastatic breast cancer"
"84859105892","Pharmacoeconomics"
"84859105892","QALY"
"84863649779","anti-angiogenic"
"84863649779","anti-proliferative"
"84863649779","metastatic breast cancer"
"84863649779","multikinase inhibitor"
"84863649779","sorafenib"
"84897023959","Bevacizumab"
"84897023959","Breast cancer"
"84897023959","Hypertension"
"84897023959","Matched pair"
"84897023959","Metastatic disease"
"84897023959","Predictive markers"
"84897023959","Survival"
"80054865022","Angiogenesis"
"80054865022","Anti-angiogenesis"
"80054865022","Anti-VEGF"
"80054865022","Endothelial cells"
"80054865022","VEGF"
"84882678245","Breast cancer"
"84882678245","Hereditary genes"
"84882678245","SNPs"
"0032905101","Chromosome 10"
"0032905101","Cowden disease"
"0032905101","Lhermitte-Duclos disease"
"0032905101","Multiple hamartoma syndrome"
"0032905101","PTEN/MMAC1"
"0032905101","Tumour suppressor gene"
"84875412193","bevacizumab"
"84875412193","biomarker"
"84875412193","metastatic breast cancer"
"84875412193","predictive"
"84875412193","vascular endothelial growth factor"
"84875412193","VEGF"
"84893393846","Anti-angiogenic agents"
"84893393846","Breast cancer"
"84893393846","Low-income and middle-income countries"
"84893393846","Microvessel density"
"84868195812","Anti-angiogenesis"
"84868195812","Breast cancer"
"84868195812","Ellagic acid"
"84868195812","Molecular docking"
"84868195812","VEGF/VEGFR2"
"84866481797","BREAST CANCER"
"84866481797","IL-6"
"84866481797","MESENCHYMAL STEM CELLS"
"84866481797","MIGRATION"
"84866481797","VEGF"
"84888294706","Bacterial Infection"
"84888294706","Hepatorenal Syndrome"
"84888294706","Liver Fibrosis"
"84888294706","MELD"
"79952039170","Contraindications"
"79952039170","HCC"
"79952039170","Hepatocellular carcinoma"
"79952039170","Intermediate stage"
"79952039170","Sorafenib"
"79952039170","TACE"
"79952039170","Transarterial chemoembolization"
"84859726758","Alanine aminotransferase"
"84859726758","Alpha-fetoprotein"
"84859726758","Aspartate aminotransferase"
"84859726758","Bilirubin"
"84859726758","Hepatic markers"
"84859726758","Sorafenib"
"84866391058","Disease control rate"
"84866391058","Hepatocellular carcinoma"
"84866391058","Overall survival"
"84866391058","Sorafenib"
"84866391058","Subset analyses"
"84866391058","Time to progression"
"84904751197","Clinical marker"
"84904751197","Early adverse events"
"84904751197","Hepatocellular carcinoma"
"84904751197","Overall survival"
"84904751197","Sorafenib"
"57849117384","Guidelines"
"57849117384","Response criteria"
"57849117384","Solid tumours"
"79960805810","Controlled trial"
"79960805810","Hepatocellular carcinoma"
"79960805810","Randomised"
"79960805810","Sorafenib"
"79960805810","Transarterial chemoembolisation"
"77349102071","AASLD-JNCI guidelines"
"77349102071","Computed tomography"
"77349102071","Hepatocellular carcinoma"
"77349102071","Imaging"
"77349102071","RECIST"
"77349102071","Response assessment"
"77349102071","Targeted therapies"
"77349102071","Time to progression magnetic resonance"
"77954528010","Hepatocellular carcinoma"
"77954528010","Liver Cancer"
"77954528010","Liver Cancer Study Group of Japan"
"77954528010","RECIST"
"77954528010","Response Evaluation Criteria"
"77954528010","WHO criteria"
"34548150925","Chemotherapy"
"34548150925","EGFR"
"34548150925","Erlotinib"
"34548150925","HCC"
"34548150925","Hepatocellular"
"34548150925","Hepatoma"
"34548150925","Signal transduction"
"84984559340","angiogenesis"
"84984559340","hepatocellular carcinoma (HCC)"
"84984559340","linifanib"
"84984559340","platelet-derived growth factor receptor (PDGFR)"
"84984559340","sorafenib"
"84984559340","vascular endothelial growth factor receptor (VEGFR)"
"84881552690","Alpha-fetoprotein"
"84881552690","Aminopyrine"
"84881552690","Methacetin"
"84881552690","PET"
"77950546450","Hepatocellular carcinoma"
"77950546450","RECIST"
"77950546450","Sunitinib"
"77950546450","Tyrosine kinase inhibitor"
"33746257413","GMP"
"33746257413","Mother vessels"
"33746257413","Permeability"
"33746257413","Vascular malformations"
"33746257413","VEGF-A"
"33746257413","VVOs"
"0842265105","Angiogenesis"
"0842265105","Gastric cancer"
"0842265105","Microvessel density"
"0842265105","p53"
"0842265105","Prognostic factors"
"0842265105","VEGF"
"84879238014","Angiogenesis"
"84879238014","Antiangiogenic drugs"
"84879238014","Paclitaxel"
"84879238014","Preclinical studies"
"84897407598","Cardia"
"84897407598","Gastric neoplasms"
"84897407598","Incidence"
"84897407598","Mortality"
"84897407598","Trends"
"84867546214","Eastern experience"
"84867546214","Gastric adenocarcinoma"
"84867546214","Gastric Cancer"
"84867546214","Gastric cancer survival"
"84867546214","Western experience"
"84893492993","Clinical practice"
"84893492993","Dose reduction"
"84893492993","End of life"
"84893492993","Metastatic gastric cancer"
"84893492993","Outcome research"
"84893492993","Second-line"
"84886739501","Gastric cancer"
"84886739501","Second-line chemotherapy"
"79952048861","Gastric carcinoma"
"79952048861","Lymphatic metastasis"
"79952048861","Prognosis"
"79952048861","VEGF-C"
"79952048861","VEGFR-3"
"57849168342","Meta-analysis"
"57849168342","Prediction"
"57849168342","Random-effects models"
"57849168342","Systematic reviews"
"84887116455","Advanced gastric cancer"
"84887116455","Best supportive care"
"84887116455","Meta-analysis"
"84887116455","Second-line chemotherapy"
"84878447869","Docetaxel"
"84878447869","Irinotecan"
"84878447869","Liposomal irinotecan"
"84878447869","Oesophago-gastric cancer"
"84878447869","Phase II"
"84878447869","Second line"
"84874114491","Chemotherapy"
"84874114491","Irinotecan"
"84874114491","Second-line"
"84874114491","Stomach cancer"
"34548739505","5â²DFUR"
"34548739505","Chemotherapy"
"34548739505","Docetaxcel"
"34548739505","Gastric cancer"
"34548739505","Second-line chemotherapy"
"34548739505","Taxan"
"84899438176","Colon and rectum neoplasms"
"84899438176","Epidemiology"
"84899438176","Health disparities"
"84899438176","Screening and early detection"
"67650073366","European Union"
"67650073366","Gastric cancer"
"67650073366","Joinpoint"
"67650073366","Latin America"
"67650073366","Mortality"
"67650073366","Trends"
"84877037180","Atrophic gastritis"
"84877037180","Chronic gastritis"
"84877037180","Diffuse (signet ring) type adenocarcinoma"
"84877037180","Helicobacter pylori"
"84877037180","Intestinal metaplasia"
"84877037180","Intestinal-type adenocarcinoma"
"84877037180","Proximal gastric cancer"
"84877037180","Spasmolytic polypeptide-expressing metaplasia"
"34547986616","Diffuse type"
"34547986616","Gastric cancer"
"34547986616","Intestinal type"
"34547986616","Photofluorography"
"34547986616","Screening examination"
"0027322443","epidemiology"
"0027322443","gastric cancer"
"0027322443","multivariate analysis"
"0027322443","prognosis"
"0027322443","surgery"
"0027322443","survival rate"
"0034830956","D2"
"0034830956","Gastrectomy"
"0034830956","Gastric cancer"
"0034830956","Racial difference"
"0034830956","Radical lymphadenectomy"
"0034830956","Stage migration"
"0032976136","D1 resection"
"0032976136","D2 resection"
"0032976136","Gastric cancer"
"0032976136","Long-term survival"
"0023621446","Gastric cancer"
"0023621446","lymph node dissection"
"0023621446","lymph node metastasis"
"0027054862","4'-epirubicin"
"0027054862","5-FU"
"0027054862","Cisplatin"
"0027054862","Gastric cancer"
"84859399146","Advanced gastric cancer"
"84859399146","Angiogenic pathway"
"84859399146","Biomarker"
"84859399146","Epidermal growth factor pathway"
"84859399146","Targeted therapy"
"0030265393","Angiogenesis"
"0030265393","Vasculogenesis"
"0030265393","VEGF"
"0030265393","VEGF receptors"
"0030265393","VPF"
"38049177080","Epidermal growth factor receptor"
"38049177080","Gastric cancer"
"38049177080","Prognostic factors"
"38049177080","Targeted biological therapy"
"38049177080","Vascular endothelial growth factor"
"0032988709","Gastric cancer"
"0032988709","Nitric oxide"
"0032988709","Serum"
"0032988709","VEGF"
"84888627652","Advanced gastric adenocarcinoma"
"84888627652","Antitarget therapies"
"84888627652","Oxaliplatin"
"84888627652","Second-line treatment"
"84888627652","Sorafenib"
"18144425093","HER1/EGFR"
"18144425093","Iressa"
"18144425093","Predictive marker"
"18144425093","Surrogate market"
"18144425093","Tarceva"
"18144425093","Tyrosine kinase inhibitor"
"0028907863","antiâcâerbBâ2 antibody"
"0028907863","antiâEGF receptor antibody"
"0028907863","câerbBâ2"
"0028907863","EGF receptor"
"0028907863","epidermal growth factor (EGF)"
"0028907863","gastric cancer"
"0037795412","Epidermal growth factor receptor"
"0037795412","Gastric cancer"
"0037795412","HER2"
"0037795412","Prognosis"
"39449115649","Dihydropyrimidine dehydrogenase"
"39449115649","Epidermal growth factor receptor"
"39449115649","Excision repair cross-complementing gene 1"
"39449115649","Gastric cancer"
"39449115649","Prognostic factor"
"0033996667","Angiogenesis"
"0033996667","Gastric cancer"
"0033996667","p53"
"0033996667","Prognosis"
"79957834501","Cetuximab"
"79957834501","Esophageal adenocarcinoma"
"79957834501","Gastric adenocarcinoma"
"33644876397","Fluorescence in situ hybridization"
"33644876397","Gastric cancer"
"33644876397","HER2"
"33644876397","Immunohistochemistry"
"50849123421","c-ErbB-2"
"50849123421","Gastric cancer"
"50849123421","Gastroesophageal adenocarcinoma"
"50849123421","HER2"
"50849123421","Prognostic factor"
"50849123421","Trastuzumab"
"0027436752","câerbBâ2 protein"
"0027436752","human gastric cancer"
"0027436752","immunohistochemistry"
"0027436752","overexpression"
"0027436752","prognosis"
"0027219281","CâerbBâ2"
"0027219281","gastric cancer"
"0027219281","invasion"
"0027219281","metastasis"
"0027219281","prognosis"
"0026510285","differentiation"
"0026510285","gastric cancer"
"0026510285","immunohistochemistry"
"77749273477","Gastric cancer"
"77749273477","HER2"
"77749273477","Immunohistochemistry"
"77749273477","Prognosis"
"44249092320","Fluorescence in situ hybridization"
"44249092320","Gastric cancer"
"44249092320","HER2"
"44249092320","Immunohistochemistry"
"44249092320","Trastuzumab"
"59849127924","Branching"
"59849127924","Kidney"
"59849127924","Met receptor"
"59849127924","Mouse"
"59849127924","Ureteric bud"
"0036966942","c-Met"
"0036966942","Gastric cancer, stage IV"
"0036966942","Hepatocyte growth factor"
"0036966942","Immunohistochemistry"
"0036966942","Liver metastasis"
"0036966942","Prognosis"
"0036966942","Proliferating cell nuclear antigen"
"0036966942","Semiquantitative reverse transcriptase-polymerase chain reaction"
"22144452507","BRAF"
"22144452507","Colorectal cancer"
"22144452507","DNA mismatch repair"
"22144452507","Gastric cancer"
"22144452507","Gastrointestinal cancer"
"22144452507","Genetic instability"
"22144452507","KRAS"
"22144452507","MSI"
"22144452507","PIK3CA"
"77956511880","Angiogenesis"
"77956511880","Cancer therapy"
"77956511880","Growth inhibition"
"77956511880","mTOR"
"77956511880","Rapamycin-like agents"
"77956511880","Renal cell carcinoma"
"39749126103","Immunohistochemistry"
"39749126103","mTOR inhibitor"
"39749126103","Phospho-S6 ribosomal protein"
"39749126103","Predictive marker"
"39749126103","Sarcoma marker"
"39749126103","Sarcoma therapy"
"77951908414","Gastric cancer"
"77951908414","Lymph node metastasis"
"77951908414","p-mTOR"
"77951908414","Prognostic marker"
"77951908414","Surgery"
"84862824218","advanced gastric cancer"
"84862824218","biomarker"
"84862824218","everolimus"
"84877744387","Gastric carcinoma"
"84877744387","p27"
"84877744387","p53"
"84880475579","Gastric cancer"
"84880475579","Lauren's classification"
"84880475579","Metallothionein 2A"
"84880475579","Prognosis"
"84878328609","CD133"
"84878328609","CD44"
"84878328609","gastric carcinoma"
"84878328609","immunohistochemistry"
"84878328609","prognosis"
"84872070036","c-erb-B2 protein"
"84872070036","Cd44 protein"
"84872070036","Gastric cancer"
"84872070036","Prognostic factor"
"84879017954","Apoptosis"
"84879017954","Bcl-2"
"84879017954","Gastric cancer"
"84879017954","p53"
"84860761077","Biomarker"
"84860761077","Gastric cancer"
"84860761077","microRNA"
"84860761077","Peripheral blood"
"84860761077","Prognosis"
"15844372318","Adenocarcinoma"
"15844372318","Non-small cell lung cancer and prognosis"
"15844372318","Nuclear excision repair genes"
"15844372318","Squamous cell carcinoma"
"84879793400","Adjuvant"
"84879793400","Cisplatin"
"84879793400","ERCC1"
"84879793400","Gastric"
"84872737647","Adjuvant chemotherapy"
"84872737647","Chemosensitivity"
"84872737647","Excision repair cross-complementing gene 1"
"84872737647","Gastric cancer"
"84872737647","Platinum"
"84872737647","Prognostic factor"
"84882729595","biomarkers"
"84882729595","ERCC1"
"84882729595","gastric adenocarcinoma"
"84882729595","thymidylate synthase"
"33847645479","ERCC1"
"33847645479","Gastric Cancer"
"33847645479","Oxaliplatin"
"84881219215","Advanced gastric cancer"
"84881219215","Drug therapy"
"84881219215","ERCC"
"84881219215","TS"
"84881219215","TUBB3"
"33748499794","Dihydropyrimidine dehydrogenase"
"33748499794","Orotate phosphoribosyltransferase"
"33748499794","S-1"
"33748499794","Thymidine phosphorylase"
"33748499794","Thymidylate synthase"
"10044280517","Cancer"
"10044280517","Europe"
"10044280517","Mortality"
"10044280517","Time trends"
"0037263849","Diet"
"0037263849","Epidemiology"
"0037263849","Gastric cancer"
"0037263849","H. pylori"
"0037263849","Heredity"
"41549131651","Cancer"
"41549131651","European Union"
"41549131651","Mortality"
"41549131651","Trends"
"56749148631","Cancer"
"56749148631","Epidemiology"
"56749148631","Italy"
"56749148631","Mortality"
"0037570623","Comprehensive review"
"0037570623","Gastric cancer"
"0037570623","S-1"
"55249096993","Advanced gastric cancer"
"55249096993","Dose-dense therapy"
"55249096993","Paclitaxel"
"55249096993","Phase II trial"
"73449121065","Chemotherapy"
"73449121065","Docetaxel"
"73449121065","Gastric cancer"
"0037687787","Adjuvant treatment"
"0037687787","Chemotherapy"
"0037687787","Gastric cancer"
"75149136556","Advanced gastric cancer"
"75149136556","Cisplatin"
"75149136556","Neoadjuvant chemotherapy"
"75149136556","Preoperative chemotherapy"
"75149136556","S-1"
"77956292811","Affibody"
"77956292811","Antibody"
"77956292811","HER2 receptor"
"77956292811","Targeted drug delivery"
"77956292811","Targeted therapy"
"77956292811","Tumor marker"
"77956895978","Diagnostic test"
"77956895978","Gastric carcinoma"
"77956895978","HER2"
"77956895978","Immunohistochemistry (IHC)"
"79955928823","Clinocopathologic significance"
"79955928823","Fluorescence in situ hybridization"
"79955928823","Gastric carcinoma"
"79955928823","Her-2"
"79955928823","Immunohistochemistry"
"78650783838","FISH"
"78650783838","Gastric carcinoma"
"78650783838","HER2"
"78650783838","immunohistochemistry"
"78650783838","trastuzumab"
"33947320114","Antitumor activity"
"33947320114","Chemotherapy"
"33947320114","Gastric cancer"
"33947320114","Human xenograft models"
"33947320114","Trastuzumab"
"24344489058","Animal model"
"24344489058","Gastric cancer"
"24344489058","HER2"
"24344489058","Molecular targeted therapy"
"24344489058","Trastuzumab"
"78649724338","Advanced gastric cancer"
"78649724338","Gastroesophagal junction"
"78649724338","HER2"
"78649724338","Lapatinib"
"78649724338","Trastuzumab"
"0032586731","C-erbB-2 oncogene"
"0032586731","Esophageal adenocarcinoma"
"0032586731","Lauren classification"
"0032586731","Prognosis"
"78651323217","Diffuse type gastric cancer"
"78651323217","Epigenetic profile"
"78651323217","Gastric cancer"
"78651323217","Genome profile"
"78651323217","Intestinal type gastric cancer"
"77954217471","Adenocarcinoma"
"77954217471","Cisplatin"
"77954217471","erbB-2"
"77954217471","Fluorescent in situ hybridisation (FISH)"
"77954217471","Fluoropyrimidine"
"77954217471","Gastric cancer"
"77954217471","HER-2"
"77954217471","Immunohistochemistry (IHC)"
"77954217471","Oesophagogastric junction"
"77954217471","Trastuzumab"
"0034883882","Angiogenesis"
"0034883882","Dendritic cells"
"0034883882","Endothelin-1"
"0034883882","Immunosuppression"
"0034883882","Interleukin-12"
"84873602673","Gastric cancer"
"84873602673","Growth factors and signal transduction"
"84873602673","Prognosis"
"84873602673","VEGF"
"23844522021","Gastric cancer"
"23844522021","Peritoneal recurrence"
"23844522021","VEGF"
"84885603623","Afatinib"
"84885603623","Biomarkers"
"84885603623","Gastric cancer"
"84885603623","Human epidermal growth factor receptor 2"
"84885603623","Lapatinib"
"84885603623","Pertuzumab"
"84885603623","Target therapies"
"84885603623","Trastuzumab"
"84885603623","Trastuzumab-DM1"
"34548427415","Clinical trial"
"34548427415","mTOR"
"34548427415","Rapamycin"
"34548427415","Sarcoma"
"0344839087","Angiogenesis"
"0344839087","Antibody affinity"
"0344839087","Antibody engineering"
"0344839087","Autocrine tumor growth"
"0344839087","Human antibody"
"0344839087","Leukemia"
"0344839087","VEGF/KDR"
"33847663871","Advanced gastric cancer"
"33847663871","Cetuximab"
"33847663871","FOLFIRI regimen"
"69949127786","Cancer"
"69949127786","Cetuximab"
"69949127786","Epidermal growth factor receptor"
"69949127786","Monoclonal antibodies"
"69949127786","Panitumumab"
"70349937924","Advanced gastric cancer"
"70349937924","Cetuximab"
"70349937924","Cisplatin/docetaxel"
"84879117062","Cisplatin"
"84879117062","Gastric"
"84879117062","Gastroesophageal"
"84879117062","Matuzumab"
"84879117062","PLF"
"84896404764","ARQ 197"
"84896404764","c-Met inhibitor"
"84896404764","Gastric cancer"
"84896404764","Phase II study"
"84896404764","Tivantinib"
"84865317182","Gastric cancer"
"84865317182","IL-11"
"84865317182","Inhibitors"
"84865317182","STAT3"
"2942590261","Angiogenesis"
"2942590261","Bevacizumab"
"2942590261","Cancer"
"2942590261","Monoclonal antibody"
"2942590261","Vascular endothelial growth factor"
"79954499886","angiogenesis"
"79954499886","BAY 73-4506"
"79954499886","DCE-MRI"
"79954499886","multikinase inhibitor"
"79954499886","regorafenib"
"79955798791","Angiogenesis"
"79955798791","IMC-1121B"
"79955798791","Monoclonal antibody"
"79955798791","Ramucirumab"
"79955798791","Targeted therapy"
"79955798791","Vascular endothelial growth factor receptor"
"79954451405","bevacizumab"
"79954451405","biomarkers"
"79954451405","colorectal cancer"
"79954451405","VEGF"
"84872197632","Antiangiogenic therapy"
"84872197632","Biomarker"
"84872197632","Drug resistance"
"84872197632","Tumor microenvironment"
"84872197632","Tumor neovascularization"
"84865129521","Affinity"
"84865129521","Aflibercept"
"84865129521","Age-related macular degeneration"
"84865129521","Placental growth factor"
"84865129521","VEGF receptor"
"84860169991","Bevacizumab"
"84860169991","Colorectal cancer"
"84860169991","Combination drug therapy"
"84860169991","Drug toxicity"
"84860169991","Vascular endothelial growth factor"
"84871536208","Bevacizumab"
"84871536208","FOLFIRI protocol"
"84871536208","FOLFOX protocol"
"84871536208","Safety"
"84871536208","Treatment outcome"
"33847061164","Epidemiology"
"33847061164","General population"
"33847061164","Helicobacter pylori"
"48249092048","Child"
"48249092048","Helicobacter infection, epidemiology"
"48249092048","Urease"
"37349072458","Childhood"
"37349072458","Epidemiology"
"37349072458","Helicobacter pylori infection"
"37349072458","Russia"
"37349072458","Transmission"
"43049097903","Gastric cancer"
"43049097903","Nutrition"
"84871551022","epidemiology"
"84871551022","gastric cancer"
"84871551022","risk factors"
"84889248416","China"
"84889248416","Gastric cancer"
"84889248416","IL-1B"
"84889248416","IL-1RN"
"84889248416","Polymorphisms"
"84889248416","Risk"
"84881006794","Gastric cancer"
"84881006794","Helicobacter pylori"
"84881006794","promoter polymorphism"
"84881006794","tumor necrosis factor alpha"
"77951992922","Chemoradiation"
"77951992922","Chemotherapy"
"77951992922","Combined modality therapy"
"77951992922","Gastric carcinoma"
"77951992922","NCCN clinical practice guidelines"
"77951992922","Resection"
"77951992922","Surgery"
"30444452979","Adjuvant chemotherapy"
"30444452979","Gastric cancer"
"30444452979","Paclitaxel"
"30444452979","S1"
"30444452979","UFT"
"84874570041","Adenocarcinoma"
"84874570041","Bevacizumab"
"84874570041","Chemotherapy"
"84874570041","Gastric"
"84874570041","Oesophagus"
"84874570041","Peri-operative"
"61849129362","Clinical design"
"61849129362","Evidenced-based outcomes"
"61849129362","Surrogate endpoints"
"84856472292","Diagnosis"
"84856472292","Hepatocellular carcinoma"
"84856472292","Prognosis"
"84856472292","Treatment"
"84864397352","Adverse events"
"84864397352","Hepatocellular carcinoma"
"84864397352","Sorafenib"
"84864397352","Targeted therapy"
"84877011264","Î±-fetoprotein"
"84877011264","biomarkers"
"84877011264","des-Î³-carboxy prothrombin"
"84877011264","hepatocellular carcinoma"
"84877011264","sorafenib"
"84861192547","Chemoembolization"
"84861192547","Drug eluting beads (DEB)"
"84861192547","Hepatocellular carcinoma"
"84861192547","Safety"
"84861192547","Survival"
"78649635336","Conversion"
"78649635336","Eastern Cooperative Oncology Group"
"78649635336","Karnofsky Performance Status"
"78649635336","Palliative Performance Scale"
"78649635336","Performance status"
"84887993101","Dose-finding"
"84887993101","Everolimus"
"84887993101","Hepatocellular carcinoma"
"84887993101","Mammalian target of rapamycin"
"84887993101","Sorafenib"
"84894236289","Adenocarcinoma"
"84894236289","Age-period-cohort analyses"
"84894236289","Age-specific trends"
"84894236289","Birth-cohort"
"84894236289","Cardia"
"84894236289","Epidemiology"
"84894236289","Gastric cancer"
"84894236289","Incidence"
"84894236289","Non-cardia"
"84878439467","Dietary patterns"
"84878439467","Gastric cancer"
"84878439467","Meta-analysis"
"84878439467","Review"
"84878439467","Score"
"84899085244","Clinical Trial"
"84899085244","Helicobacter pylori"
"84899085244","Stomach Neoplasm"
"84899085244","Therapy"
"84893568071","Immunotherapy"
"84893568071","Ipilimumab"
"84893568071","Lung cancer"
"84893568071","Nivolumab"
"84893568071","Nursing"
"84893568071","Vaccination"
"84860792754","Anti-angiogenic therapy"
"84860792754","Biomarkers"
"84860792754","Hypoxia"
"84860792754","Resistance"
"84860792754","VEGF"
"84860792754","VEGFR"
"33344474964","Angiogenesis"
"33344474964","Lymphangiogenesis"
"33344474964","Receptor"
"33344474964","Signal transduction"
"33344474964","VEGF"
"33746012247","Cancer"
"33746012247","FGF"
"33746012247","HGF"
"33746012247","IGF"
"33746012247","Lymph node"
"33746012247","Lymphatic vessel"
"33746012247","Metastasis"
"33746012247","VEGF-A"
"33746012247","VEGF-C"
"33746012247","VEGF-D"
"33846029123","STEMCELL"
"0032953872","Antisense oligodeoxynucleotide"
"0032953872","Flt-1"
"0032953872","Kinase insert domain-containing receptor"
"0032953872","Reverse transcription-polymerase chain reaction"
"0033141411","Angiogenesis"
"0033141411","Branched chain amino acid"
"0033141411","Hepatocyte growth factor"
"0033141411","Tyrosine"
"9144247005","Angiogenesis"
"9144247005","Angiopoietin"
"9144247005","Astrocytoma"
"9144247005","Fibroblast growth factor"
"9144247005","Genetics"
"9144247005","Glioblastoma multiforme"
"9144247005","Placenta growth factor"
"9144247005","Vascular endothelial growth factor"
"84899646145","Asia"
"84899646145","Epidemiology"
"84899646145","Gastric cancer"
"84899646145","Gastric cancer incidence"
"84899646145","Gastric cancer mortality"
"84877018955","Cardia"
"84877018955","Epidemiology"
"84877018955","Gastric cancer"
"84877018955","Helicobacter"
"84877018955","Noncardia"
"84877018955","Risk factors"
"84866436255","Apoptosis"
"84866436255","Gastric cancer"
"84866436255","RNA interference"
"84866436255","Vascular endothelial growth factor"
"67349196067","bevacizumab"
"67349196067","gastric cancer"
"67349196067","peritoneal metastasis"
"84892167721","Combination treatment"
"84892167721","Gastric cancer"
"84892167721","HER2"
"84892167721","Trastuzumab"
"84892167721","VEGF-Trap"
"79959990517","angiogenesis"
"79959990517","gastric cancer"
"79959990517","insulin-like growth factor-I receptor"
"79959990517","lymphangiogenesis"
"79959990517","vascular endothelial growth factor"
"84862809405","Chemosensitizer"
"84862809405","PDGFRA overexpression"
"84862809405","Sunitinib"
"0032402444","Chemotherapy"
"0032402444","Enzyme-linked immunosorbent assay"
"0032402444","Gastrointestinal cancer"
"0032402444","Vascular endothelial growth factor"
"78649556207","Gastric cancer"
"78649556207","Platelet count"
"78649556207","Vascular endothelial growth factor"
"84876474637","Angiogenesis"
"84876474637","Gastric cancer"
"84876474637","Lymph node metastasis"
"84876474637","Lymphangiogenesis"
"84876474637","Serum VEGF"
"84876474637","Serum VEGF-C"
"84876474637","Survival"
"0037474752","Gastric cancer"
"0037474752","Lymph nodes"
"0037474752","Vascular endothelial growth factor"
"84868583483","Gastric cancer"
"84868583483","Meta-analysis"
"84868583483","Prognosis"
"84868583483","Vascular endothelial growth factor"
"33748678896","alcohol"
"33748678896","cardia"
"33748678896","diet"
"33748678896","environmental risk factors"
"33748678896","geographical variation"
"33748678896","Helicobacter pylori"
"33748678896","incidence"
"33748678896","mortality"
"33748678896","obesity"
"33748678896","physical activity"
"33748678896","smoking"
"33748678896","time trends"
"84895431267","C-MET"
"84895431267","EGFR"
"84895431267","Esophageal cancer"
"84895431267","Gastric cancer"
"84895431267","HER2"
"84895431267","MTOR"
"84895431267","Targeted therapy"
"84895431267","VEGFR"
"80054012347","Angiogenic factors"
"80054012347","Myeloid cells"
"80054012347","Stroma"
"80054012347","VEGF"
"79851479215","Endothelial progenitor cells"
"79851479215","Pathological neovascularization"
"79851479215","Tumor therapy"
"79952129849","Adult stem cells"
"79952129849","Angiogenesis"
"79952129849","Bone marrow"
"79952129849","Endothelial progenitor cells"
"79952129849","Hematopoietic stem cells"
"79952129849","Mesenchymal stem cells"
"79952129849","Stem cells"
"79952129849","Tumor"
"79952129849","Tumor microenvironment"
"79952129849","Tumor stroma"
"83455233831","Angiogenesis"
"83455233831","Antineoplastic drug combination"
"83455233831","Biological markers"
"83455233831","Neovascularization"
"83455233831","Non-small cell lung cancer"
"83455233831","Pathology"
"83455233831","Polymorphism"
"83455233831","Vascular endothelial growth factor"
"74549133965","HUMDISEASE"
"74549133965","SIGNALING"
"84890367084","Angiogenesis"
"84890367084","Anti-angiogenic"
"84890367084","Cancer"
"84890367084","Carcinogenesis"
"84890367084","Lung"
"84890367084","Therapy"
"84890367084","VEGF"
"84889059175","cancer"
"84889059175","chemotherapy"
"84889059175","gastric"
"84889059175","genotype"
"84889059175","polymorphisms"
"84889059175","VEGF"
"84859562692","angiogenesis"
"84859562692","docetaxel"
"84859562692","EGCG"
"84859562692","gastric cancer"
"84859562692","metronomic chemotherapy"
"80054747516","Angiogenesis"
"80054747516","Docetaxel"
"80054747516","Gastric cancer"
"80054747516","Metronomic chemotherapy"
"84864037592","Advanced gastric cancer"
"84864037592","Capecitabine"
"84864037592","Elderly patients"
"84864037592","Metronomic chemotherapy"
"84878477682","Gastric cancer"
"84878477682","Prognosis"
"84878477682","Tumor growth"
"84878477682","Vascular endothelial growth factor-A"
"84878477682","Vascular endothelial growth factor-C"
"84878685761","Gastric cancer"
"84878685761","Lymphangiogenesis"
"84878685761","RNA interference"
"84878685761","Vascular endothelial growth factor-C"
"84873262272","Class III beta-tubulin"
"84873262272","Hypoxia-inducible factor 1 alpha"
"84873262272","Paclitaxel"
"84873262272","Vascular endothelial growth factor"
"84863056697","(-)-epigallocatechin-3-gallate"
"84863056697","Angiogenesis"
"84863056697","Capecitabine"
"84863056697","Gastric cancer"
"84863056697","Metronomic chemotherapy"
"84875804295","Cancer"
"84875804295","Europe"
"84875804295","Incidence"
"84875804295","Mortality"
"84875804295","Predictions"
"84866407702","cervical neoplasms"
"84866407702","epidemiology"
"84866407702","health disparities"
"84866407702","Hispanic"
"84866407702","immigrants"
"84858013655","chemotherapy"
"84858013655","EGFR"
"84858013655","gastric cancer"
"84858013655","HER2"
"84858013655","review"
"84858013655","VEGF"
"0025955217","Autocrine mechanism"
"0025955217","Epidermal growth factor"
"0025955217","Epidermal growth factor receptor"
"0025955217","Gastric cancer"
"0028952926","EGF receptor"
"0028952926","Gastric cancer"
"0028952926","Gene amplification"
"84883556549","Epidermal growth factor receptor"
"84883556549","Gastric cancer"
"84883556549","Prognosis"
"84883556549","Survival"
"33845689934","HER-2 amplification and overexpression"
"33845689934","Primary and metastatic esophageal carcinomas"
"33845689934","Tissue microarray"
"67349222954","FISH"
"67349222954","Gastric cancer"
"67349222954","Her-2"
"67349222954","Immunohistochemistry"
"67349222954","TMA"
"67349222954","Trastuzumab"
"79955468866","FISH"
"79955468866","gastric cancer"
"79955468866","HER2"
"79955468866","immunohistochemistry"
"84892943896","biomarker"
"84892943896","gastric adenocarcinoma"
"84892943896","gastric cancer"
"84892943896","HER2"
"84892943896","human epidermal growth factor receptor 2"
"84895917842","advanced gastric cancer"
"84895917842","human epidermal growth factor receptor 2"
"84895917842","prognosis"
"84895917842","trastuzumab"
"79958202400","Adenocarcinoma"
"79958202400","Gastric cancer"
"79958202400","Gastroesophageal junction"
"79958202400","HER2"
"79958202400","Phase II"
"79958202400","Trastuzumab"
"55949117201","Combination drug therapy"
"55949117201","Gastric cancer"
"55949117201","Lapatinib"
"72449149848","Colon"
"72449149848","EGFR"
"72449149848","Gastric"
"72449149848","HER-2"
"72449149848","Irinotecan"
"72449149848","Lapatinib"
"72449149848","SN-38"
"79955475247","Antibody-drug conjugate"
"79955475247","Herceptin"
"79955475247","Maytansine"
"79955475247","T-DM1"
"79955475247","Trastuzumab resistance"
"0037142184","Breast cancer"
"0037142184","Cell surface"
"0037142184","ErbB2"
"0037142184","Herceptin"
"0037142184","Muc4"
"77952240483","Adjuvant"
"77952240483","Antibody"
"77952240483","Biological"
"77952240483","Cancer"
"77952240483","Chemotherapy"
"77952240483","Drug"
"77952240483","Gastric"
"77952240483","Metastatic"
"77952240483","Neoadjuvant"
"77952240483","Perioperative"
"77952240483","TKI"
"84889095358","Gene amplification"
"84889095358","Immunohistochemistry"
"84889095358","MET"
"84889095358","Overexpression"
"84889095358","Prognosis"
"79955429299","Bacterial pathogenesis"
"79955429299","Hepatocyte growth factor"
"79955429299","InlB"
"79955429299","Internalin"
"79955429299","Met"
"79955429299","Protein structure"
"79955429299","Receptor tyrosine kinase"
"79955429299","Signal transduction"
"79955429299","Transmembrane signaling"
"84881405670","HGFR"
"84881405670","MetMAb"
"84881405670","OA5D5"
"84881405670","Scatter factor"
"84888642452","Capecitabine"
"84888642452","Chemotherapy"
"84888642452","Everolimus"
"84888642452","Refractory gastric cancer"
"13644262798","Cancer models"
"13644262798","Cancer therapy"
"13644262798","Insulin-like growth factor binding proteins"
"13644262798","Insulin-like growth factor-I"
"13644262798","Insulin-like growth factor-I receptor"
"13644262798","Insulin-like growth factor-II"
"13644262798","Insulin-like growth factor-II receptor"
"46249131607","Advanced gastric cancer"
"46249131607","EGFR"
"46249131607","Gastric cancer prognosticators"
"46249131607","HER2"
"46249131607","IGF-1R"
"83455236504","Cancer"
"83455236504","Clinical trials"
"83455236504","Igf-1r"
"83455236504","Igf-1r inhibitor"
"83455236504","Insulin receptor"
"83455236504","Insulin-like growth factor"
"83455236504","Monoclonal antibody"
"83455236504","Targeted therapy"
"83455236504","Tyrosine kinase inhibitor"
"77955049754","chemosensitisation"
"77955049754","docetaxel"
"77955049754","figitumumab (CP-751,871)"
"77955049754","insulin-like growth factor type 1 receptor (IGF-IR)"
"77955049754","monoclonal antibody"
"84876312892","Cisplatin"
"84876312892","Drug resistance"
"84876312892","Gastric cancer"
"84876312892","MiR-21"
"84876312892","PTEN"
"84870551976","Bcl-2"
"84870551976","microRNA expression profile"
"84870551976","Prognostic value"
"84872496432","Biomarkers"
"84872496432","Cancer"
"84872496432","Circulation"
"84872496432","Diagnosis"
"84872496432","MicroRNA"
"84872496432","Prognosis"
"0028959887","Chemotherapy"
"0028959887","Gastric cancer"
"0028959887","Survival"
"0027217474","chemotherapy"
"0027217474","doxorubicin"
"0027217474","fluorouracil"
"0027217474","folinic acid"
"0027217474","gastric cancer"
"0027217474","methotrexate"
"0027217474","outpatients"
"8044236424","chemotherapy"
"8044236424","gastric cancer"
"8044236424","palliation"
"8044236424","randomized study"
"0037294483","Advanced gastric cancer"
"0037294483","Chemotherapy"
"0037294483","Cyclosporin A"
"0037294483","Paclitaxel"
"0037294483","Toxicity"
"0141887353","Irinotecan"
"0141887353","Metastatic gastric cancer"
"0141887353","Phase II"
"34547923762","Advanced gastric cancer"
"34547923762","Pharmacogenomics"
"34547923762","Pharmacokinetics"
"34547923762","Predictive marker"
"34547923762","S-1"
"38749089075","5-fluorouracil"
"38749089075","Advanced gastric cancer"
"38749089075","Low-dose leucovorin"
"38749089075","Malignant ascites"
"38749089075","Oxaliplatin"
"23844507339","Camptothecin"
"23844507339","DX-8951f"
"23844507339","Exatecan mesylate"
"23844507339","Gastric cancer"
"23844507339","Topoisomerase I"
"33645315211","Capecitabine"
"33645315211","Chemotherapy"
"33645315211","Docetaxel"
"33645315211","Gastric cancer"
"33645315211","Gastroesophageal Junction"
"33645315211","Stomach"
"54949137348","Docetaxel"
"54949137348","Esophageal"
"54949137348","FLOT"
"54949137348","Gastric"
"54949137348","Oxaliplatin"
"38649116966","Antineoplastic combined chemotherapy protocols"
"38649116966","Ãrgano platinum compounds"
"38649116966","Stomach neoplasms"
"77950048210","Capecitabine"
"77950048210","Gastric cancer"
"77950048210","Oxaliplatin"
"77950048210","Phase II trial"
"48849094297","5-fluorouracil"
"48849094297","Cisplatin"
"48849094297","Gastric"
"48849094297","Irinotecan"
"48849094297","Phase III"
"36348949060","Advanced gastric cancer"
"36348949060","Chemotherapy"
"36348949060","Irinotecan"
"36348949060","Toxicity"
"84855180351","Cetuximab"
"84855180351","Gastric cancer"
"84855180351","Irinotecan"
"84855180351","KRAS phase II trial"
"84855180351","Oxaliplatin"
"84857043129","Cetuximab"
"84857043129","Irinotecan"
"84857043129","Second-line treatment"
"84857043129","Stomach cancer"
"84875216936","advanced gastric cancer"
"84875216936","advanced oesophageal cancer"
"84875216936","cetuximab"
"84875216936","docetaxel"
"61749085803","Akt"
"61749085803","Gastric cancer"
"61749085803","mTOR"
"0034051390","Accessory cells"
"0034051390","Bispecific antibody"
"0034051390","Phagocytosis"
"0034051390","Tumour"
"77954676136","catumaxomab"
"77954676136","clinical trial"
"77954676136","epithelial cancer"
"77954676136","malignant ascites"
"77954676136","trifunctional antibody"
"84857020475","Angiogenesis"
"84857020475","Brivanib"
"84857020475","Fibroblast growth factor"
"84857020475","Hepatocellular carcinoma"
"84857020475","Sorafenib"
"84857020475","Tumor response"
"84857020475","Vascular endothelial growth factor"
"84866259301","Adenocarcinoma"
"84866259301","Angiogenesis"
"84866259301","Esophageal cancer"
"84866259301","Squamous cell carcinoma"
"84866259301","Targeted therapy"
"0032533670","Adenocarcinoma"
"0032533670","Esophagus"
"0032533670","Neoplasms"
"0032533670","Squamous cell carcinoma"
"0032533670","Stomach"
"0033853456","Adenocarcinoma"
"0033853456","Europe"
"0033853456","Incidence"
"0033853456","Oesophagus"
"0033853456","Stomach"
"0033853456","Trends"
"0030783061","Biomonitoring"
"0030783061","Endogenous formation"
"0030783061","Exposure assessment"
"0030783061","N-nitroso compounds"
"48149101466","Cohort studies"
"48149101466","Meta-analysis"
"48149101466","Smoking"
"48149101466","Stomach neoplasms"
"57449097365","Angiogenesis"
"57449097365","Carcinogenesis"
"57449097365","Microvessel density"
"57449097365","Pre-malignant"
"67649300463","Hypoxia-inducible factor 1, alpha"
"67649300463","Stomach neoplasms"
"67649300463","Vascular endothelial growth factor"
"84863364424","Angiogenesis"
"84863364424","Esophageal"
"84863364424","Gastroesophageal junction"
"84863364424","Paclitaxel"
"84863364424","Sunitinib"
"84863364424","Tyrosine kinase inhibitors"
"33745738260","Angiogenesis"
"33745738260","Angiogenesis inhibitor"
"33745738260","Bevacizumab"
"33745738260","Cancer"
"33745738260","Clinical trials"
"33745738260","Monoclonal antibodies targeting VEGF"
"33745738260","Pre-clinical studies"
"33745738260","VEGF"
"84865606568","Immunomodulatory drugs (IMiDs)"
"84865606568","Lenalidomide"
"84865606568","Multiple myeloma (MM)"
"84865606568","Non-Hodgkin's lymphoma (NHL)"
"84865606568","Pomalidomide"
"84865606568","Thalidomide"
"0025835071","box plot"
"0025835071","geographic distribution"
"0025835071","HCC"
"0025835071","risk factors"
"0027183608","Hepatitis C virus"
"0027183608","Hepatocellular carcinoma"
"0027183608","Risk factor"
"84881294686","Early-stage hepatocellular carcinoma"
"84881294686","Hepatic resection"
"84881294686","Meta-analysis"
"84881294686","Radiofrequency ablation"
"84880948632","Hepatectomy"
"84880948632","Percutaneous ethanol injection"
"84880948632","Radiofrequency ablation"
"84880948632","Surgical resection"
"84866354969","Complication"
"84866354969","Hepatectomy"
"84866354969","Hepatocellular carcinoma"
"84866354969","Radiofrequency ablation"
"84866354969","RCTs"
"78650130194","cancer"
"78650130194","liver"
"78650130194","recurrence"
"78650130194","survival"
"78650130194","treatment"
"33646072148","Carcinoma, hepatocellular"
"33646072148","Catheter ablation"
"33646072148","Randomized controlled trials"
"33646072148","Surgical procedures, operative"
"15344349946","Carcinoma"
"15344349946","Hepatectomy"
"15344349946","Hepatocellular"
"15344349946","Radiofrequency"
"84885736419","Hepatocellular carcinoma"
"84885736419","Influencing elements"
"84885736419","Relapse"
"13144251151","Donor"
"13144251151","Liver transplantation"
"13144251151","MELD"
"13144251151","Mortality"
"13144251151","Organs"
"13144251151","SRTR"
"13144251151","Supply"
"13144251151","Survival benefit"
"13144251151","Waiting list"
"0034850187","Cancer"
"0034850187","Diagnostic laparoscopy"
"0034850187","Laparoscopic ultrasonography"
"0034850187","Neoplasms"
"0034850187","Staging"
"84871809241","Hepatocellular carcinoma"
"84871809241","Laparoscopic approach"
"84871809241","Outcome"
"84871809241","Radiofrequency ablation"
"84871809241","Review"
"1542751065","Hepatocellular cancer"
"1542751065","Liver metastases"
"1542751065","Radiofrequency ablation"
"1542751065","Resection"
"84888416350","Hepatocellular carcinoma"
"84888416350","Meta-analysis"
"84888416350","Percutaneous ethanol injection"
"84888416350","Radiofrequency ablation"
"84888416350","Surgical resection"
"73449129338","Colorectal carcinoma"
"73449129338","Hepatocellular carcinoma"
"73449129338","Liver metastasis"
"73449129338","Microwave ablation"
"73449129338","Radiofrequency ablation"
"37149020675","Hepatocellular carcinoma"
"37149020675","Microwave ablation"
"37149020675","Minimally invasive therapy"
"77954410215","Hepatocellular carcinoma"
"77954410215","Microwave ablation"
"77954410215","Ultrasound guidance"
"84875054274","Hepatocellular carcinoma"
"84875054274","Microwave ablation"
"33846847728","Doxorubicin"
"33846847728","Drug eluting beads"
"33846847728","Hepatocellular carcinoma"
"33846847728","Pharmacokinetics"
"33846847728","RECIST"
"33846847728","Response rate"
"33846847728","TACE"
"84858236081","Chemoembolization"
"84858236081","DC beads"
"84858236081","Lipiodol"
"77949264899","Chemoembolization"
"77949264899","Doxorubicin"
"77949264899","Drug-eluting beads"
"77949264899","Hepatocellular carcinoma"
"55949123393","Allocation"
"55949123393","Hepatocellular carcinoma"
"55949123393","Liver transplantation"
"55949123393","MELD score"
"55949123393","Patient survival"
"55949123393","Selection criteria"
"55949123393","Tumor recurrence"
"67650938388","Chemoembolization"
"67650938388","Downstaging"
"67650938388","Hepatocellular carcinoma"
"67650938388","Radioembolization"
"67650938388","Yttrium-90 microspheres"
"79251575901","Clinical Trial"
"79251575901","Comparative Effectiveness"
"79251575901","Liver Cancer"
"79251575901","Radiotherapy"
"0028783988","90Yttrium-microspheres"
"0028783988","Hepatic tumors"
"0028783988","Lung shunting"
"0028783988","Radiation pneumonitis"
"84883855857","Ablation"
"84883855857","Hepatocellular carcinoma"
"84883855857","Sorafenib"
"84883855857","Therapy"
"84883855857","Transarterial chemoembolization"
"84874928300","hepatocellular carcinoma"
"84874928300","sorafenib"
"84874928300","transarterial chemoembolization"
"84880732021","Hepatocellular carcinoma"
"84880732021","Sorafenib"
"84880732021","Transarterial chemoembolization"
"84872600260","Hepatocellular carcinoma"
"84872600260","liver cirrhosis"
"84872600260","liver function"
"84872600260","MET inhibitor"
"84872600260","tivantinib"
"84879774804","Bevacizumab"
"84879774804","Erlotinib"
"84879774804","Hepatocellular carcinoma"
"84879774804","Phase II study"
"84860224913","bevacizumab"
"84860224913","epidermal growth factor receptor"
"84860224913","erlotinib"
"84860224913","hepatocellular cancer"
"84860224913","vascular endothelial growth factor"
"84878832178","bevacizumab"
"84878832178","erlotinib"
"84878832178","hepatocellular carcinoma"
"17044380150","Bioheat equation"
"17044380150","Cancer therapy"
"17044380150","Electropermeabilization"
"79955467554","ECG"
"79955467554","electrocardiography"
"79955467554","IRE"
"79955467554","irreversible electroporation"
"79955467554","radiofrequency"
"79955467554","RF"
"84875235955","hepatic metastasis"
"84875235955","hepatocellular carcinoma"
"84875235955","irreversible electroporation"
"84895077252","Advanced gastric cancer"
"84895077252","Chemotherapy"
"84895077252","Docetaxel"
"84895077252","S-1"
"0036526681","Ethnicity"
"0036526681","Gastric cancer survival"
"0036526681","Surgical comorbidity"
"79953685152","Bioinformatics"
"79953685152","Genetic variation"
"79953685152","Genomics"
"79953685152","Next-generation sequencing"
"79953685152","Polymorphism"
"79953685152","Targeted sequence enrichment"
"84890571260","colorectal cancer"
"84890571260","gastric cancer"
"84890571260","meta-analysis"
"84890571260","mutation"
"84890571260","PI3K"
"84890571260","PI3K inhibitor"
"37049028991","Angiogenesis"
"37049028991","CD34"
"37049028991","Gastric cancer"
"37049028991","Hypoxia-inducible factor 1Î±"
"37049028991","Vascular endothelial growth factor"
"78449254848","Clinicopathology"
"78449254848","E-cadherin"
"78449254848","Gastric cancer"
"78449254848","MMPs"
"78449254848","Patient survival"
"78449254848","VEGF"
"84884552646","Angiogenesis inhibitors"
"84884552646","Antibodies, monoclonal, humanized"
"84884552646","Bevacizumab"
"84884552646","Colorectal neoplasms"
"84856829698","FGFR2"
"84856829698","gastric cancer"
"84856829698","gene amplification"
"33144462553","Gene amplification"
"33144462553","Molecular marker"
"33144462553","Oncogene addiction"
"33144462553","Targeted therapy"
"78049499656","Akt"
"78049499656","Gastric cancer"
"78049499656","Metastasis"
"78049499656","Phosphatidylinositol 3-kinase/Akt pathway"
"78049499656","PIK3CA"
"31944444234","Chorioallantoic membrane"
"31944444234","Hemangiosarcoma"
"31944444234","p110"
"31944444234","Phosphatidylinositol 3-kinase"
"84862789569","Gastric cancer"
"84862789569","PI3K/Akt pathway"
"84862789569","PIK3CA amplification"
"84862789569","PIK3CA mutations"
"84862789569","Poor survival"
"84860157670","Gastric cancer"
"84860157670","Gene amplification"
"84860157670","Oncogenes"
"84860157670","Poor prognosis"
"84856392824","5-Fluorouracil"
"84856392824","Combination index"
"84856392824","E2F1"
"84856392824","PI3-kinase"
"84856392824","Thymidylate synthase"
"84863080780","drug resistance"
"84863080780","FKBP4"
"84863080780","neoadjuvant chemotherapy"
"84863080780","quantitative proteomics"
"84863080780","S100A9"
"84887108577","Biomarkers"
"84887108577","Breast cancer"
"84887108577","Molecular subtypes"
"84887108577","Proteomics"
"84887108577","Review"
"84898401323","Breast cancer"
"84898401323","Functional proteomics"
"84898401323","Predictive marker"
"84898401323","Prognostic marker"
"84861706473","Biomarker"
"84861706473","Gastric cancer"
"84861706473","Mass spectrometry"
"84861706473","Proteomics"
"84856104831","Met receptor"
"84856104831","oncogene addiction"
"84856104831","surrogate biomarkers"
"84856104831","targeted therapies"
"84881106311","chemotherapy response"
"84881106311","glucose-regulated proteins"
"84881106311","heat-shock proteins"
"84881106311","oesophageal adenocarcinoma"
"84881106311","reverse phase protein array (RPPA)"
"0033602501","Androgen"
"0033602501","Breast cancer"
"0033602501","Estrogen"
"0033602501","Tamoxifen"
"0033602501","Toremifene"
"0033602501","Vascular endothelial growth factor"
"77954682879","angiogenesis"
"77954682879","antiangiogenic agent"
"77954682879","IMC-1121B"
"77954682879","monoclonal antibody"
"77954682879","VEGFR2"
"77951296573","Advanced breast cancer"
"77951296573","Capecitabine"
"77951296573","Sunitinib malate"
"77951296573","Tyrosine kinase inhibitor"
"80051713290","Advanced breast cancer"
"80051713290","Bevacizumab"
"80051713290","Paclitaxel"
"80051713290","Sunitinib malate"
"80051713290","Tyrosine kinase inhibitor"
"84867503535","NSCLC"
"84867503535","Previously treated"
"84867503535","Ramucirumab"
"84867503535","VEGF"
"84880530647","Gastric cancer"
"84880530647","Genetic alterations"
"84880530647","Pathology"
"84861746773","chromosomal instability"
"84861746773","epigenetics"
"84861746773","gastric cancer"
"84861746773","genetics"
"84861746773","intrinsic subtypes"
"84861746773","Lauren's subtype"
"84861746773","microsatellite instability"
"79951580512","Antitumor activity"
"79951580512","Chemotherapeutic agents"
"79951580512","Gastric cancer"
"79951580512","HM781-36B"
"79951580512","Pan-HER inhibitor"
"84862256003","Gastric cancer"
"84862256003","Monoclonal antibody"
"84862256003","Targeted therapy"
"84862256003","Tyrosine kinase inhibitor"
"51449124276","Advanced"
"51449124276","Anti-EGFR therapy"
"51449124276","Chemotherapy"
"51449124276","ECX"
"51449124276","Oesophagogastric cancer"
"84879552381","5-fluorouracil"
"84879552381","Advanced gastric cancer"
"84879552381","Cisplatin"
"84879552381","Sunitinib"
"84866418084","Clinical trial"
"84866418084","Ganitumab"
"84866418084","Gemcitabine"
"84866418084","Insulin-like growth factor receptor type 1"
"84866418084","Phase 1"
"82255194078","everolimus"
"82255194078","gastric adenocarcinoma"
"82255194078","gastric cancer"
"82255194078","mTOR"
"82255194078","mTOR inhibitors"
"80052188068","26S proteasome"
"80052188068","Cancer"
"80052188068","Clinical trials"
"80052188068","Heat shock protein 70 (HSP70)"
"80052188068","Heat shock protein 90 (HSP90)"
"80052188068","Proteasomal degradation"
"80052188068","Simultaneous inhibition"
"34548357028","Akt"
"34548357028","Bortezomib (PS341, Velcade)"
"34548357028","ERK"
"34548357028","Gastric cancer"
"34548357028","Nuclear factor-ÎºB"
"84856031653","Bortezomib"
"84856031653","Gastric cancer"
"84856031653","Nuclear factor-kB (NF-KB)"
"84856031653","Proteasome"
"84876147144","Chemosensitization"
"84876147144","Cisplatin-resistance"
"84876147144","PARP-1 inhibitor"
"84887792084","ATM"
"84887792084","Breast cancer"
"84887792084","Iniparib"
"84887792084","Olaparib"
"84887792084","PARP inhibitors"
"84860485132","Advanced solid malignancies"
"84860485132","AT9283"
"84860485132","Aurora kinase inhibitor"
"84860485132","Phase I"
"33646811208","Gastric carcinoma"
"33646811208","p53"
"33646811208","Polo-like kinase"
"33646811208","Survival"
"84863720628","BI 2536"
"84863720628","pancreatic cancer"
"84863720628","phase II"
"84863720628","Plk1 inhibitor"
"84864304530","Esophagogastric cancer"
"84864304530","Gastric cancer"
"84864304530","Gastroesophageal cancer"
"84864304530","Matrix metalloproteinase-9"
"84864304530","RNA"
"39849100541","CELLCYCLE"
"3042802135","Gastric cancer"
"3042802135","Marimastat"
"3042802135","Matrix metalloproteinase inhibitors"
"79958155469","Celecoxib"
"79958155469","COX-2"
"79958155469","Esophageal cancer"
"79957638275","Claudins"
"79957638275","Conservation"
"79957638275","Ortholog"
"79957638275","Tight junction"
"59249095362","Gastric carcinoma"
"59249095362","Helicobacter pylori"
"59249095362","Hypergastrinemia"
"59249095362","Neuroendocrine"
"59249095362","Proton pump inhibitor"
"84883185766","Keywords Stomach Cancer GC-Class Personalized Cancer Treatment Cancer Classification PI3K"
"79960052850","Cancer"
"79960052850","Developmental syndromes"
"79960052850","Mutation"
"79960052850","Oncogenes"
"79960052850","Ras"
"79960052850","Ras-MAPK pathway"
"84903694472","Antibody"
"84903694472","Chemotherapy"
"84903694472","FOLFOX"
"84903694472","Metastatic colorectal cancer"
"84903694472","Panitumumab"
"84862026304","BRAF"
"84862026304","Cetuximab"
"84862026304","Colorectal cancer"
"84862026304","KRAS"
"79958817037","BRAF"
"79958817037","colorectal cancer"
"79958817037","metastases"
"79958817037","microsatellite instability"
"79958817037","survival"
"84866406301","BRAF"
"84866406301","Colorectal cancer"
"84866406301","Gene expression profile"
"84866406301","Oncogenes"
"84866406301","Signalling pathways"
"84866406301","Signatures"
"84891629487","Bevacizumab"
"84891629487","BRAF"
"84891629487","Chemotherapy"
"84891629487","Colorectal cancer"
"84891629487","FOLFOXIRI"
"84925105975","BRAF mutation"
"84925105975","Cetuximab"
"84925105975","Colorectal cancer"
"84925105975","Meta-analysis"
"84925105975","Panitumumab"
"0026700235","Apoptosis"
"0026700235","Growth factor deprivation"
"0026700235","Immunoglobulin superfamily"
"0026700235","Programmed cell death"
"0026700235","Subtractive hybridization"
"84861459479","colorectal cancer"
"84861459479","KRAS"
"84861459479","multi-kinase inhibitor"
"84861459479","regorafenib"
"84861459479","tumour angiogenesis"
"84873441401","Colorectal neoplasms"
"84873441401","Placenta growth factor"
"84860250957","And interleukin-8"
"84860250957","Antagonists"
"84860250957","Colorectal cancer"
"84860250957","CXCR2"
"70649112122","Renal cell carcinoma"
"70649112122","Selection of extreme phenotypes"
"70649112122","Sunitinib"
"70649112122","TNF-Î± MMP-9"
"25444511051","Carboplatin"
"25444511051","Cisplatin"
"25444511051","Combination therapy"
"25444511051","Etoposide"
"25444511051","Non-small-cell lung cancer"
"25444511051","Paclitaxel"
"84920655625","non-small-cell lung cancer"
"84920655625","PD-1"
"84920655625","PD-L1"
"84920655625","tyrosine kinase inhibitors"
"84898856600","Cisplatin"
"84898856600","Gastric cancer"
"84898856600","Irinotecan"
"84898856600","Second-line chemotherapy"
"0031870832","Angiogenesis"
"0031870832","KDR"
"0031870832","Monoclonal antibody"
"0031870832","VEGF"
"84878492693","angiogenesis"
"84878492693","antiangiogenesis agent"
"84878492693","IMC-1121B"
"84878492693","ramucirumab"
"84878492693","VEGF"
"84878492693","VEGFR2"
"84873406666","clinical trials"
"84873406666","gastric cancer"
"84873406666","multimodality therapy"
"84925965379","Iodine-refractory"
"84925965379","Sorafenib"
"84925965379","Sunitinib"
"84925965379","Systemic therapy"
"84925965379","Thyroid carcinoma"
"84925965379","VEGF"
"0020617781","cell division"
"0020617781","conditioned medium"
"0020617781","growth substances"
"0020617781","neovascularisation"
"0020617781","Organ culturey"
"0020617781","wound healing"
"35648971655","Colorectal cancer"
"35648971655","HIF1Î±"
"35648971655","VEGF"
"35648971655","VEGFR2/KDR"
"84893805528","Axitinib"
"84893805528","Cancer"
"84893805528","Cediranib"
"84893805528","Gastrointestinal perforation"
"84893805528","Meta-analysis"
"84893805528","Pazopanib"
"84893805528","Sorafenib"
"84893805528","Sunitinib"
"84893805528","Vandetanib"
"84922681694","bleeding"
"84922681694","cardiovascular toxicities"
"84922681694","hypertension"
"84922681694","left ventricular dysfunction"
"84922681694","meta-analysis"
"84922681694","myocardial ischemia"
"84922681694","sorafenib"
"84925283518","cancer"
"84925283518","fatigue"
"84925283518","meta-analysis"
"84925283518","pazopanib"
"84925283518","renal cell carcinoma"
"84925283518","sorafenib"
"84925283518","sunitinib"
"84925283518","tyrosine kinase inhibitors"
"84871978557","digital image analysis"
"84871978557","gastric cancer"
"84871978557","gastroesophageal junction cancer"
"84871978557","monoclonal antibody"
"84871978557","tumor heterogeneity"
"84871978557","whole-slide imaging"
"84921460787","gastric cancer"
"84921460787","HGF"
"84921460787","MET"
"84921460787","systemic treatment"
"84921460787","targeted therapy"
"84930919608","Gastric cancer"
"84930919608","Hedghog"
"84930919608","Vismodegib"
"84899112560","CD137"
"84899112560","Checkpoint blockade"
"84899112560","Immunogenic chemotherapy"
"84899112560","Immunosuppression"
"84899112560","IPH2101"
"84899112560","Lirilumab"
"84899112560","PD-L1"
"84921398753","CTLA4"
"84921398753","ipilimumab"
"84921398753","Keytrudaâ¢"
"84921398753","nivolumab"
"84921398753","PD-1"
"84921398753","Yervoyâ¢"
"84883219603","Bevacizumab"
"84883219603","Dalotuzumab"
"84883219603","Ipilimumab"
"84883219603","Nimotuzumab"
"84883219603","Ramucirumab"
"84883219603","Trastuzumab"
"84899115962","Bevacizumab"
"84899115962","Brentuximab vedotin"
"84899115962","Cetuximab"
"84899115962","Nimotuzumab"
"84899115962","Trastuzumab"
"84899115962","Tumor-associated antigen"
"84886944943","ADCC"
"84886944943","Cetuximab-activated nk cells"
"84886944943","Cross-priming"
"84886944943","EGFR-specific cd8+ t cells"
"84886944943","Poly-ICLC"
"84886944943","TLR3"
"77952912435","Apoptosis"
"77952912435","Biomarkers"
"77952912435","Caspase"
"77952912435","Combination therapy"
"77952912435","Conatumumab"
"77952912435","Death receptor"
"77952912435","TRAIL"
"84885366553","Antibody-dependant cell cytotoxicity"
"84885366553","Cancer"
"84885366553","Immunotherapy"
"84885366553","Monoclonal antibody"
"84885366553","Synapse"
"84886944363","ADCC"
"84886944363","Antibody"
"84886944363","CD137"
"84886944363","NK cell"
"84886944363","Synergy"
"84877135653","ADCC"
"84877135653","Breast cancer"
"84877135653","Flow cytometry"
"84877135653","Trastuzumab"
"84877135653","xCELLigence"
"79955011744","Antibody-dependent cellular cytotoxicity"
"79955011744","Apoptosis"
"79955011744","CD20"
"79955011744","Chronic Lymphocytic Leukemia"
"79955011744","Complement"
"79955011744","Monoclonal antibodies"
"79955011744","Non hodgkin lymphoma"
"79955011744","Ofatumumab"
"79955011744","Review"
"79955011744","Rituximab"
"79955011744","Tositumomab"
"73849090193","Adaptive immunity"
"73849090193","Complement"
"73849090193","Host defense"
"73849090193","Inflammation"
"73849090193","Innate immunity"
"83655196673","Anti-CD3"
"83655196673","Anti-EpCAM"
"83655196673","Catumaxomab"
"83655196673","Epithelial cell adhesion molecule (EpCAM)"
"83655196673","Malignant ascites"
"83655196673","Targeted cancer immunotherapy"
"83655196673","Trifunctional antibody"
"84886945370","Î³Î´ T cells"
"84886945370","EpCAM (CD326)"
"84886945370","Hepatoblastoma"
"84886945370","Immunotherapy"
"84886945370","PBMC"
"84886945370","Therapeutic antibodies"
"84906043250","Antibody-drug conjugate"
"84906043250","Cancer therapy"
"84906043250","Linker"
"84906043250","Payload"
"84906043250","Quantitative translational systems pharmacology"
"84876872556","Bevacizumab"
"84876872556","Colorectal cancer"
"84876872556","Dendritic cells"
"84876872556","Tumor microenvironment"
"33846564399","ADCC"
"33846564399","Cetuximab"
"33846564399","EGFR"
"33846564399","Esophageal cancer"
"33846564399","TGF-Î²"
"84886945205","Antibody"
"84886945205","Epidermal growth factor receptor"
"84886945205","Expression levels"
"84896712625","Bispecific antibodies"
"84896712625","Central nervous system neoplasms"
"84896712625","Epidermal growth factor receptor"
"84896712625","Glioblastoma"
"84896712625","Granzymes"
"84896712625","Regulatory T cells"
"84881552775","Bispecific antibodies"
"84881552775","Central nervous system neoplasms"
"84881552775","Epidermal growth factor receptor"
"84881552775","Immunotherapy"
"84881552775","T lymphocytes"
"84867858547","Bispecific antibody"
"84867858547","BiTEÂ®"
"84867858547","Leukemia"
"84867858547","Lymphoma"
"79955662260","Antibody"
"79955662260","Bispecific"
"79955662260","BiTE"
"84900844248","Acute myeloid leukemia"
"84900844248","AMG 330"
"84900844248","Antibody"
"84900844248","Bispecific"
"84900844248","Bite"
"84900844248","Cd3"
"84900844248","Cd33"
"84900844248","Gemtuzumab ozogamicin"
"84900844248","Immunotherapy"
"77957995258","C-reactive protein"
"77957995258","interleukin-6"
"77957995258","metastatic renal cell cancer"
"77957995258","siltuximab"
"79951556761","Akt"
"79951556761","Interleukin-6"
"79951556761","Melphalan"
"79951556761","Multiple myeloma"
"79951556761","Siltuximab"
"84907056599","Castleman disease"
"84907056599","IL-6"
"84907056599","monoclonal antibody"
"84907056599","siltuximab"
"84907056599","targeted therapy"
"84857349967","Antibody"
"84857349967","CD20"
"84857349967","Chronic lymphocytic leukemia"
"84857349967","Lymphoma"
"84886943665","Bevacizumab"
"84886943665","Cytotoxic T cells"
"84886943665","IL-6"
"84886943665","Immunity"
"84886943665","Metastatic melanoma"
"84880732251","Breast carcinoma"
"84880732251","Calreticulin"
"84880732251","HMGB1"
"84880732251","Hyperploidy"
"84880732251","Immunogenic cell death"
"84880732251","Mitotic catastrophe"
"84883233976","Breast carcinoma"
"84883233976","Digitalis purpurea"
"84883233976","Estrogen receptor"
"84883233976","Immunogenic cell death"
"84883233976","Ouabain"
"84883233976","Phytoestrogens"
"84885432340","Cross-presentation"
"84885432340","Dendritic cells"
"84885432340","Electroporation"
"84885432340","Mucosal immunity"
"84885432340","Saccharomyces cerevisiae"
"84885432340","Salmonella typhimurium"
"84885162273","Chimeric antigen receptor"
"84885162273","Cyclophosphamide"
"84885162273","FOXP3+ regulatory T cells"
"84885162273","Lymphodepletion"
"84885162273","T-cell receptor"
"84885162273","Tumor-infiltrating lymphocytes"
"75649113373","Immunohistochemistry"
"75649113373","Lymphadenitis"
"75649113373","PD-1"
"75649113373","Reactive lymphadenopathy"
"75649113373","T-cell lymphoma"
"75649113373","Viral"
"84902449791","Anti-CTLA-4"
"84902449791","Anti-OX40"
"84902449791","Cancer"
"84902449791","Immunotherapy"
"84902449791","Interleukin-4"
"84902449791","Ipilimumab"
"84902449791","Lymphocyte"
"84902449791","Prostate cancer"
"84902449791","SPAS-1"
"84902449791","TRAMP-C1"
"84899128381","Anti-CTLA4 antibody"
"84899128381","Immunomodulating antibody"
"84899128381","Mesothelioma"
"84899128381","Therapy"
"84899128381","Tremelimumab"
"84906510279","CTLA-4"
"84906510279","MK-3475"
"84906510279","PBMC"
"84906510279","PD-1"
"84906510279","sequencing"
"84906510279","TCR"
"84906510279","Tremelimumab"
"79955556128","Castleman's disease"
"79955556128","Human herpes virus-8"
"79955556128","Interleukin-1"
"79955556128","Interleukin-6"
"79955556128","Molecular therapeutics"
"79955556128","Targeted therapy"
"84896265113","Activatable imaging agent"
"84896265113","Activatable therapeutic agent"
"84896265113","Molecular imaging"
"84896265113","Ovarian cancer"
"84896265113","Photodynamic therapy"
"84899096210","Antibody-dependent cellular cytotoxicity"
"84899096210","M2 polarization"
"84899096210","NK cells"
"84899096210","Tumor-associated macrophages"
"84890291467","CD19"
"84890291467","Chimeric receptor"
"84890291467","Gangliosides"
"84890291467","Target antigen"
"84890291467","Tumor microenvironment"
"84892409564","Glycolysis"
"84892409564","Ketogenic diet"
"84892409564","Lactate"
"84892409564","MDSCs"
"84892409564","NK cells"
"84884990167","Antibody combinations"
"84884990167","CD5"
"84884990167","Chronic lymphocytic leukaemia"
"84884990167","Complement-dependent cytotoxicity"
"84884990167","Epitope binning"
"84930696140","Cdk4/6 inhibitor"
"84930696140","Cell cycle"
"84930696140","Combination therapy"
"84930696140","In vivo antitumor activity"
"84930696140","Kinase inhibitor"
"84930696140","LY2835219"
"0036044579","Anthracyclines"
"0036044579","Campath-1H"
"0036044579","Complete remission"
"0036044579","Cyclophosphamide"
"0036044579","Fludarabine"
"0036044579","Infections"
"0036044579","Mitoxantrone"
"0036044579","Rituximab"
"84884204298","ABT-263"
"84884204298","ATPase-binding cassette (ABC) transporters"
"84884204298","MG-132"
"84884204298","MOLM-13"
"84884204298","Obatoclax"
"84884204298","SKM1"
"79960456078","ATM"
"79960456078","ATR"
"79960456078","DNMT1"
"79960456078","HL-60"
"79960456078","MOLM-13"
"79960456078","SKM-1"
"84886944438","Chemokines"
"84886944438","Myelodysplastic syndrome"
"84886944438","T cells"
"84892409579","CC-5013"
"84892409579","Chronic lymphocytic leukemia"
"84892409579","IMiDs"
"84892409579","Pomalidomide"
"84892409579","Regulatory T cells"
"84892409579","TNFÎ±"
"84899051541","Apoptosis"
"84899051541","Cereblon"
"84899051541","IKZF1"
"84899051541","IKZF3"
"84899051541","IMiD"
"84899051541","Thalidomide"
"84859771379","ATP7B"
"84859771379","CTR1"
"84859771379","ERCC1"
"84859771379","glutathione"
"84859771379","metallothioneins"
"84859771379","TP53"
"0033839790","Bisphosphonates"
"0033839790","Osteoporosis"
"0002761965","BGP"
"0002761965","Bisphosphonates"
"0002761965","DXA bone mineral density"
"0002761965","Osteoporosis"
"0002761965","Pamidronate"
"0002761965","Postmenopausal"
"0033764107","Acute myeloid leukaemia"
"0033764107","Gemtuzumab ozogamicin (CMA-676)"
"84863650195","antibody"
"84863650195","bispecific"
"84863650195","CD19"
"84863650195","CD30"
"84863650195","diabody"
"84863650195","Hodgkins lymphoma"
"84863650195","non-Hodgkins lymphoma"
"84863650195","TandAbÂ®"
"39449125850","Epidermal growth factor receptor"
"39449125850","Genetic alteration"
"39449125850","Monoclonal antibody"
"39449125850","Nimotuzumab"
"39449125850","Non-small cell lung cancer"
"39449125850","Radiosensitisation"
"45349101800","Anti-EGF-R monoclonal antibody"
"45349101800","Brain tumor"
"45349101800","Gliomas"
"45349101800","h-R3"
"45349101800","Nimotuzumab"
"45349101800","Radioimmunotherapy"
"45349101800","Rhenium"
"79954442316","Clinical trial"
"79954442316","Monoclonal antibody"
"79954442316","Nimotuzumab"
"79954442316","Non-small cell lung cancer"
"79954442316","Toxicity"
"34548561684","Anti-HGF antibody"
"34548561684","c-Met"
"34548561684","Cancer"
"34548561684","Hepatocyte growth factor"
"34548561684","Tyrosine kinase"
"84869477687","Calcein"
"84869477687","Cytarabine"
"84869477687","KO-143"
"84869477687","MK-571"
"84869477687","Verapamil"
"84869477687","VP16"
"77954663766","Bendamustine"
"77954663766","Indolent non-Hodgkin's lymphoma"
"77954663766","Lymphoproliferative disorders"
"77954663766","Novel therapy"
"8944242603","Ganglioside"
"8944242603","GM-CSF"
"8944242603","Melanoma"
"84886945545","Î²-glucan"
"84886945545","3F8"
"84886945545","Antibody"
"84886945545","Immunotherapy"
"84886945545","Neuroblastoma"
"84877799310","Antibody-dependent cell-mediated cytotoxicity (ADCC)"
"84877799310","Chimeric"
"84877799310","Complement mediated cytotoxicity (CMC)"
"84877799310","Humanized"
"84877799310","Monoclonal antibodies (MoAb)"
"84877799310","Peripheral blood mononuclear cells (PBMC)"
"84877799310","Polymorphonuclear leukocytes (PMN)"
"84886943238","Chemokines"
"84886943238","GM-CSF"
"84886943238","IFN"
"84886943238","IL-2"
"84886943238","TGFÎ²"
"84886943238","TNFÎ±"
"84906489918","Chemokines"
"84906489918","GM-CSF"
"84906489918","IFN"
"84906489918","IL-2"
"84906489918","TGFÎ²1"
"84906489918","TNFÎ±"
"84858797619","bevacizumab"
"84858797619","Dalotuzumab"
"84858797619","Ipilimumab"
"84858797619","Nimotuzumab"
"84858797619","Ramucirumab"
"84858797619","Trastuzumab"
"84875552922","ATP"
"84875552922","Autophagy"
"84875552922","Calreticulin"
"84875552922","Damage-associated molecular patterns"
"84875552922","HMGB1"
"84875552922","TLR4"
"84885692390","ATP"
"84885692390","Autophagy"
"84885692390","Calreticulin"
"84885692390","Dendritic cells"
"84885692390","Epothilone B"
"84885692390","HMGB1"
"67650436410","Cixutumumab"
"67650436410","IGF-1R"
"67650436410","IMC-A12"
"67650436410","Monoclonal antibody"
"84902593489","Cross-presentation"
"84902593489","Dendritic cells"
"84902593489","Electroporation"
"84902593489","Listeria monocytogenes"
"84902593489","Mucosal immunity"
"84902593489","Saccharomyces cerevisiae"
"84894553314","Adjuvants"
"84894553314","Dendritic cells"
"84894553314","Ipilimumab"
"84894553314","NY-ESO-1"
"84894553314","Survivin"
"84894553314","TLR agonists"
"77953678688","Cetuximab"
"77953678688","Monoclonal antibodies"
"77953678688","Resistance"
"77953678688","Rituximab"
"77953678688","Trastuzumab"
"84857139331","Antibody dependent cellular cytotoxicity (ADCC)"
"84857139331","Antibody-like molecule"
"84857139331","Cancer"
"84857139331","Complement dependent cytotoxicity (CDC)"
"84857139331","Drug resistance"
"84857139331","Immunology"
"84857139331","Monoclonal antibody"
"84871186416","Chemotherapy"
"84871186416","Gemcitabine"
"84871186416","Hepatocellular carcinoma"
"84871186416","Oxaliplatin"
"84871186416","Prognostic factors"
"84871186416","Survival"
"79959978255","advanced"
"79959978255","anti-angiogenesis"
"79959978255","bevacizumab"
"79959978255","capecitabine"
"79959978255","chemotherapy"
"79959978255","cirrhosis"
"79959978255","hepatocellular carcinoma"
"79959978255","metastatic"
"79959978255","oxaliplatin"
"79959978255","phase 2"
"75149112376","Doxorubicin"
"75149112376","Drug delivery systems"
"75149112376","Hepatocellular carcinoma"
"75149112376","Intra-arterial injection"
"84875609144","Hepatocellular carcinoma"
"84875609144","Sorafenib"
"84875609144","Survival"
"84875609144","Transarterial chemoembolization"
"78249288161","Advanced hepatocellular carcinoma"
"78249288161","Angiogenesis"
"78249288161","Doxorubicin"
"78249288161","PTK787"
"84864348077","AZD2171"
"84864348077","cediranib"
"84864348077","hepatocellular carcinoma"
"84864348077","phase II"
"84864348077","VEGF"
"33746624000","Hepatocellular carcinoma"
"33746624000","Molecularly targeted agents"
"33746624000","Systemic therapy"
"34547102484","Cetuximab"
"34547102484","Clinical trial"
"34547102484","Epidermal growth factor receptor inhibition"
"34547102484","Hepatocellular carcinoma"
"34547102484","Pharmacokinetics"
"46049097410","Cetuximab"
"46049097410","Chemotherapy"
"46049097410","Cirrhosis"
"46049097410","Epidermal growth factor receptor"
"46049097410","Hepatocellular carcinoma"
"46049097410","Phase 2 clinical trial"
"24344489502","Cisplatin"
"24344489502","Combination treatment"
"24344489502","Docetaxel"
"24344489502","Doxorubicin"
"24344489502","Epidermal growth factor receptor"
"24344489502","HepG2"
"24344489502","Huh-7"
"24344489502","SN-38"
"24344489502","Tarceva"
"68149164263","Biliary tree cancer"
"68149164263","Hepatocellular cancer"
"68149164263","Lapatinib"
"68149164263","Phase II study"
"77949875878","A12"
"77949875878","Hepatocellular carcinoma"
"77949875878","IGF signaling"
"77949875878","miR-100"
"77949875878","Molecular therapy"
"84892493984","Cixutumumab (IMC-A12, NSC742460)"
"84892493984","Diabetes"
"84892493984","Free IGF1"
"84892493984","Hepatocellular Carcinoma"
"84892493984","IGF-IR"
"84892493984","IGF2"
"84892493984","IGFBP 1"
"84892493984","IGFBP 3"
"77954218447","Hepatocellular carcinoma"
"77954218447","Molecular therapies"
"77954218447","Tyrosine kinase inhibitors"
"53749101792","Cancer"
"53749101792","Immunosuppression"
"53749101792","Intracellular signalling"
"53749101792","Transplantation"
"80555126830","angiogenesis"
"80555126830","clinical trial"
"80555126830","everolimus"
"80555126830","hepatocellular carcinoma"
"80555126830","mTOR inhibitors"
"84861344950","Hepatocellular carcinoma"
"84861344950","MTOR inhibitor"
"84861344950","Sirolimus"
"84901611471","Apoptosis"
"84901611471","Growth"
"84901611471","HCC"
"84901611471","Invasion"
"84901611471","Platelets"
"84901611471","Regorefenib"
"35148864569","Anti-sense RNA"
"35148864569","c-met"
"35148864569","Hepatocellular carcinoma cells"
"35148864569","RNA interference"
"84921032058","1-year survival"
"84921032058","melanoma"
"84921032058","PD-L1"
"84921032058","PD1 checkpoint inhibitors"
"84921032058","PFS"
"84921032058","response rates"
"33845865002","Gastric carcinoma"
"33845865002","Monoclonal antibody"
"33845865002","PD-L1"
"44949233175","Chemo-radiotherapy"
"44949233175","Pancreatic cancer"
"44949233175","Target therapy"
"79952008530","HBx"
"79952008530","Hepatocellular carcinoma"
"79952008530","Molecularly targeted therapy"
"79952008530","Sorafenib"
"79952008530","Sunitinib"
"84902537135","angiogenesis"
"84902537135","hepatocellular carcinoma"
"84902537135","rs2010963"
"84902537135","rs4604006"
"84902537135","single nucleotide polymorphisms"
"84902537135","sorafenib"
"84902537135","VEGF"
"84890406096","Angiogenic inhibitors"
"84890406096","Chemotherapy"
"84890406096","Colorectal cancer"
"84890406096","Epidermal growth factor receptor inhibitors"
"84890406096","First-line"
"84890406096","Maintenance"
"84926356283","Cetuximab"
"84926356283","CMET"
"84926356283","Colorectal cancer"
"84926356283","EGFR"
"84926356283","HER-3"
"84926356283","IGF1-R"
"84926356283","Panitumumab"
"84922480584","biomarker"
"84922480584","colorectal carcinoma"
"84922480584","HER2/neu"
"84922480584","immunohistochemistry"
"84922480584","in situ hybridisation"
"84922480584","tissue microarray"
"77953666101","Antibodies"
"77953666101","Cancer therapy"
"77953666101","VEGF"
"77953666101","VEGF receptors"
"33845991161","CELLCYCLE"
"77951879147","Conformational epitope"
"77951879147","Hybridoma technology"
"77951879147","Linear epitope"
"77951879147","Monoclonal antibody"
"77951879147","Vascular endothelial growth factor receptor 2"
"0037058302","Angiogenesis"
"0037058302","Anti-angiogenic therapy"
"0037058302","Gemcitabine"
"0037058302","Pancreatic cancer"
"0037058302","VEGF"
"84901301933","metastatic"
"84901301933","monoclonal antibody"
"84901301933","phase 2"
"84901301933","ramucirumab"
"84901301933","renal cell carcinoma"
"84899494014","Antiangiogenic therapy"
"84899494014","Breast cancer"
"84899494014","Clinical trial"
"84899494014","Predictive biomarker"
"84860287080","Association"
"84860287080","Genetics"
"84860287080","Liver Cancer"
"84860287080","Virology"
"84863522066","Barcelona Clinic Liver Cancer (BCLC) staging"
"84863522066","Hepatocellular carcinoma"
"84863522066","Prognosis"
"84863522066","Survival"
"84863522066","Treatment"
"65549105393","Hepatocellular carcinoma"
"65549105393","Prognosis"
"65549105393","Survival"
"65549105393","Vascular endothelial growth factor"
"0030823411","Basic fibroblast growth factor"
"0030823411","Fibroblast growth factor receptor- l"
"0030823411","Hepatocellular carcinoma"
"0030823411","Hepatoma cell"
"20044385758","Cancer"
"20044385758","Fibrogenesis"
"20044385758","Hepatic stellate cells"
"57849106330","CELLBIO"
"57849106330","HUMDISEASE"
"57849106330","SIGNALING"
"36549013178","AKT"
"36549013178","ERK"
"36549013178","Hepatocellular carcinoma"
"36549013178","Immunohistochemistry"
"36549013178","Prognosis"
"77956627711","Epidermal growth factor receptor"
"77956627711","Hepatocellular carcinoma"
"77956627711","Multikinase inhibitor"
"77956627711","Signaling"
"77956627711","Sorafenib"
"77956627711","Vascular endothelial growth factor"
"84891370054","c-MET"
"84891370054","Copy number variation"
"84891370054","Hepatocellular carcinoma"
"84891370054","Immunohistochemistry"
"84891370054","Prognosis"
"84904445789","Angiogenesis"
"84904445789","Lenvatinib"
"84904445789","Maximum tumor shrinkage"
"84904445789","Pharmacodynamic biomarkers"
"84904445789","SDF1Î±"
"84904445789","sVEGFR2"
"84904445789","VEGF"
"79959609860","C-MET"
"79959609860","EGFR"
"79959609860","Epithelial growth factor inhibitor"
"79959609860","Hepatocyte growth factor"
"79959609860","Kinase receptor inhibitor"
"59349121044","Angiogenesis"
"59349121044","Liver cancer"
"59349121044","Liver fibrosis"
"59349121044","Liver regeneration"
"59349121044","Portal hypertension"
"84862027112","c-Jun"
"84862027112","cancer stem cells"
"84862027112","CD133"
"84862027112","extracellular signal-regulated protein kinase (ERK)"
"80054954581","Angiogenesis"
"80054954581","Biomarker"
"80054954581","Cytokine"
"80054954581","Hepatocellular carcinoma"
"80054954581","Sorafenib"
"80053212846","Alpha-fetoprotein"
"80053212846","Hepatocellular carcinoma"
"80053212846","Sorafenib"
"80053212846","Surrogate"
"81555231534","Î±-Fetoprotein"
"81555231534","Antitumor response"
"81555231534","Chemotherapy"
"81555231534","Des-Î³-carboxy prothrombin"
"81555231534","Hepatocellular carcinoma"
"81555231534","Sorafenib"
"81555231534","Tumor markers"
"80051745537","Antiangiogenic therapy"
"80051745537","Des-Î³-carboxyprothrombin"
"80051745537","Hepatocellular carcinoma"
"80051745537","Hypoxia"
"80051745537","Protein-induced vitamin K absence II"
"80051745537","Sorafenib"
"84885025687","Des-Î³-carboxyprothrombin"
"84885025687","Hepatocellular carcinoma"
"84885025687","NX-des-Î³-carboxyprothrombin"
"84885025687","Sorafenib"
"84891887901","Î±-fetoprotein"
"84891887901","antiangiogenic therapy"
"84891887901","biomarker"
"84891887901","hepatocellular carcinoma"
"84891887901","prognosis"
"40849124295","Clinical trials"
"40849124295","Early diagnosis"
"40849124295","Evidence-based medicine"
"40849124295","Hepatocellular carcinoma"
"40849124295","Molecular diagnosis"
"40849124295","Molecular targeted therapies"
"40849124295","Randomised controlled trials"
"40849124295","Sorafenib"
"40849124295","Survival"
"40849124295","Systematic review"
"84864651241","biologic markers"
"84864651241","interleukins"
"84864651241","liver neoplasms"
"84864651241","neoplasm staging"
"84864651241","prognosis"
"84877153703","Anti-angiogenic drugs"
"84877153703","Cardiovascular risk factors"
"84877153703","Hypertension"
"84877153703","Left ventricular dysfunction"
"84877153703","Multitargeted tyrosine kinase inhibitors"
"84877153703","VEGF"
"55949098114","Angiogenesis"
"55949098114","Automated image analysis"
"55949098114","Breast cancer"
"55949098114","Neuropilin"
"55949098114","VEGF"
"0033566969","Early gastric carcinoma"
"0033566969","Prognostic factor"
"0033566969","Tumor angiogenesis"
"0033566969","Vascular endothelial growth factor"
"84873038775","Gastric cancer"
"84873038775","Polymorphism"
"84873038775","VEGF"
"33747097563","Gastric carcinoma"
"33747097563","HIF-1Î±"
"33747097563","IGF-2"
"33747097563","Microvessel density"
"33747097563","Prognosis"
"33747097563","VEGF"
"34248171966","Gastric carcinoma"
"34248171966","HIF-1Î±"
"34248171966","Microvascular density"
"34248171966","Prognosis"
"34248171966","Vascular endothelial growth factor"
"0035054199","Flt4"
"0035054199","Gastric cancer"
"0035054199","Lymphangiogenesis"
"0035054199","VEGF-C"
"0035054199","VEGFR-3"
"0036288934","Endoscopic mucosal resection"
"0036288934","Gastric cancer"
"0036288934","Immunohistochemistry"
"0036288934","Lymph node metastases"
"0036288934","mRNA expression"
"0036288934","Submucosal invasion"
"0036288934","Vascular endothelial growth factor-C"
"0037267293","Early gastric carcinoma"
"0037267293","Lymphatic metastasis"
"0037267293","Undifferentiated carcinoma"
"0037267293","Vascular endothelial growth factor C (VEGF-C) and D (VEGF-D)"
"20844451192","Gastric carcinoma"
"20844451192","Lymphangiogenesis"
"20844451192","Podoplanin"
"20844451192","VEGF"
